

Le patologie da Complemento in ematologia

**Starhotels Majestic
corso Vittorio Emanuele II 54, Torino**

8 giugno 2026

RAZIONALE SCIENTIFICO

L'anemia emolitica da anticorpi freddi (CAD) e l'emoglobinuria parossistica notturna (EPN) sono condizioni ematologiche rare, ma significative. Sono caratterizzate da distruzione dei globuli rossi in seguito all'attivazione di anticorpi in contesti principalmente di basse temperature (CAD) oppure in seguito ad acquisizione di mutazioni che comportino una maggiore labilità di membrana (EPN). La diagnosi e la gestione di queste patologie richiedono una conoscenza approfondita e l'aggiornamento continuo da parte dei professionisti del settore.

OBIETTIVO

L'iniziativa intende offrire ai partecipanti un'opportunità di aggiornamento su CAD e EPN, focalizzando la loro attenzione sugli aspetti diagnostici, biologici e terapeutici di queste rare malattie complemento-mediate.

RESPONSABILE SCIENTIFICO

Roberto Freilone, SC Ematologia, AOU Città della Salute e della Scienza di Torino.

SEGRETERIA SCIENTIFICA

Chiara Frairia, SC Ematologia, AOU Città della Salute e della Scienza di Torino.

Valentina Gai, SC Ematologia, AOU Città della Salute e della Scienza di Torino.

FACULTY

Eloise Beggiato, SC Ematologia, AOU Città della Salute e della Scienza di Torino.

Matteo Bellia, SCDU Ematologia, AOU Maggiore della Carità, Novara.

Eleonora Boscaro, SC Ematologia, AOU Città della Salute e della Scienza di Torino.

Benedetto Bruno, SC Ematologia Universitaria, AOU Città della Salute e della Scienza di Torino - Università degli Studi di Torino.

Daniela Cilloni, SCDU Ematologia, AO Ordine Mauriziano di Torino.

Bruno Fattizzo, Dipartimento di Ematologia e Emato-Oncologia, Università degli Studi di Milano; Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milano.

Simone Ferrero, SC Ematologia Universitaria, AOU Città della Salute e della Scienza di Torino - Università degli Studi di Torino

Chiara Frairia, SC Ematologia, AOU Città della Salute e della Scienza di Torino.

Roberto Freilone, SC Ematologia, AOU Città della Salute e della Scienza di Torino.

Gianluca Gaidano, SCDU Ematologia, AOU Maggiore della Carità - Università degli Studi di Novara.

Valentina Gai, SC Ematologia, AOU Città della Salute e della Scienza di Torino.

Monia Marchetti, SC Ematologia, Azienda Ospedaliera-Universitaria di Alessandria.

Andrea Patriarca, SS Innovazione clinica e terapeutica in Ematologia, AOU Maggiore della Carità, Novara.

Giuseppina Prato, SC Anatomia e Istologia patologica 1U, AOU Città della Salute e della Scienza di Torino

Davide Rapezzi, SC Ematologia, AO S. Croce e Carle, Cuneo.

Matilde Scaldaferrì, SC Farmacia Ospedaliera, AOU Città della Salute e della Scienza di Torino.

Gianluca Ubezio, UOC Medicina Trasfusionale, IRCCS Ospedale Policlinico San Martino - Università degli Studi di Genova.

Candida Vitale, SC Ematologia Universitaria, AOU Città della Salute e della Scienza di Torino.

PROVIDER ECM E SEGRETERIA ORGANIZZATIVA

HealthData Consulting S.r.l.
via Morghen 27, 10143 Torino
P.IVA 01429280058
Tel. 011.0267950 - Fax 011.0267954
segreteria@hdcons.it

SEDE E DATA

- Starhotels Majestic corso Vittorio Emanuele II 54, Torino
- 8 giugno 2026

PARTECIPANTI

L'accesso al corso è riservato a **30 Medici chirurghi** (Ematologia, Oncologia, Medicina interna, Anatomia patologica, Genetica medica, Medicina trasfusionale, Patologia clinica) e **Farmacisti ospedalieri**, a titolo gratuito.

VERIFICA FINALE E CREDITI ECM

Al termine dell'incontro i partecipanti dovranno compilare un questionario a risposte multiple, le cui domande sono basate sugli argomenti trattati.

L'acquisizione dei Crediti Formativi è subordinata alla presenza al 100% dei lavori. E' inoltre obbligatoria la firma della presenza e la compilazione del Questionario di Valutazione.

PROGRAMMA SCIENTIFICO PRELIMINARE

9:00 Iscrizione e registrazione ECM

9:30 Obiettivi del corso (**R. Freilone**)

SESSIONE I – Emoglobinuria parossistica notturna (Moderatori: B. Bruno, G. Gaidano)

9:50 Fisiopatologia del complemento (**B. Fattizzo**)
10:10 La diagnostica laboratoristica dell'EPN (**G. Prato**)
10:30 Inquadramento clinico di EPN (**V. Giai**)
10:50 Discussione plenaria
11:20 Pausa caffè

SESSIONE II – Malattia da agglutinine fredde (Moderatori: B. Bruno, G. Gaidano)

11:40 La diagnostica laboratoristica della CAD (**G. Ubezio**)
12:00 Inquadramento clinico della CAD (**A. Patriarca**)
12:20 Discussione plenaria
13:00 Pausa pranzo

SESSIONE III – EPN e CAD (Moderatori: R. Freilone, D. Cilloni)

14:00 Terapia standard nell'EPN (**E. Beggiato**)
14:20 Nuovi farmaci nell'EPN (**V. Giai**)
14:40 Terapia standard della CAD (**C. Vitale**)
15:00 Nuove terapie per la CAD (**C. Frairia**)
15:20 La metodologia delle linee guida nelle terapie anti-complemento (**M. Marchetti**)
15.40 Il punto di vista del Farmacista Ospedaliero (**M. Scaldaferrì**)

16:00 Discussione plenaria
16:20 Presentazione e discussione interattiva di casi clinici:

- Caso clinico 1 (**D. Rapezzi**)
- Caso clinico 2 (**M. Bellia**)
- Caso clinico 3 (**E. Boscaro**)
- Caso clinico 4 (**S. Ferrero**)

17:20 Conclusioni
17:30 Questionario ECM e valutazione evento

La Dott.ssa Eloise Beggiato è una Ematologa e Dirigente Medico presso la SC Ematologia U dell'Azienda Ospedaliera Città della Salute e della Scienza di Torino (Molinette). Specializzata nella diagnosi e trattamento delle malattie mieloproliferative, ha esperienza nella gestione di protocolli clinici sperimentali e si occupa anche di emoglobinuria parossistica notturna.

- **Ruolo Attuale:** Dirigente Medico Ematologia Universitaria, Ospedale Molinette di Torino.
- **Formazione:** Laurea in Medicina e Chirurgia, formazione presso l'Università degli Studi di Torino.
- **Competenze:** Malattie mieloproliferative acute e croniche, protocolli terapeutici, trattamenti sperimentali.
- **Attività Scientifica/Professionale:** Partecipazione come esperta in trasmissioni di sanità (Eccellenze in Sanità), gestione di studi clinici, e collaborazione per la cura di malattie rare del sangue

CURRICULUM VITAE



INFORMAZIONI PERSONALI



Cognome e Nome

BELLIA MATTEO

Codice Fiscale

BLLMTT97P01D332F

Indirizzo

Corso del popolo 10 – 28845 Domodossola (VB) Italia

Telefono

+39 3465988355

E-mail

mbelli9787@gmail.com matteo.bellia@uniupo.it

Cittadinanza

Italiana

Data e Luogo di nascita

01/09/1997 Domodossola (VB)

Sesso

M

OCCUPAZIONE

Medico in Formazione Specialistica in Ematologia
PhD in Scienze e Biotecnologie Mediche

ESPERIENZA LAVORATIVA

- Dal 10/2022

Medico in Formazione Specialistica in Ematologia
SCDU Ematologia, AOU Maggiore della Carità di Novara

- 10/2018 – 06/2022

Dottorando in Scienze e Biotecnologie Mediche: PhD titolo conseguito in data 26/02/2026
Dipartimento di Medicina Traslazionale, Università del Piemonte Orientale, Novara

Tirocinante di Medicina e Chirurgia
AOU Maggiore della Carità, Novara
Ospedale sant'Andrea di Vercelli

- 2019 – 2020

Ciclista Professionista
2019: Società Biesse Carrera (sede della Società Gavardo (BS), Italia)
2020: Società Akros Excelsior Thomus (sede della Società Gerlfagingen (SO), Svizzera)

ISTRUZIONE E FORMAZIONE

- 2024

Advanced Scientific English Course “Grant Writing and Stage Presentation”

- 2023

Advanced Medical English Writing: C1 level

- 2023

ICH Good clinical practice E6 (R2)

- 2016 – 2022

Laurea in Medicina e Chirurgia, Università del Piemonte Orientale, Novara
Laura magistrale a ciclo unico conseguita nel 2022 con la votazione 110/110 e lode

- 2011 - 2015
- 2015
- 2015
- 2013

Diploma di Scuola secondaria Superiore ad indirizzo Liceo Scientifico
Liceo Scientifico Giorgio Spezia, Domodossola (VB), Italia
Diploma conseguito nel 2015 con la votazione 100/100 e lode
Diplôme d'études en langue française DELF B2

First Certificate in English B2 level

ECDL (European Computer Driving Licence)

COMPETENZE PERSONALI

Madrelingua

Altre lingue

ITALIANO

INGLESE (fluente, buone capacità di espressione verbale, comprensione orale, lettura
E scrittura)

FRANCESE (fluente, buone capacità di espressione verbale, comprensione orale, lettura
E scrittura)

COMPETENZE RELAZIONALI

Capacità organizzativa
Attitudine alla collaborazione ed al lavoro di gruppo
Capacità comunicativa, empatia

COMPETENZE TECNICHE

- Pubblicazioni

Moia R, di Terzi Bergamo L, Talotta D, Bomben R, Forestieri G, Spina V, Bruscazzin A, Cosentino C, Almasri M, Dondolin R, Bittolo T, Zucchetto A, Baldoni S, Del Giudice I, Mauro FR, Maffei R, Chiarenza A, Tafuri A, Laureana R, Del Principe MI, Zaja F, D'Arena G, Olivieri J, Rasi S, Mahmoud A, Al Essa W, Awikeh B, Kogila S, **Bellia M**, Mouhssine S, Sportoletti P, Marasca R, Scarfò L, Ghia P, Gattei V, Foà R, Rossi D, Gaidano G. XPO1 mutations identify early-stage CLL characterized by shorter time to first treatment and enhanced BCR signalling. *Br J Haematol* 2023 Nov;203(3):416-425. doi: 10.1111/bjh.19052. Epub 2023 Aug 14.

Riccardo Dondolin; **Matteo Bellia**; Silvia Rasi; Clara Deambrogi; Donatella Talotta; Samir Mouhssine; Wael Al Essa; Abdurraouf Mokhtar Mahmoud; Danilo Faraci; Gianluca Gaidano; Riccardo Moia. Prognostic value of clonal evolution identified by sequential FISH in chronic lymphocytic leukaemia. *J Cancer Metastasis Treat* 2024; 10:2. doi:10.20517/2394-4722.2023.131

Moia R, Talotta D, Terzi Di Bergamo L, Almasri M, Dondolin R, Salehi M, Cosentino C, Soscia R, Della Starza I, Bruscazzin A, Andorno A, Mercalli F, Cresta S, Bomben R, Bittolo T, Vit F, Bulian P, Zucchetto A, Bruna R, Rivolta GM, Schipani M, Secomandi E, Kogila S, **Bellia M**, Mouhssine S, Nabki J, Al Deeban B, Ghanej J, Cividini L, Maher N, Melle F, Motta G, Leutner M, Lorenzi A, Mahmoud AM, Al Essa W, Deambrogi C, Rasi S, Petrucci L, Boldorini RL, Di Rocco A, Del Giudice I, Spina M, Palazzolo S, Canal F, Canzonieri V, Martelli M, Pileri S, Gattei V, Foà R, Rossi D, Gaidano G. Molecular clustering on ctDNA improves the prognostic stratification of patients with DLBCL compared with ctDNA levels. *Blood Adv*. 2025 Apr 8;9(7):1692-1701

Dondolin R, Garrou F, Almasri M, Terzi Di Bergamo L, Cosentino C, Bruscazzin A, Salehi M, Talotta D, Bruna R, Rivolta GM, **Bellia M**, Nabki J, Al Deeban B, Cividini L, Mouhssine S, Maher N, Ghanej J, Maiellaro F, Andorno A, Mercalli F, Leutner M, Lorenzi A, Mahmoud AM, Al Essa W, Diop NM, Secomandi E, Deambrogi C, Rasi S, Boldorini RL, Gentile M, Palumbo GA, Gattei V, Foà R, Rossi D, Sacchetti GM, Gaidano G, Moia R. Integration of [¹⁸F]FDG-PET radiomics with liquid biopsy improves outcome prediction in newly diagnosed diffuse large B-cell lymphoma. *Leukemia*. 2025 Sep;39(9):2207-2214

Schipani M, Bellia M, Sella C, Dondolin R, Greco M, Mahmoud AM, Deambrogi C, Moia R, Gaidano G, Bruna R. Bispecific Monoclonal Antibodies in Diffuse Large B-Cell Lymphoma: Dawn of a New Era in Targeted Therapy. *Cancers (Basel)*. 2025 Oct 8;17(19):3258

Nabki J, Al Deeban B, Meari Sium A, Cosentino C, Almasri M, Awikeh B, Maher N, Bellia M, Dondolin R, Mouhssine S, Talotta D, Secomandi E, Kogila S, Ghanej J, Maaiellaro F, Cividini L, Rasi S, Bomben R, Vit F, Bittolo T, Zucchetto A, Gattei V, Gaidano G, Moia R. Immunoglobulin light chain mutational status refines IGHV prognostic value in identifying chronic lymphocytic leukemia patients with early treatment requirement. *Leukemia*. 2025 Mar;39(3):643-649

Sacchetti S, Bellia M, Vidali M, Zanotti V, Giacomini L, Gaidano G, Patriarca A, Dianzani U, Rolla R. Comparative analysis of the performance of automated digital cell morphology analyzers for leukocyte differentiation in hematologic malignancies: Mindray MC-80 versus West Medical Vision Hema. *Int J Lab Hematol*. 2025 Aug;47(4):643-650

Bellia M, Moia R, Schipani M, Sella C, Greco M, Al Essa W, Mahmoud AM, Gaidano G, Patriarca. Innovative Use of Foastamatinib in Managing Refractory Immune Thrombocytopenia in an HIV-Positive Patients: A Case Report. *Clin Case Rep*. 2025 Jun 26;13(7):e70577

Sacchetti S, Bellia M, Zanotti V, Giacomini L, Rolla R. Detection of a lymphoproliferative disorder with suspected scattergram analysis using the Mindray BC-6800 plus automated hematology analyzer: a case report. *Int J Lab Hematol*. 2025 Jun;47(3):373-375

Bellia M, Greco M, Lunghi M, Moia R, Gaidano G, Patriarca A. A rare case of life-threatening jaundice caused by Epstein-Barr Virus infection and secondary cold agglutinin syndrome successfully treated with rituximab. *Int Med Case Rep J*. 2024 Oct 22;17:861-867

- Peer Reviewer

Esperienza di peer reviewer per case report della rivista Clinical Case Reports

- Congressi

29th European Hematology Association (EHA) congress dal 13 al 16 giugno 2024 a Madrid, Spagna

“Aggiornamento su diagnosi e terapia delle emoglobinopatie” congresso il 06 giugno 2024 Cuneo (CN), Italia

NET2TREAT, un percorso di identificazione e presa in carico urgente del paziente con BDPCN congresso il 10 maggio 2024, Torino (TO), Italia

Hematology Passport congress on-line sulle sindrome mielodisplastiche e malattie mieloproliferative dal 5 al 6 luglio 2023, Milano (MI), Italia.

“Progressi in Ematologia: I giovani come protagonisti” congresso dal 22 al 23 giugno 2023, Napoli (NA), Italia

“Beclose2 Hematology: creating new connections” congress dal 4 al 5 maggio 2023, Roma (RO), Italia.

Workshop of Clinical Research Methodology and Public Health il 20 e 27 gennaio 2023, Il 10 e 17th febbraio 2023, Novara (NO), Italia.

Dati personali

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali" e del Regolamento UE 2016/679.e ss.mm.i.

In fede

Matteo Bellia

DICHIARAZIONE SOSTITUTIVA DI CERTIFICAZIONE (ai sensi degli Artt. 46 e 47 D.P.R. 28/12/2000, n. 445)

Il sottoscritto Bellia Matteo, consapevole delle sanzioni penali, nel caso di dichiarazioni non veritiere, di formazione o uso di atti falsi, richiamate dall'art. 76 del D.P.R. 445 del 28/12/2000, si assume la responsabilità di quanto indicato nel seguente curriculum, composto da N. 3 pagine compresa la presente, sottoscrivendo tale dichiarazione e sottoscrivendo in calce il curriculum stesso.

Novara, 18/03/2026

Il Dichiarante

Matteo Bellia

Eleonora Boscaro è una medica chirurga operante a Torino, specializzata in Ematologia presso la divisione di Oncologia dell'Azienda Ospedaliera Città della Salute e della Scienza (Presidio Molinette). Il suo profilo scientifico include pubblicazioni nel campo emato-oncologico.

Dettagli Professionali Principali:

- **Ruolo:** Medical Doctor / Ematologa.
- **Affiliazione:** Azienda Ospedaliera Città della Salute e della Scienza, Torino (Presidio Molinette).
- **Area di Ricerca:** Ematologia, oncologia.
- **Pubblicazioni:** Risulta attiva con pubblicazioni scientifiche

- **Benedetto BRUNO, MD, PhD**



Biographical Sketch

CURRENT POSITION AND AFFILIATIONS (2022 to date): Director, Division of Hematology and Cell Therapy Unit, University of Torino, AOU Città della Salute e della Scienza di Torino, Professor of Hematology, Department of Molecular Biotechnology and Health Sciences, School of Medicine, University of Torino, Torino, Italy

2022 to date Director Laboratory of Clinical and Translational Research in Hematology, AOU Città della Salute e della Scienza di Torino and University of Torino, Torino, Italy,

2021-2022 Myeloma Transplant and Immune and Cell Therapy (Program Coordinator) - Blood and Marrow Transplant and Cellular Therapy Program - NYU Grossman School of Medicine - Perlmutter Cancer Center - NYU Langone Health/ New York, NY

2020-2022 Professor of Medicine (Clinical) - Division of Hematology and Medical Oncology - NYU Grossman School of Medicine - Perlmutter Cancer Center - NYU Langone Health / New York, NY

2018-2020 Deputy Director, Educational Activity, Department of Molecular Biotechnology and Health Sciences, School of Medicine, University of Torino, Torino, Italy

2014-2020 Associate Professor of Hematology, Division of Hematology, A.O.U. Città' della Salute e della Scienza di Torino, Presidio Molinette, University of Torino and Department of Molecular Biotechnology and Health Sciences, School of Medicine, University of Torino, Torino, Italy

2013-2020 Program Head, Bone Marrow Transplantation Unit (CIC-231- To01), Azienda Ospedaliera Universitaria Città della Salute e della Scienza, and School of Medicine, University of Torino, Italy

2007 – Visiting Professor – Bone Marrow Transplant Unit – Stanford University – Stanford – CA - USA

1999 – 2014 Assistant Professor of Hematology, Department of Hematology, Bone Marrow Transplantation Unit, School of Medicine, University of Torino, Torino, Italy, Department of Hematology, School of Medicine, University of Turin, Italy

1995-1999 Visiting Physician and Visiting Investigator on Inpatient and Outpatient Services, and Department of Transplantation Biology, The Fred Hutchinson Cancer Research Center, Seattle, WA

BOARD CERTIFICATIONS:

1991 Italian Board Examination for M.D.

1995 Italian Board of Hematology

1995-1997 Nominated Oncology Specialist for a Limited License to Practice Medicine as a Fellow in the State of Washington

2000 Doctorate in Experimental Hematology

2020 Full Medical License – State of New York – USA - #303804 (active)

SOCIETY MEMBERSHIPS:

Member, Italian Society of Hematology

Member, Italian Society of Experimental Hematology

Member, Italian Group for Bone Marrow Transplantation and Cell Therapies (GITMO) Member, European Group for Blood and Marrow Transplantation (EBMT)

Member American Society for Blood and Marrow Transplantation (ASBMT)

Member American Society of Hematology (ASH)

FUNDING ID (PAST 5 YERS)

M.I.U.R. (Ministry of University and Scientific Research) Research Grants (2018-2023):

1. Role of Plasmatic Extracellular vesicles as biomarkers of inflammatory and endothelial complications after hematopoietic stem cell transplantation
2. Plasmatic Extracellular Vesicles in Cytomegalovirus reactivation and acute Graft Versus Host Disease after Haploidentical Stem Cell Transplantation
3. Plasmatic Extracellular Vesicles as potential biomarkers of viral infection and endothelial complications after allogeneic stem cell transplantation
4. Extracellular vesicles as potenzial biomarkers of chronic GVHD"

Unrestricted grant support form Companies:

1. Integrating Next Generation Sequencing in minimal residual disease and prognosis stratification of acute myeloid leukemia and high risk myelosplastic syndromes patients. (JANSSEN/CILAG)
2. Efficacy of the biosimilar filgrastim Nivestim on the mobilization of hematopoietic CD34+ cells and on the kinetics of engraftment after high dose chemotherapy and mobilized peripheral hematopoietic cell support. (HOSPIRA ITALIA SRL)

Progetti di Rilevante Interesse Nazionale (PRIN) – M.I.U.R.

1. Bando Prin 2022 PNRR – Settore LS7 – Endothelial cell dysfunction and extracellular vesicles as biomarkers of clinical outcomes (toxicity and disease responses) after chimeric antigen receptor (CAR) T-cell therapy for lymphoproliferative diseases.

SELECTED PUBLICATIONS (Total no. >250, H index 58, Citations>11000)

- 1) **Bruno B**, Goerner MA, Nash RA, Storb R, Kiem HP, McSweeney PA. Purified canine CD34+Lin-marrow cells transduced with retroviral vectors give rise to long-term multi-lineage hematopoiesis. **Biol Blood Marrow Tr.** 2001;7:543-51. doi: **10.1016/s1083-8791(01)70020-1**
- 2) **Bruno B**, Rotta M, Patriarca F, Mordini N, Allione B, Carnevale-Schianca F, Giaccone L, Sorasio R, Omedè P, Baldi I, Bringhen S, Massaia M, Aglietta M, Levis A, Gallamini A, Fanin R, Palumbo A, Storb R, Ciccone G, Boccadoro M. A comparison of allografting with autografting for newly diagnosed myeloma. **New Engl J Med.** 2007; 356:1110-20. doi: **10.1056/NEJMoa065464**
- 3) **Bruno B**, Rotta M, Patriarca F, Mattei D, Allione B, Carnevale-Schianca F, Sorasio R, Rambaldi A, Casini M, Parma M, Bavaro P, Onida F, Busca A, Castagna L, Benedetti E, Iori AP, Giaccone L, Palumbo A, Corradini P, Fanin R, Maloney D, Storb R, Baldi I, Ricardi U, Boccadoro M. Non-myeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo. **Blood.** 2009;113:3375-82. doi: **10.1182/blood-2008-07-167379**
- 4) Giaccone L, Storer B, Patriarca F, Rotta M, Sorasio R, Allione B, Carnevale-Schianca F, Festuccia M, Brunello L, Omedè P, Bringhen S, Aglietta M, Levis A, Mordini N, Gallamini A, Fanin R, Massaia M, Palumbo A, Ciccone G, Storb R, Gooley TA, Boccadoro M, **Bruno B**. Long-term follow-up of a comparison of nonmyeloablative allografting with autografting for newly diagnosed myeloma. **Blood.** 2011;117:6721-7. doi: **10.1182/blood-2011-03-339945**
- 5) Lia G, Brunello L, Bruno S, Carpanetto A, Omedè P, Festuccia M, Tosti L, Maffini E, Giaccone L, Arpinati M, Ciccone G, Boccadoro M, Evangelista A, Camussi G, **Bruno B**. Extracellular vesicles as potential biomarkers of acute graft-vs-host disease. **Leukemia.** 2018;32:765-773. doi: **10.1038/leu.2017.277**
- 6) Mariotti J, Raiola AM, Evangelista A, Carella AM, Martino M, Patriarca F, Risitano A, Bramanti S, Busca A, Giaccone L, Brunello L, Merla E, Savino L, Loteta B, Console G, Fanin R, Sperotto A, Marano L, Marotta S, Frieri C, Sica S, Chiusolo P, Harbi S, Furst S, Santoro A, Bacigalupo A, Blaise D, Angelucci E, Mavilio D, Castagna L, **Bruno B**. Impact of donor age and kinship on clinical outcomes after T-cell-replete haploidentical transplantation with PT-Cy. **Blood Adv.**

2020;4:3900-3912. doi: [10.1182/bloodadvances.2020001620](https://doi.org/10.1182/bloodadvances.2020001620)

- 7) **Bruno B**, Wäsch W, Engelhardt M, Gay F, Giaccone L, D'Agostino M, Rodríguez-Lobato LG, Danhof S, Gagelmann N, Kröger N, Popat, van de Donk NWCJ, Terpos E, Dimopoulos MA, Sonneveld P, Einsele H, Boccadoro M. European Myeloma Network Perspective on CAR T-Cell Therapies for Multiple Myeloma. **Haematologica**, 2021;106:2054-2065. doi: [10.3324/haematol.2020.276402](https://doi.org/10.3324/haematol.2020.276402)
- 8) Lia G, Di Vito C, Bruno S, Tapparo M, Brunello L, Santoro A, Mariotti J, Bramanti S, Zaghi E, Calvi M, Comba L, Fasci M, Giaccone L, Camussi G, Castagna L, Evangelista A, Mavilio D, **Bruno B**. Extracellular Vesicles as Biomarkers of acute Graft-vs.-host Disease after Haploidentical Stem Cell Transplantation and Post-transplant Cyclophosphamide. **Front in Immunol** ;12:816231. doi: [10.3389/fimmu.2021.816231](https://doi.org/10.3389/fimmu.2021.816231)
- 9) Rejeski K, Subklewe M, Aljurf M, Bachy E, Balduzzi AC, Barba P, **Bruno B**, Benjamin R, Carrabba MG, Chabannon C, Ciceri F, Corradini P, Delgado J, Di Blasi R, Greco R, Houot R, Iacoboni G, Jaeger U, Kersten MJ, Mielke S, Nagler A, Onida F, Peric Z, Roddie C, Ruggeri A, Sanchez-Guijo FM, Sánchez-Ortega I, Schneidawind D, Schubert ML, Snowden J, Thieblemont C, Topp MS, Zinzani PL, Gribben JG, Bonini C, Sureda Balari A, Yakoub-Agha I. Immune Effector Cell-Associated Hematotoxicity (ICAHT): EHA/EBMT Consensus Grading and Best Practice Recommendations. **Blood**. 2023. doi: [10.1182/blood.2023020578](https://doi.org/10.1182/blood.2023020578).
- 10) Levis MJ, et al Gilteritinib as Post-Transplant Maintenance for Acute Myeloid Leukemia With Internal Tandem Duplication Mutation of *FLT3*. **J Clin Oncol**. 2024 Mar 12;JCO2302474. doi: [10.1200/JCO.23.02474](https://doi.org/10.1200/JCO.23.02474).

Torino 18 aprile 2024



Il sottoscritto è a conoscenza che, ai sensi dell'art. 76 del DPR 445/2000, le dichiarazioni mendaci, la falsità negli atti e l'uso di atti falsi sono puniti ai sensi del codice penale e delle leggi speciali. Inoltre, il sottoscritto autorizza al trattamento dei dati personali ai sensi dell'art. 13 GDPR 679/16 – "Regolamento europeo sulla protezione dei dati personali")



Curriculum Vitae Europeo

Informazioni personali

Cognome/Nome **Cilloni Daniela**
Indirizzo Via Mombasiglio 37 10136 TORINO
Telefono 0115085521
E-mail daniela.cilloni@unito.it
Cittadinanza Italiana
Data di nascita 26 gennaio 1970
Sesso Femminile

Mobile: 333 2818086

Posizione attuale

Professore Ordinario di Ematologia , Dipartimento di Scienze Cliniche e Biologiche , Università degli Studi di Torino

Direttore SCU di Ematologia e Terapie cellulari Ospedale Umberto I Ordine Mauriziano-TO

Attività clinica

1993-1996: Allieva Interna presso la Clinica di Patologia Medica diretta dal Prof U. Mazza.

Dal 1998 al 2004 ha svolto attività clinico-assistenziale presso la Clinica di Medicina Interna II diretta dal Prof. G. Saglio in qualità di specializzanda fino a 2000 e di dottoranda fino al 2004.

Dal 1/8/2003 al 31/01/2004 e dal 15/02/2004 al 15/12/2004 è stata titolare di Contratti di Collaborazione Coordinata e Continuativa con l'Azienda Ospedaliera S.Luigi di Orbassano- Torino per lo svolgimento di attività clinico-assistenziale presso la divisione di Medicina Interna II diretta dal prof. G. Saglio.

Dal 28/12/2004 ad oggi svolge attività clinica presso la Clinica di Medicina Interna II diretta dal Prof. G. Saglio in qualità di ricercatore di Medicina Interna convenzionato con l'ASO S. Luigi come dirigente medico di I° livello.

Dal 2012 al 2022 è responsabile del centro trapianti di midollo presso la struttura di Medicina Interna II a indirizzo ematologico AOU San Luigi Orbassano

E' responsabile di diversi protocolli sperimentali nazionali e internazionali per il trattamento delle leucemie acute, sindromi mielodisplastiche e malattie mieloproliferative croniche Ph negative.

Attività scientifica

- Dal 1996 al 1998 si è recata per uno stage formativo presso l'Istituto di Ematologia dell'Università di Parma diretto dal Prof. V. Rizzoli. Durante tale periodo ha svolto attività di ricerca presso il laboratorio di Biologie Cellulare diretto dal Prof. Carmelo Carlo-Stella.
- Dal 1998 ad oggi svolge attività di ricerca presso il laboratorio di Biologia e Oncologia Molecolare, Dipartimento di Scienze Cliniche e Biologiche dell'Università di Torino, diretto dal Prof. Saglio.
- Autore di 203 lavori scientifici su riviste dotate di IF su temi di particolare interesse nell'ambito dell'ematologia e di oltre 400 abstracts presentati a congressi internazionali. H index =46 (calcolato con scopus)
- Socio ordinario della Società Italiana di Ematologia Sperimentale (SIES)
- Socio ordinario della Società Italiana di Ematologia (SIE)
- Socio ordinario della American Society of Hematology (ASH)
- Socio ordinario della American Association for Cancer Research (AACR)
- Membro del consiglio direttivo della Società Italiana di Ematologia Sperimentale (SIES) dal 2008 al 2012
- Dal 2022 membro della CAF della società italiana di ematologia
-
- **Titolare dei seguenti grants:**
- 1999: titolare di grant dall'Università di Torino nell'ambito del "progetto giovani ricercatori" per lo studio dal titolo "cinetica di mobilitazione delle cellule staminali mesenchimali"
- 2000: titolare di grant dall'Università di Torino nell'ambito del "progetto giovani ricercatori" per lo studio dal titolo "Studio del pattern di espressione del gene WT1 come marcatore tumorale nelle leucemie".
- 2001: titolare di grant dall'Università di Torino nell'ambito del "progetto giovani ricercatori" per lo studio dal titolo "studio del ruolo del gene della mieloblastina nel processo differenziale dei progenitori emopoietici.
- 2005, 2006, 2007, 2008, 2009 Titolare di grants dell'Università di Torino (ex fondi 60%)
- 2005, 2006, 2007, 2008, 2009: Titolare di grants della regione Piemonte
- 2008: Titolare di finanziamento Prin.
- 2010-2015: Titolare di finanziamento AIRC 5 per Mille
- 2016, 2017, 2018, 2019 titolare dei fondi RILO università degli studi di Torino
- 2023 Titolare del Grant PRIN-PNRR
- 2024: PI del Grant PRIN-PNRR
- **Titolare dei seguenti brevetti:**
- Brevetto per invenzione industriale TO2007A000401/1379715 del 7/6/2007 dal titolo: vaccino Vaccino Anti-tumorale "
- Brevetto dal titolo: "Sviluppo del test diagnostico per la rivelazione e quantificazione in Real-time PCR del gene Menigioma 1 (MN1) come marcatore molecolare in pazienti affetti da Leucemia Mieloide Acuta (LAM).
- Brevetto n 102016000042586 del 01-06-2016 dal titolo: "procedimento per la rilevazione di mutazioni di tipo I e II del gene calreticulina (CALR)

Attività didattica

- Brevetto n PO20528IT-01 dal titolo : kit per la rilevazione delle mutazioni R140Q e R172K del gene IDH2
- 2004-2010 Titolare della disciplina di Fisiopatologia Molecolare I e II- Terapie Biotecnologiche in Medicina Interna- Corso di Laurea di II livello in Biotecnologie Molecolari, Università degli Studi di Torino
- 2004-2007 Titolare della disciplina di Medicina Interna – Area di Metodologia Clinica- II° Scuola di Specializzazione in Medicina Interna- Università degli Studi di Torino, Polo S. Luigi
- 2006-2008 Titolare del corso di Medicina d'urgenza presso Facoltà di Medicina e Chirurgia San Luigi Gonzaga, corso di Laurea Infermieristica, Cuneo.

Dal 2000 ad oggi ha seguito in qualità di tutore oltre 30 tesisti del corso di laurea in Medicina e Chirurgia, Biotecnologie Mediche, Scienze Biologiche, di specializzazione in medicina Interna e di Dottorato di Ricerca.

Attività didattica

Insegnamenti al corso di Laurea in Medicina e Chirurgia

- Ha svolto attività di didattica integrativa nell'ambito del corso di Medicina Interna I e II e Metodologia Clinica della Facoltà di Medicina e Chirurgia e dell'Università di Torino negli anni accademici 2000-2001, 2001-2002, 2002-2003, 2003-2004.
- Dall'anno 2004 al 2019 titolare della disciplina di Immunologia Clinica- Corso di Laurea in Medicina e Chirurgia. Università degli Studi di Torino.
- Dall'anno accademico 2019-2020 titolare del corso di "Hematology" English Course. School of Medicine, University of Turin.
- Dall'anno accademico 2020-2021 coordinatore del corso "Hematology, Infectious diseases and dermatology", English Course. Medicine and Surgery, University of Turin.

Insegnamenti al corso di Laurea in Biotecnologie Molecolari e Biotecnologie Mediche e Biotecnologie Applicate alla Sanità umana e Animale

- Dall'anno accademico 2004-2005 all'anno 2010-2011 titolare della disciplina di Fisiopatologia Molecolare I e II- Terapie Biotecnologiche in Medicina Interna- Corso di Laurea di II livello in Biotecnologie Molecolari, Università degli Studi di Torino
- Dall'anno accademico 2004-2005 all'anno 2009-2010 Titolare della disciplina di Fisiopatologia Molecolare – Corso integrato di diagnostiche Biotecnologiche- Corso di Laurea di II livello in Biotecnologie Mediche, Università degli Studi di Torino
- Dall'anno 2005-2006 all'anno 2007-2008 Titolare del corso integrato di Metodiche Biotecnologiche avanzate II- modulo "Meccanismi molecolari alla base di patologie umane, aree di diagnosi e intervento" Corso di Laurea in Biotecnologie Applicate alla Sanità umana e Animale, Università degli Studi di Torino

Insegnamenti a Scienze Infermieristiche

- Dal 2009 al 2011 titolare del corso di Medicina d'urgenza presso la Scuola di Scienze Infermieristiche-sede di Cuneo

Insegnamenti presso la Scuola di Dottorato di Ricerca

- Dal 2010 ad oggi docente presso la Scuola di Dottorato di Medicina e Terapia Sperimentale, Università degli Studi di Torino.
- 2016: controrelatore di tesi di dottorato, Università degli Studi di Antwerpen, Belgio.
- Dal 2019 referee esterno per le tesi di dottorato in Oncologia, Ematologia e Patologia. Presso Università di Bologna
- Dal 2020 referee esterno per le tesi di dottorato, Università degli Studi di Perugia

Insegnamenti presso le Scuole di Specializzazione

- Dall'anno 2004-2005 all'anno 2007-2008 docente di Medicina Interna- Area di Metodologia Clinica- II° Scuola di Specializzazione in Medicina Interna- Università degli Studi di Torino, Polo S. Luigi
- Dall'anno 2014 docente alla scuola di Specializzazione in Ematologia Università degli Studi di Torino
- Dall'anno 2019 docente alla scuola di Specializzazione in Oncologia. Università degli Studi di Torino
- Dall'AA 2020-2021 docente dell'insegnamento di ematologia alla Scuola di Specializzazione in Genetica Medica. Università degli Studi di

Torino

Attività clinica

Dal 1995 ha svolto attività clinica presso la Clinica di Medicina Interna II diretta dal Prof. G. Saglio in qualità prima di specializzanda, poi dal 2004 di ricercatore convenzionato con l'ASO S. Luigi come dirigente medico di 1° livello., dal 2014 come professore associato di ematologia

Da gennaio 2012 al 2021 è stata responsabile di programma dell'unità di trapianto di midollo autologo e allogenico presso la SCU di Medicina Interna I e Ematologia dell'azienda San Luigi Gonzaga-Orbassano -Torino all'interno del centro trapianti metropolitano TO2 di Torino

Da Novembre 2020 Direttore della SCU di ematologia, Ospedale Mauriziano.

PI di oltre 100 studi clinici di fase II-III e IV per il trattamento delle leucemie acute sindromi mielodisplastiche, malattie mieloproliferative coniche e trapianto di cellule staminali.

Istruzione e formazione

Data

2004

Titolo della qualifica rilasciata

Dottorato di ricerca in Farmacologia e terapie sperimentali e cliniche

Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione

Università di Torino - Facoltà di Medicina e Chirurgia - Corso Bramante 88 - 10126 TORINO

Data

2000 Specializzazione in Medicina Interna

Titolo della qualifica rilasciata

Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione

Università di Torino - Facoltà di Medicina e Chirurgia - Corso Bramante 88 - 10126 TORINO

Data

1995

Titolo della qualifica rilasciata

Laurea in Medicina e Chirurgia con voto 110/110 e lode

Nome e tipo d'organizzazione erogatrice dell'istruzione e formazione

Università di Torino - Facoltà di Medicina e Chirurgia - Corso Bramante 88 - 10126 TORINO

Training GCP R2


09/09/2020

Capacità e competenze personali

Madrelingua	Italiano
Altre lingue	Inglese
Capacità di lettura	Ottima
Capacità di scrittura	Buona
Capacità di espressione orale	Buona

Autorizzo il trattamento dei dati personali ai sensi del. art.13 del D.Lgs n. 196/2003 sulla privacy ai sensi del GDPR e del decreto legislativo 30 giugno 2003 n 196 codice in materia di protezione dei dati personali ai fini di attività di ricerca e Selezione del personale e contratti lavorativi

Torino 23/04/2024



CURRICULUM VITAE

PERSONAL INFORMATION

NAME **FATTIZZO BRUNO**
ADDRESS Via S.Giovanni Battista De La Salle 10, 20132, Milano, Italia
PHONE **+39 3896873204**
MAIL **brunofattizzo@gmail.com**

NATIONALITY ITALIAN
D.O.B. 18/11/1987

EDUCATION AND POSITIONS

Education

- University of Milan. Degree of Specialization in Hematology (70/70) 2018
- University of Milan. Degree in Medicine (honor) 2012 Medicine
- Q. Ennio High School, Gallipoli (Lecce). High School Diploma (100/100) 2006

Positions

- University of Milan, Faculty of Medicine. Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan. **Practical Trainer** 1/3/2010 to 30/7/2012
- Department of Hematology. Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan. **Researcher and resident physician** 31/7/2012 to 8/8/2013
- University of Milan School of Specialty in Hematology Fondazione IRCCS **Resident** 2013 to 2018
- Department of Hematology. Hematology Unit and PNH trial Unit, directed by prof. G. Mufti. King's College Hospital, London. **Visiting scientist** 1/7/2017 to 1/1/2018.
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico of Milan. **Consultant Hematologist** 06/09/2018 ongoing
- University of Milan, Department of Oncology and Onco-Hematology. **University Researcher** 01/01/2020 ongoing

LANGUAGES

ENGLISH	
reading	VERY GOOD
writing	VERY GOOD
speaking	VERY GOOD
FRENCH	
reading	VERY GOOD
writing	VERY GOOD
speaking	GOOD
GERMAN	
reading	SUFFICIENT
writing	SUFFICIENT
speaking	SUFFICIENT

COMPUTER ABILITIES

Microsoft Office, European computer driving licence ECDL

AWARDS AND HONORS

- Research travel grant by European Hematology Association, aimed to attend the annual meeting and present original data on AIHA Madrid, annual meeting of the European Hematology association 2017. June 2017
- Research travel grant by British Society of Hematology, aimed to attend the annual meeting and present original data on PNH and AA . Liverpool, annual meeting of the British society of Hematology 2018. April 2018
- Research travel grant by European Hematology Association, aimed to attend the annual meeting and present original data on PNH. Stockholm, annual meeting of the European Hematology association 2018. June 2018
- Research travel grant by American Society of Hematology, aimed to attend the annual meeting and present original data on PNH. San Diego, annual meeting of the American Society of Hematology 2019. December 2019
- Research travel grant by European Hematology Association, aimed to attend the annual meeting and present original data on AIHA. Amsterdam, annual meeting of the European Hematology association 2019. June 2019

OTHER SCIENTIFIC ACTIVITIES

Speaker at international meetings

Red cell biology 30 years after, Milan 24-26 Sept 2015, Invited speaker: "Cases on hemolytic anemia".

Second Annual Symposium on Complement Immunotherapy, Miami 26-28 Jan 2018, Invited Speaker: "Role of complement inhibition in warm autoimmune hemolytic anemia"

Annual meeting of the British Society of Haematology, Liverpool 16-18 Apr 2018, Selected Speaker: "Prevalence of PNH clones and their clinical and prognostic significance in 3085 patients with cytopenia: a twenty-year single center experience".

Annual meeting of the British Society of Haematology, Liverpool 16-18 Apr 2018, Selected Speaker: "Eltrombopag in a real world cohort of aplastic anemia patients: large retrospective analysis of two UK centers".

Third Annual Symposium on Complement Immunotherapy, Miami 25-27 Jan 2019, Invited Speaker: "APL-2 in autoimmune hemolytic anemia: interim analysis from the phase 2 study and beyond"

Annual meeting of the British Society of Haematology, Glasgow 1-3 Apr 2019, Selected Speaker: "Inhibition of C3 with APL-2 Controls Hemolysis and Increases Haemoglobin Levels in Subjects with Autoimmune Haemolytic Anaemia (AIHA)".

Annual meeting of the European Hematology Association, Amsterdam 13-16 Jun 2019, Selected Speaker: "Inhibition of C3 with APL-2 controls haemolysis and increases haemoglobin levels in subjects with autoimmune haemolytic anaemai (AIHA)".

Annual meeting of the European Hematology Association, Amsterdam 13-16 Jun 2019, Selected Speaker: "Evidence based use of erythropoietin in patients with autoimmune hemolytic anemia: a multicenter international study".

Speaker at Italian meetings

Burning topics nell'anemia emolitica, Milano 8 Nov 2013, Invited Speaker: "Un caso clinico di AEA grave e refrattaria con associata ITP in terapia con TPO mimetico".

Under 40 in Hematology, Roma 13-14 Nov 2014, Selected Speaker: "25-OH Vitamin D and immunomodulatory cytokines in autoimmune cytopenias"

Under 40 in Hematology, Verona 17-18 Nov 2016, Selected Speaker: "Impact of Bone Marrow Fibrosis and Early Response on Outcome after Azacitidine Therapy in 94 Patients with Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Acute Myeloid Leukemia".

Società italiana di Ematologia, Roma 7-9 Oct 2017, Selected Speaker: "Clinical follow-up of 378 patients with autoimmune hemolytic anemia: prognostic impact of hemoglobin levels, autoantibody class, and reticulocytopenia at onset on the relapse risk and outcome".

Under 40 in Hematology, Roma 15-16 Nov 2018, Selected Speaker: "Valore predittivo e prognostico dei piccoli cloni di emoglobinuria parossistica notturna (PNH) in un'ampia coorte di pazienti con sindrome mielodisplastica (MDS) e anemia aplastica (AA): l'esperienza di un singolo centro".

"EPN 10 anni di storia", Bologna 5-6 Apr 2019, Invited Speaker: "I piccoli cloni in EPN quale risvolto clinico?".

Under 40 in Hematology, Milan 7-8 Nov 2019, Invited Speaker: "TPO stimulation: from megakaryopoiesis to immunomodulation".

Referee for peer reviewed journals

British Journal of Haematology, Blood Transfusion, British Medical Journal Case Reports, AJLM, Annals of Hematology, Nutrients, International Journal of Molecular Sciences, Journal of Clinical Medicine, Epidemiology

PUBBLICAZIONI

Peer reviewed publications (excluding abstracts) HI Scopus 9; HI Google Scholar: 11

- 1) Fattizzo B, Rosa J, Giannotta JA, et al. The Physiopathology of T- Cell Acute Lymphoblastic Leukemia: Focus on Molecular Aspects. *Front Oncol.* 2020 Feb; *In press*.
- 2) Fattizzo B, Barcellini W. Autoimmune Cytopenias in Chronic Lymphocytic Leukemia: Focus on Molecular Aspects. *Front Oncol.* 2020 Jan 10;9:1435.
- 3) Fattizzo B, Kulasekararaj AG. Second-Generation C5 Inhibitors for Paroxysmal Nocturnal Hemoglobinuria. *BioDrugs.* 2020 Jan 8.
- 4) Barcellini W, Fattizzo B, Zaninoni A. Management of refractory autoimmune hemolytic anemia after allogeneic hematopoietic stem cell transplantation: current perspectives. *J Blood Med.* 2019 Aug 8;10:265-278.
- 5) Cantoni S, Fattizzo B. Clinical course and management of adult-onset immune-mediated cytopenia associated with Kabuki syndrome. *Eur J Intern Med.* 2019 Aug 16. pii: S0953-6205(19)30273-0.
- 6) Fattizzo B, Levati G, Cassin R, Barcellini W. Eltrombopag in immune thrombocytopenia, aplastic anemia, and myelodysplastic syndrome: from megakaryopoiesis to immunomodulation. *Drugs* 2019 [In press].
- 7) Fattizzo B, Cavallaro F, Milesi G, Barcellini W. Iron mobilization in a real life cohort of aplastic anemia patients treated with eltrombopag. *Am J Hematol* 2019 [In press].
- 8) Fattizzo B, Kulasekararaj A, Hill A, et al. Clinical and morphologic predictors of outcome in older aplastic anemia patients treated with eltrombopag. *Haematologica* 2019 [In press].
- 9) Fattizzo B e Corradini P. Cap. 7 - Aplasia Midollari. *Manuale di EMATOLOGIA* III edizione 2019. Edizione Minerva Medica. Paolo Corradini e Robin Foà [In press]
- 10) Fattizzo B, Pasquale R, Carpenedo M, et al. Bone marrow characteristics predict outcome in a multicenter cohort of primary immune thrombocytopenia patients treated with thrombopoietin analogues. *Haematologica* 2019 [In press].
- 11) Barcellini W, Zaninoni A, Gregorini AI, Soverini G, Duca L, Fattizzo B, et al. Iron overload in congenital haemolytic anaemias: role of hepcidin and cytokines and predictive value of ferritin and transferrin saturation. *Br J Haematol.* 2019 Mar 3. doi: 10.1111/bjh.15811. [Epub ahead of print]
- 12) Fattizzo B, Zaninoni A, Pettine L, et al. Low-dose rituximab in autoimmune hemolytic anemia: 10 years after. *Blood.* 2019 Feb 28;133(9):996-998.
- 13) Reda G, Cassin R, Gentile M, Mauro FR, Giannarelli D, Fattizzo B, et al. IgA hypogammaglobulinemia predicts outcome in chronic lymphocytic leukemia. *Leukemia.* 2019 Jan 11. doi: 10.1038/s41375-018-0344-1. [Epub ahead of print]
- 14) Barcellini W, Fattizzo B, Cortelezzi A. Autoimmune hemolytic anemia, autoimmune neutropenia and aplastic anemia in the elderly. *Eur J Intern Med.* 2018 Dec;58:77-83.
- 15) Reda G, Riva M, Fattizzo B, et al. Bone Marrow Fibrosis and Early Hematological Response as Predictors of Poor Outcome in Azacitidine Treated High Risk-Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia. *Semin Hematol.* 2018 Oct;55(4):202-208.

- 16) Barcellini W, Fattizzo B, Zaninoni A. Current and emerging treatment options for autoimmune hemolytic anemia. *Expert Rev Clin Immunol*. 2018 Oct;14:857-872.
- 17) Barcellini W and Fattizzo B. Autoimmune hemolytic anemia - progress in emerging treatment options. *Expert Opinion on Orphan Drugs*. 2018; 6:4, 273-282.
- 18) Barcellini W, Pezzetti G, Fattizzo B, Cavallaro F, De Cobelli F. Utility of dynamic contrast-enhanced MRI to assess small bowel perfusion in paroxysmal nocturnal hemoglobinuria before and after eculizumab. *Eur J Intern Med*. 2018 Aug 17. pii: S0953-6205(18)30322-4.
- 19) Barcellini W, Zaninoni A, Fattizzo B, Giannotta JA, Lunghi M, Ferrari A, Leporace AP, Maschio N, Scaramucci L, Cantoni S, Chiurazzi F, Consonni D, Rossi G, De Fabritiis P, Gaidano G, Zanella A, Corteletti A. Predictors of refractoriness to therapy and healthcare resource utilization in 378 patients with primary autoimmune hemolytic anemia from 8 Italian Reference Centers. *Am J Hematol*. 2018 Jul 7. [Epub ahead of print]
- 20) Rossi G, Gramegna D, Paoloni F, Fattizzo B, Binda F, D'Adda M, Farina M, Lucchini E, Mauro FR, Salvi F, Marchetti M, Fazi P, Zaja F, Barcellini W. Short course of bortezomib in anemic patients with relapsed cold agglutinin disease: a phase 2 prospective GIMEMA study. *Blood*. 2018 Aug 2;132(5):547-550.
- 21) Reda G, Fattizzo B, Cassin R, Mattiello V, Tonella T, Giannarelli D, Massari F, Corteletti A. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study. *J Hematol Oncol*. 2018 Jun 11;11(1):79.
- 22) Barcellini W, Scola E, Lanfranconi S, Grottaroli M, Binda F, Fattizzo B, Zaninoni A, Valcamonica G, Cinnante CM, Boschetti C, Buoli M, Altamura CA, Bresolin N, Triulzi F, Zanella A, Corteletti A. Paroxysmal Nocturnal Hemoglobinuria (Pnh): Brain MRI Ischemic Lesions In Neurologically Asymptomatic Patients. *Sci Rep*. 2018 Jan 11;8(1):476.
- 23) Reda G, Cassin R, Artoni A, Fattizzo B, Lecchi A, La Marca S, Bucciarelli P, Levati GV, Peyvandi F, Corteletti A. Idelalisib rapidly improves platelet function tests in patients with chronic lymphocytic leukaemia. *Br J Haematol*. 2018 Jan 7. [Epub ahead of print]
- 24) Fattizzo B, Zaninoni A, Gianelli U, Zanella A, Corteletti A, Kulasekararaj AG, Barcellini W. Prognostic impact of bone marrow fibrosis and dyserythropoiesis in autoimmune hemolytic anemia. *Am J Hematol*. 2018 Aug;93(4):E88-E91.
- 25) Fracchiolla NS, Fattizzo B, Corteletti A. Mesenchymal Stem Cells in Myeloid Malignancies: A Focus on Immune Escaping and Therapeutic Implications. *Stem Cells Int*. 2017;2017:6720594.
- 26) Fracchiolla NS, Iurlo A, Ferla V, Fattizzo B, Freyrie A, Reda G, Corteletti A. Concomitant Occurrence of Blastic Plasmacytoid Dendritic Cell Neoplasm and Acute Myeloid Leukaemia after Lenalidomide Treatment for 5q- syndrome. *Clin Lab*. 2017 Sep 1;63(9):1513-1517.
- 27) Ferla V, Zaninoni A, Fattizzo B, Fermo E, Gianelli U, Barcellini W. Paroxysmal nocturnal hemoglobinuria with spontaneous clinical remission. *Eur J Intern Med*. 2017 Sep;43:e11-e14.

- 28) Reda G, Fattizzo B, Cassin R, Flosspergher E, Orofino N, Gianelli U, Barcellini W, Cortelezzi A. Multifactorial neutropenia in a patient with acute promyelocytic leukemia and associated large granular lymphocyte expansion: A case report. *Oncol Lett.* 2017 Mar;13(3):1307-1310.
- 29) Reda G, Cassin R, Fattizzo B, Giannarelli D, Mattiello V, Barcellini W, Cortelezzi A. Chronic lymphocytic leukemia and prognostic models: A bridge between clinical and biological markers. *Am J Hematol.* 2017 Jul;92(7):E135-E137.
- 30) Barcellini W, Fattizzo B, Zaninoni A, Valli V, Ferri V, Gianelli U, Cortelezzi A. Clinical evolution of autoimmune cytopenias to idiopathic cytopenias/dysplasias of uncertain significance (ICUS/IDUS) and bone marrow failure syndromes. *Am J Hematol.* 2017 Mar;92(3):E26-E29.
- 31) Marangon M, Vianelli N, Palandri F, Mazzucconi MG, Santoro C, Barcellini W, Fattizzo B, Volpetti S, Lucchini E, Polverelli N, Carpenedo M, Isola M, Fanin R, Zaja F. Rituximab in immune thrombocytopenia: gender, age, and response as predictors of long-term response. *Eur J Haematol.* 2017 Apr;98(4):371-377.
- 32) Fracchiolla NS, Annaloro C, Guidotti F, Fattizzo B, Cortelezzi A. 2,3,7,8-Tetrachlorodibenzo-pdioxin (TCDD) role in hematopoiesis and in hematologic diseases: A critical review. *Toxicology.* 2016 Dec 30;374:60-68.
- 33) Reda G, Cassin R, Fabris S, Ciceri G, Fattizzo B, Sciumè M, Orofino N, Gianelli U, Neri A, Cortelezzi A. Biological and molecular characterization of a rare case of cutaneous Richter syndrome. *Hematol Oncol.* 2017 Dec;35(4):869-874.
- 34) Fattizzo B, Zaninoni A, Giannotta JA, Binda F, Cortelezzi A, Barcellini W. Reduced 25-OH vitamin D in patients with autoimmune cytopenias, clinical correlations and literature review. *Autoimmun Rev.* 2016 Jul;15(7):770-5.
- 35) Reda G, Orofino N, Cassin R, Sciumè M, Fattizzo B, Cortelezzi A. Treating chronic lymphocytic leukemia with obinutuzumab: safety and efficacy considerations. *Expert Opin Drug Saf.* 2016 Jun;15(6):865-73.
- 36) Barcellini W, Fattizzo B. Clinical Applications of Hemolytic Markers in the Differential Diagnosis and Management of Hemolytic Anemia. *Dis Markers.* 2015;2015:635670.
- 37) Zaninoni A, Vercellati C, Imperiali FG, Marcello AP, Fattizzo B, Fermo E, Bianchi P, Grossi C, Cattaneo A, Cortelezzi A, Zanella A, Barcellini W. Detection of red blood cell antibodies in mitogen-stimulated cultures from patients with hereditary spherocytosis. *Transfusion.* 2015 Dec;55(12):2930-8.
- 38) Fattizzo B, Zaninoni A, Consonni D, Zanella A, Gianelli U, Cortelezzi A, Barcellini W. Is chronic neutropenia always a benign disease? Evidences from a 5-year prospective study. *Eur J Intern Med.* 2015 Oct;26(8):611-5.
- 39) Migone De Amicis M, Fattizzo B, Poggiali E, Minonzio F, Gianelli U, Cappellini MD. Anemia and splenomegaly: what lies behind? *Intern Emerg Med.* 2015 Sep;10(6):711-4.
- 40) Fattizzo B, Zaninoni A, Nesa F, Sciumbata VM, Zanella A, Cortelezzi A, Barcellini W. Lessons from very severe, refractory, and fatal primary autoimmune hemolytic anemias. *Am J Hematol.* 2015 Aug;90(8):E149-51.

- 41) Fattizzo B, Radice T, Cattaneo D, Pomati M, Barcellini W, Iurlo A. Three hematologic malignancies in the same patient: chronic lymphocytic leukemia, followed by chronic myeloid leukemia and acute myeloid leukemia. Clin Lab. 2014;60(11):1929-32.
- 42) Barcellini W, Fattizzo B, Zaninoni A, Radice T, Nichele I, Di Bona E, Lunghi M, Tassinari C, Alfinito F, Ferrari A, Leporace AP, Niscola P, Carpenedo M, Boschetti C, Revelli N, Villa MA, Consonni D, Scaramucci L, De Fabritiis P, Tagariello G, Gaidano G, Rodeghiero F, Cortelezzi A, Zanella A. Clinical heterogeneity and predictors of outcome in primary autoimmune hemolytic anemia: a GIMEMA study of 308 patients. Blood. 2014 Nov 6;124(19):2930-6.
- 43) Barcellini W, Imperiali FG, Zaninoni A, Reda G, Consonni D, Fattizzo B, Lonati S, Nobili L, Zanella A, Cortelezzi A. Toll-like receptor 4 and 9 expression in B-chronic lymphocytic leukemia: relationship with infections, autoimmunity and disease progression. Leuk Lymphoma. 2014 Aug;55(8):1768-73.
- 44) Barcellini W, Iurlo A, Radice T, Imperiali FG, Zaninoni A, Fattizzo B, Guidotti F, Bianchi P, Fermo E, Consonni D, Cortelezzi A. Increased prevalence of autoimmune phenomena in myelofibrosis: relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patterns. Leuk Res. 2013 Nov;37(11):1509-15
- 45) Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Di Bona E, Fattizzo B, Consonni D, Cortelezzi A, Zanella A. Sustained response to low-dose rituximab in idiopathic autoimmune hemolytic anemia. Eur J Haematol. 2013 Dec;91(6):546-51.
- 46) Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Battista ML, Di Bona E, Fattizzo B, Consonni D, Cortelezzi A, Fanin R, Zanella A. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood. 2012 Apr 19;119(16):3691-7.

Published Abstracts

1. Barcellini W, Imperiali FG, Zaninoni A, Reda G, Fattizzo B, et al; Expression of TLRS in B-CLL: relationship with disease activity. ASH Annual Meeting Abstracts, Blood 2011.118:4597
2. Fattizzo B, Radice T, Guidotti F, et al. Chronic benign neutropenia in adults: laboratory and clinical parameters of a 6 year follow up. EHA annual meeting Stockholm 2013.
3. Guidotti F, Radice T, Imperiali FG, Zaninoni A, Fattizzo B, et al. Increased prevalence of autoimmune phenomena in myelofibrosis: relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patterns. EHA annual meeting Stockholm 2013.
4. Barcellini W, Fattizzo B, Imperiali FG, et al. Reduced expression of TOLL-Like receptor 4 in B-chronic lymphocytic leukemia patients with autoimmune complications. EHA annual meeting Stockholm 2013.
5. Fattizzo B, Radice T, Guidotti F, et al. Chronic idiopathic neutropenia in adults: clinical features in a 4 year prospective study. ASH annual meeting New Orleans 2013. Blood 2013.122:1026

6. Barcellini W, Fattizzo B, Radice T, et al. Clinical heterogeneity of autoimmune hemolytic anemia: a 35 years retrospective study of 157 patients. ASH annual meeting New Orleans 2013, Blood 2013. 122:3428
7. Zaninoni A, Vercellati C, Imperiali FG, Marcello AP, Fermo E, Bianchi P, Fattizzo B, et al. Mitogen stimulated direct antiglobulin test in patients with hereditary spherocytosis. EHA annual meeting Milano 2014.
8. Fattizzo B, Zaninoni A, Nesa F, et al. Reduced 25-OH vitamin D levels in patients with autoimmune cytopenias: correlation with haematological parameters and clinical severity. EHA annual meeting Milano 2014.
9. Barcellini W, Fattizzo B, Zaninoni A, et al. Predictors of outcome and response to therapy in primary autoimmune hemolytic anemia: a GIMEMA study of 307 patients. ASH annual meeting San Francisco 2014, Blood 2014.124:1346
10. Fattizzo B, Zaninoni A, Bianchi P, et al. 25-OH vitamin D, vitamin D receptor and immunomodulatory cytokines in patients with autoimmune cytopenias. ASH annual meeting San Francisco 2014, Blood 2014. 124:1346
11. Fattizzo B, Zaninoni A, Giannotta J, et al W. 25-OH vitamin D down-regulates in vitro production of anti-erythrocyte antibodies in autoimmune hemolytic anemia. EHA annual meeting Vienna 2015.
12. Reda G, Fattizzo B, Cassin R, et al. Secondary malignancies in CLL: a single centre retrospective analysis of 514 cases. ASH annual meeting Orlando 2015, Blood 2015.126:5279
13. Cassin R, Reda G Fabris, Orofino N, Fattizzo B, et al. Comprehensive Biological and Molecular Characterization of a rare Case of Cutaneous Richter Syndrome. ASH annual meeting Orlando 2015, Blood 2015.126:5281
14. Reda G, Riva M, Cassin R, Fattizzo B, et al. Impact of bone marrow fibrosis in response to azacitidine in 94 patients with myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML), and acute myeloid leukemia (AML). EHA annual meeting Copenhagen 2016.
15. Barcellini W, Scola E, Lanfranconi S, Grottaroli M, Binda F, Fattizzo B, et al. Neuro-psychiatric involvement in paroxysmal nocturnal hemoglobinuria (PNH). EHA annual meeting Copenhagen 2016.
16. Reda G, Riva M, Cassin R, Fattizzo B, et al. Impact of bone marrow fibrosis and early response on outcome after azacitidine therapy in 94 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia. ASH annual meeting San Diego 2016, Blood 2016;128:3187.
17. Reda G, Cassin R, Artoni A, Lecchi A, Fattizzo B, et al. Idelalisib Rapidly Improves Platelets Function in Patients with Chronic Lymphocytic Leukemia. ASH annual meeting San Diego 2016, Blood 2016; 128:5566
18. Fattizzo B, Zaninoni A, Giannotta J, et al. Clinical follow-up of 378 patients with autoimmune hemolytic anemia: prognostic impact of hemoglobin levels, autoantibody class, and reticulocytopenia at onset on the relapse risk and outcome. EHA annual meeting Madrid 2017.

19. Reda G, Fattizzo B, Cassin R, et al. Heminsight to assess patient reported outcomes of patients affected by CLL in daily clinical practice. EHA international meeting Madrid 2017.
20. Reda G, Cassin R, Mattiello V, et al. Atrial fibrillation and ibrutinib, a monocentric experience: should cardiological evaluation be a guide in clinical practice? ASH annual meeting Atlanta 2017, Blood 2017; 130:1747.
21. Fattizzo B, Zaninoni A, Gianelli U, et al. Prevalence of bone marrow fibrosis in 47 cases of autoimmune hemolytic anemia patients: clinical and biological relationships. ASH annual meeting Atlanta 2017, Blood 2017; 130:3491.
22. Reda G, Cassin R, Levati G, Fattizzo B, et al. Hypogammaglobulinemia in chronic lymphocytic leukemia: a predictor of outcome? ASH annual meeting Atlanta 2017, Blood 2017;130:2997.
23. Rossi G, Paoloni F, Fattizzo B, et al. Short course of bortezomib in anemic patients with refractory or relapsed cold agglutinin disease. A phase II prospective study by the GIMEMA group. ASH annual meeting Atlanta 2017, Blood 2017;130:2199.
24. Barcellini W, Fattizzo B, Zaninoni A, et al. Healthcare resource utilization in autoimmune hemolytic anemia patients: analysis of 190 cases from a single center. ASH annual meeting Atlanta 2017, Blood 2017;130:3370.
25. Fattizzo B, Dunlop A, Ireland R, et al. Prevalence of PNH clones and their clinical and prognostic significance in 3085 patients with cytopenia: a twenty-year single center experience. BSH annual meeting Liverpool 2018, BJH,181, (Suppl. 1), 5–211.
26. Fattizzo B, Benson-Quarm N, Hill A, et al. Eltrombopag in a real world cohort of aplastic anemia patients: large retrospective analysis of two UK centers. BSH annual meeting Liverpool 2018, BJH,181,(Suppl. 1), 5–211.
27. Fattizzo B, Benson-Quarm N, Hilla A, et al. Clinical and morphologic predictors of outcome in aplastic anemia patients treated with eltrombopag. EHA annual meeting Stoccolma 2018.
28. Fattizzo B, Zaninoni A, Pasquale R, et al Prevalence and clinical significance of small PNH clones in patients with primary autoimmune hemolytic anemia. EHA annual meeting Stoccolma 2018.
29. Fattizzo B, Dunlop A, Ireland R, et al. Clinical significance of PNH clones in 3085 patients with cytopenia: a large single center experience. EHA annual meeting Stoccolma 2018.
30. Fattizzo B, Pasquale R, Carpenedo M, et al. Clinical and morphologic predictors of outcome in a multicenter cohort of ITP patients treated with thrombopoietin analogues. ASH annual meeting San Diego 2018, Blood 2018, 132:3764.
31. Fattizzo B, Dunlop A, Ireland R, et al. Prognostic and predictive impact of small PNH clones in a large cohort of patients with myelodysplastic syndromes and aplastic anemia: a single center experience. ASH annual meeting San Diego 2018, Blood 2018;132:3870.
32. Gertz M, Roman E, Fattizzo B, et al. Inhibition of C3 with APL-2 Controls

Haemolysis and Increases Haemoglobin Levels in Subjects with Autoimmune Haemolytic Anaemia (AIHA). BSH annual meeting Glasgow 2019, BJH,185, (Suppl. 1), 3–202.

33. Fattizzo B, Dunlop A, Ireland R, et al. Prevalence of small PNH clones and their prognostic significance in patients tested for unusual indications: a single center experience,. BSH annual meeting Glasgow 2019, BJH,185, (Suppl. 1), 3–202.
34. Gertz M, Roman E, Fattizzo B, et al. Inhibition of C3 with APL-2 Controls Haemolysis and Increases Haemoglobin Levels in Subjects with Autoimmune Haemolytic Anaemia (AIHA). EHA annual meeting Amsterdam 2019.
35. Cavallaro F, Fattizzo B, Levati G, et al. Iron mobilization in a real life cohort of aplastic anemia patients treated with eltrombopag. EHA annual meeting Amsterdam 2019.
36. Fattizzo B, Languille L, Levati G, et al. Evidence based use of erythropoietin in patients with autoimmune hemolytic anemia: a multicenter international study. EHA annual meeting Amsterdam 2019.
37. Fattizzo B, Michel M, Languille L, et al. Predictors of Response to Erythropoietin in Autoimmune Hemolytic Anemia. ASH annual meeting Orlando 2019, Blood 2019, 134 (Suppl. 1):3516.

Other Abstracts

1. Iurlo A, Radice T, Fattizzo B, et al. Thrombotic events in myelofibrosis: relationship with clinical and morphological characteristics, JAK2V617F mutational status and autoimmune phenomena. SIE annual meeting Verona 2013.
2. Radice T, Fattizzo B, Pomati M, et al. A case of chronic lymphocytic leukemia developing chronic myeloid leukemia with high platelets and followed by acute myeloid leukemia. SIE annual meeting Verona 2013.
3. Iurlo A, Rapezzi D, Binda F, Cattaneo D, Zaninoni A, Fattizzo B, et al. Myelofibrosis and following chronic myeloid leukemia: imatinib and ruxolitinib treatment in two cases. SIE annual meeting Verona 2013.
4. Fattizzo B, Radice T, Guidotti F, et al. Chronic idiopathic neutropenia in adults: clinical features in a 4 year prospective study. SIE annual meeting Verona 2013.
5. Barcellini W, Zaja F, Zaninoni A, Imperiali FG, Battista M, Di Bona E, Fattizzo B, et al. Low dose rituximab in idiopathic autoimmune hemolytic anemia. SIE annual meeting Napoli 2011.
6. Barcellini W, Imperiali FG, Zaninoni A, Reda G, Fattizzo B, et al. Expression of TLRs in B-CLL: Relationship with disease activity; International Workshop on CLL 2011, Cologne, Germany.

Other publications

- 1) Fattizzo B. La neutropenia nell'adulto e nel bambino. Inserto cultura.

<http://www.invenadisapere.it/insertocultura>

- 2) Fattizzo B. Anemia emolitica autoimmune dall'approccio classico ai nuovi farmaci. Editoriale. <http://www.invenadisapere.it/editoriale/nopage/AEA>

CURRICULUM VITAE

Simone Ferrero, MD



Personal data

Date of birth:	September 9, 1982
Place of birth:	Savigliano (CN), Italy
Citizenship:	Italian
Mailing address:	Divisione Universitaria di Ematologia Via Genova 3, 10126 Torino, Italy Fax: + 39-011-696-3737; Phone (work): +39-011-633-4220/6884/4251 E-mail: simone.ferrero@unito.it

Education

2007

Medical degree (with distinction), University of Torino, Italy

2012

Post-graduate degree in Hematology (with distinction), University of Torino, Italy

2012

German language degree "Goethe-Zertifikat B2", "Goethe Institut" of Berlin, Germany

2015-2017

Interuniversity, II level master classes in "Diagnosis and treatment of lymphomas", University of Udine, Italy

Professional records

2005-2007

Internship, Division of Hematology, University of Torino, Italy

2008-2012

Post-doctoral fellow, Division of Hematology, University of Torino, Italy

2012-2016

Research fellow, Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Italy

10/2012-05/2013

Research fellow by "Medizinische Klinik und Poliklinik III, Klinikum der Universität München, Campus Großhadern" and „Helmholtz Zentrum München, Deutsches Forschungszentrum für Gesundheit und Umwelt“ – Munich, Germany

11/2013-12/2013

Research fellow by Molecular genetics laboratory - "Universitätsklinikum S.-H. Campus Kiel 2. Medizinische Klinik und Poliklinik im Städtischen Krankenhaus" - Kiel, Germany.

09/2016-08/2017

Visiting research fellow, Division of Hematology, "SS Antonio e Biagio e C. Arrigo Hospital", Alessandria, Italy

01/12/2016-30/06/2024

Assistant Professor in Hematology, Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Italy

01/12/2016-today

Phase I Unit Study Physician, Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Italy

2018

National Scientific Abilitation, ASN 06/D3 - MALATTIE DEL SANGUE, ONCOLOGIA E REUMATOLOGIA, II fascia

01/07/2024-today

Associate Professor in Hematology, Division of Hematology, Department of Molecular Biotechnologies and Health Sciences, University of Torino, Italy

Clinical activity

Clinical management of onco-hematological in- and out-patients, comprising bone marrow transplantation. Specifically focused on mature lymphoproliferative disorders, comprising patients enrollment in clinical trials.



Europass Curriculum Vitae

Personal information

First name / Surname **Chiara Frairia**
E-mail cfrairia@cittadellasalute.to.it
Nationality Italian
Date of birth 15/07/1983
Gender Female

Occupational field **Medical Doctor, hematologist**

Work experience

Dates	August 1 st , 2017 – till now
Occupation or position held	MD
Main activities and responsibilities	Hematology malignancies
Name and address of employer	Hematology. Città della Salute e della Scienza di Torino – Italy. Director: Dr. Roberto Freilone.
Dates	November 2 nd , 2015 – July 31 st , 2017
Occupation or position held	MD
Main activities and responsibilities	Hematology malignancies
Name and address of employer	Hematology. AOU Maggiore della Carità, Novara – Italy. Director: Prof. Gainluca Gaidano.
Dates	September 2015-October 2015
Occupation or position held	Research project: identification of biological risk factors predictive of response and independent from treatment, responsible for chemo resistance and survival in a phase III clinical trial in patients with high risk diffuse large B cell lymphoma.
Main activities and responsibilities	Diagnosis, treatment and management of hematological malignancies, focused on aggressive lymphoma.
Name and address of employer	Hematology. Città della Salute e della Scienza di Torino – Italy. Director: Dr. Umberto Vitolo.
Dates	August 2014 – July 2015
Occupation or position held	Research project: Out-patient management of neutropenia induced by treatment with consolidation chemotherapy in patients with acute myeloid leukemia"
Main activities and responsibilities	Diagnosis, treatment and management of hematological malignancies, especially acute myeloid leukemia.
Name and address of employer	Hematology. Città della Salute e della Scienza di Torino – Italy. Director: Dr. Umberto Vitolo.
Dates	June 2009 – June 2014
Occupation or position held	Hematology Fellowship with the thesis "Prognostic value of minimal residual disease in acute myeloid leukemia detected by Wilms Tumor gene 1 expression and multiparameter flow cytometry". Marks 70/70 cum laude.
Main activities and responsibilities	Hematological malignancies, chemotherapy, biological therapies, biology and treatment of lymphoma, leukemia, myelodysplastic syndrome and myeloproliferative disorders.

Name and address of employer	University of Turin - Hematology. Città della Salute e della Scienza di Torino – presidio Molinette, 88, C.so Bramante, Turin, Italy. Director: Dr. Umberto Vitolo.
Type of business or sector	Oncohematology focusing on Lymphoma, Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders. Transplantation.
Dates	June 2013 – December 2013
Occupation or position held	Hematology Observership according to the Academic Visitor and Scholar Program at Lee Moffitt Cancer Center – University of South Florida – Tampa, Florida (USA)
Main activities and responsibilities	Observership, clinical research and academic program. From June 2013 to October 2013 at Leukemia/MDS unit under the tutorage of Dr. Rami Komrokji. From October 2013 to December 2013 at Bone Marrow Transplant Unit under the tutorage of Dr. Claudio Anasetti.
Name and address of employer	Lee Moffitt Cancer Center – University of South Florida – Tampa, Florida (USA)
Type of business or sector	Main interest on MDS/acute leukemias, transplant and transplant complications.

Education and training

Dates	March 2009
Title of qualification awarded	Professional Enabling with the evaluation: 264,75/270. Medical licence registration number: 21554.
Principal subjects/occupational skills covered	General Medicine. General Surgery.
Name and type of organisation providing education and training	University of Turin
Dates	2002 – 2008
Title of qualification awarded	Degree in Medicine and Surgery with an experimental thesis on Oncohematology: "Evaluation of long term effectiveness and safety of dose-dense and high dose immuno-chemotherapy followed by Autologous Stem Cell Transplantation (ASCT) in young patients with unpoor prognosis Diffuse Large B-cell Lymphoma and correlation with immunophenotypic expression evaluated by "tissue microarrays". Marks 110/110 with publication's right.
Principal subjects/occupational skills covered	Onco-Hematology. Transplantation. Pathology.
Name and type of organisation providing education and training	University of Turin
Dates	1997 – 2002
Title of qualification awarded	High School Diploma with the evaluation: 100/100
Principal subjects/occupational skills covered	Biology. Chemistry. Biochemistry. Science of Earth. Physics.
Name and type of organisation providing education and training	Scientific High School "G.B. Bodoni", Saluzzo (CN), Italy.

Publications

Breast isolated FLT3 positive AML relapse treated with gilteritinib in monotherapy: long-term follow-up and review of the literature. Arrigo G, D'Ardia S, Cerrano M, Freilone R, Gai V, Urbino I, Audisio E, Frairia C. *Medical Research Archives* 2025, Volume 13 Issue 5. DOI <https://doi.org/10.18103/mra.v13i5.6559>

Unmet Needs and Their Impact on Quality of Life and Symptoms in Myelodysplastic Neoplasm Patients and Caregivers. Crisà E, Cilloni D, Riva M, Balleari E, Barraco D, Manghisi B, Borin L, Calmasini M, Calvisi A, Capodanno I, Della Porta MG, Diral E, Fattizzo B, Fenu S, Paolini S, Finelli C, Fozza C, Frairia C, Gai V, Turrini M, Isoni MA, Itri F, Maurillo L, Molteni A, Palumbo GA, Pelizzari AM, Pilo F, Poloni A, Bosi C, Sanpaolo G, Sancetta R, Amato C, Santini V, Voso MT, Salek S, Ionova T, Nosari A, Oliva EN. *Cancers (Basel)*. 2025 May 7;17(9):1587.

Arsenic trioxide neurotoxicity in acute promyelocytic leukemia patients: a single center experience. Arrigo G, Scaldaferri M, Audisio E, Boscaro E, Catania F, Cattell F, Celona L, Cerrano M, Freilone R, Gai V, Urbino I, D'Ardia S, Frairia C. *Leuk Lymphoma*. 2025 Mar;66(3):567-568.

Transfusion independence after lenalidomide discontinuation in patients with del(5q) myelodysplastic neoplasm: a HARMONY Alliance study. Crisà E, Mora E, Germing U, Bally C, Diez Campelo M, Myllymäki M, Jädersten M, Komrokji R, Platzbecker U, Haase D, Hofmann WK, Al Ali NH, Barraco D, Bargay JJ, Bernal T, López Cadenas F, Calvisi A, Capodanno I, Cerrano M, Ciancia R, Crugnola M, Kündgen A, Finelli C, Fozza C, Frairia C, Freja E, Ganster C, Kubasch AS, Jimenez MJ, Latagliata R, Hernandez Mohedo F, Molero A, Vara Pampliega M, Perez CA, Pietrantonio G, Poloni A, Pomares H, Recasens V, Rüfer A, Signori A, Hellstrom-Lindberg E, Fenaux P, Sanz G, Santini V. *Leukemia*. 2024 Oct;38(10):2259-2265.

Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience. Urbino I, Secretò C, Apolito V, Olivi M, Arrigo G, Boscaro E, Catania FM, D'Ardia S, Frairia C, Gai V, Freilone R, Bruno B, Lanzarone G, Giaccone L, Busca A, Dellacasa CM, Ferrero D, Audisio E, Cerrano M. *Leuk Res*. 2024 Jan;136:107421.

Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors. Boscaro E, Urbino I, Catania FM, Arrigo G, Secretò C, Olivi M, D'Ardia S, Frairia C, Gai V, Freilone R, Ferrero D, Audisio E, Cerrano M. *Cancers* 2023, 15, 3512. <https://doi.org/10.3390/cancers15133512>.

Validation of SIE/SIES/GITMO consensus criteria for unfit to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax. Apolito V, Arrigo G, Vasseur L, Olivi M, Perrone S, Gai V, Secretò C, Di Biase F, De Simone MC, Cioia C, Gravetti A, Freilone R, Bruno B, Lanzarone G, Beggiato E, Frairia C, Audisio E, D'Ardia S, Ferrero D, Cerrano M, Ferrara F. *Br J Haematol*. 2023;00:1–4

Validation of National Early Warning Score and Quick Sequential (sepsis-related) Organ Failure Assessment in acute myeloid leukaemia patients treated with intensive chemotherapy. Frairia C, Nicolino B, Secretò C, Messa E, Arrigo G, Busca A, Cerrano M, D'Ardia S, Dellacasa C, Evangelista A, Freilone R, Gai V, Priolo G, Urbino I, Audisio E. *Eur J Haematol*. 2023 Jun;110(6):696-705

Levofloxacin Prophylaxis Versus no Prophylaxis in Acute Myeloid Leukemia During Post-Induction Aplasia: a Single Center Study. Urbino I, Frairia C, Busca A, Corcione S, D'Ardia S, Dellacasa CM, Gai V, Secretò C, Freilone R, De Rosa FG, Aydin S, Ciccone G, Rosato R, Cerrano M, Audisio E. *Mediterr J Hematol Infect Dis*. 2023 Mar 1;15(1):e2023022.

Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature. Arrigo G, D'Ardia S, Audisio E, Cerrano M, Freilone R, Gai V, Secretò C, Urbino I, Frairia C. *Acta Haematol*. 2022;145(5):566-570.

Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study. Martella F, Cerrano M, Di Cuonzo D, Secretò C, Olivi M, Apolito V, D'Ardia S, Frairia C, Gai V, Lanzarone G, Urbino I, Freilone R, Giaccone L, Busca A, Dellacasa C, Audisio E, Ferrero D, Beggiato E. *Annals of Hematology* 2022. <https://doi.org/10.1007/s00277-022-04770-6>

Evolving Therapeutic Approaches for Older Patients with Acute Myeloid Leukemia in 2021. Urbino I, Secreto C, Olivi M, Apolito V, D'Ardia S, Frairia C, Giai V, Aydin S, Freilone R, Dellacasa C, Giaccone L, Ferrero D, Audisio E, Busca A, Cerrano M. *Cancers* 2021, 13, 5075.

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission. Wei A, Döhner H, Pocock M, Montesinos P, Afanasyev B, Sci Z, Dombret H, Ravandi F, Sayar H, Jang J, Porkka K, Delleslag K, Sandhu I, Turgut M, Giai V, Ofran Y, Çakar K, Botelho de Sousa A, Rybka, Frairia C, Borin L, Beltrami G, Čermák J, Ossenkoppele G, La Torre I, Skikne B, Kumar K, Dong Q, Roboz G for the QUAZAR AML-001 Trial Investigators. *N Engl J Med* 2020; 383:2526-37.

Sole Upfront Therapy with Beclomethasone and Budesonide for Upper Gastrointestinal Acute Graft-versus-Host Disease. Frairia C, Nicolosi M, Shapiro J, Kim J, Betts BC, Fernandez HF, Locke FL, Mishra A, Nishihori T, Ochoa-Bayona JL, Perez L, Pidala J, Anasetti C. *Biol Blood Marrow Transplant.* 2020 Jul;26(7):1303-1311.

The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. Efficace F, Cottone F, Oswald LB, Cella D, Patriarca A, Niscola P, Breccia M, Platzbecker U, Palumbo GA, Caocci G, Stauder R, Ricco A, Petranovic D, Caers J, Luppi M, Fianchi L, Frairia C, Capodanno I, Follini E, Sarlo C, Fazi P, Vignetti M. *Leukemia.* 2020

Long-term results of all-trans retinoic acid and arsenic trioxide in non-high-risk acute promyelocytic leukemia: update of the APL0406 Italian-German randomized trial. Cicconi L, Platzbecker U, Avvisati G, Paoloni F, Thiede C, Vignetti M, Fazi P, Ferrara F, Divona M, Albano F, Efficace F, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Annibali O, Wattad M, Lubbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Fozza C, Maria D'Arco A, Di Renzo N, Cortelezzi A, Fabbiano F, Dohner K, Ganser A, Dohner H, Amadori S, Mandelli F, Voso MT, Ehninger G, Schlenk RF, Lo-Coco F. *Leukemia.* 2020 Mar;34(3):914-918

The use of erythropoiesis-stimulating agents is safe and effective in the management of anaemia in myelofibrosis patients treated with ruxolitinib. Crisà E, Cilloni D, Elli EM, Martinelli V, Palumbo GA, Pugliese N, Beggiato E, Frairia C, Cerrano M, Lanzarone G, Marchetti M, Mezzabotta M, Boccadoro M, Ferrero D. *Br J Haematol.* 2018 Sep;182(5):701-704

Hematopoietic cell transplantation comorbidity index and risk of developing invasive fungal infections after allografting. Busca A, Passera R, Maffini E, Festuccia M, Brunello L, Dellacasa CM, Aydin S, Frairia C, Manetta S, Butera S, Iovino G, Giaccone L, Sorror M, Storb R, De Rosa FG, Bruno B. *Bone Marrow Transplant.* 2018 Oct;53(10):1304-1310

Post-remissional and pre-transplant role of minimal residual disease detected by WT1 in acute myeloid leukemia: A retrospective cohort study. Frairia C, Aydin S, Audisio E, Riera L, Aliberti S, Allione B, Busca A, D'Ardia S, Dellacasa CM, Demurtas A3, Evangelista A, Ciccone G, Francia di Celle P, Nicolino B, Stacchini A, Marmont F, Vitolo U. *Leuk Res.* 2017 Oct;61:10-17.

Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F. *J Clin Oncol.* 2016 Jul 11. pii: JCO671982.

Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic Leukemia. Giaccone L, Audisio E, Bruno B, Maffini E, D'Ardia S, Caracciolo D, Ferrando F, Butera S, Brunello L, Frairia C, Aydin S, Nicolino B, Festuccia M, Crisà E, Bruna R, Passera R, Boccadoro M, Vitolo U, Busca A, Falda M, Marmont F. *Clin Lymphoma Myeloma Leuk.* 2016;16(2):96-103.
ent of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.
Ferrero D, Crisà E, Marmont F, Audisio E, Frairia C, Giai V, Gatti T, Festuccia M, Bruno B, Riera L, Passera R, Boccadoro M. *Ann Hematol.* 2014;93(8):1391-400.

Improved Outcomes With Retinoic Acid and Arsenic Trioxide Compared With Retinoic Acid and Chemotherapy in Non-High-Risk Acute Promyelocytic Leukemia: Final Results of the Randomized Italian-German APL0406 Trial. Platzbecker U, Avvisati G, Cicconi L, Thiede C, Paoloni F, Vignetti M, Ferrara F, Divona M, Albano F, Efficace F, Fazi P, Sborgia M, Di Bona E, Breccia M, Borlenghi E, Cairoli R, Rambaldi A, Melillo L, La Nasa G, Fiedler W, Brossart P, Hertenstein B, Salih HR, Wattad M, Lübbert M, Brandts CH, Hänel M, Röllig C, Schmitz N, Link H, Frairia C, Pogliani EM, Fozza C, D'Arco AM, Di Renzo N, Cortelezzi A, Fabbiano F, Döhner K, Ganser A, Döhner H, Amadori S, Mandelli F, Ehninger G, Schlenk RF, Lo-Coco F. J Clin Oncol. 2017 Feb 20;35(6):605-612.

Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic Leukemia. Giaccone L, Audisio E, Bruno B, Maffini E, D'Ardia S, Caracciolo D, Ferrando F, Butera S, Brunello L, Frairia C, Aydin S, Nicolino B, Festuccia M, Crisà E, Bruna R, Passera R, Boccadoro M, Vitolo U, Busca A, Falda M, Marmont F. Clin Lymphoma Myeloma Leuk. 2016 Feb;16(2):96-103.

Survival improvement of poor-prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents. Ferrero D, Crisà E, Marmont F, Audisio E, Frairia C, Giai V, Gatti T, Festuccia M, Bruno B, Riera L, Passera R, Boccadoro M. Ann Hematol. 2014 Aug;93(8):1391-400.

Allogeneic stem cell transplant for adults with myelodysplastic syndromes: relevance of pre-transplant disease status. Busca A, Pecoraro C, Giaccone L, Bruno B, Allione B, Corsetti MT, Pini M, Marmont F, Audisio E, D'Ardia S, Frairia C, Castiglione A, Ciccone G, Levis A, Vitolo U, Falda M. Leuk Lymphoma. 2014;55(4):863-9.

Prevention of invasive fungal infections in patients with acute myeloid leukaemia: results of a single centre retrospective observational study with the use of posaconazole versus conventional mould-active azoles. Dellacasa CM, Busca A, Audisio E, Marmont F, Barbui AM, Falda M, De Rosa FG, Frairia C, Allione B, D'Ardia S, Aydin S, Pecoraro C, Manetta S, Vitolo U. J Chemother. 2014;26(5):315-320.

Epidemiology of bloodstream infections in patients with acute myeloid leukemia undergoing levofloxacin prophylaxis. De Rosa FG, Motta I, Audisio E, Frairia C, Busca A, Di Perri G, Marmont F. BMC Infect Dis. 2013;13:563.

Core binding factor acute myeloid leukaemia and C-KIT mutations. Riera L, Marmont F, Toppino D, Frairia C, Sismondi F, Audisio E, Di Bello C, D'Ardia S, Di Celle PF, Messa E, Inghirami G, Vitolo U, Pich A. Oncol Rep. 2013 May;29(5):1867-72.


RD-CODOX-M/IVAC with rituximab and intrathecal liposomal cytarabine in adult Burkitt lymphoma and "unclassifiable" highly aggressive B-cell lymphoma. Corazzelli G, Frigeri F, Russo F, Frairia C, Arcamone M, Esposito G, De Chiara A, Morelli E, Capobianco G, Becchimanzi C, Volzone F, Saggese M, Marcacci G, De Filippi R, Vitolo U, Pinto A. Br J Haematol. 2012 Jan;156(2):234-44

The efficacy and safety of bortezomib and dexamethasone as a maintenance therapy in patients with advanced multiple myeloma who are responsive to salvage bortezomib-containing regimens. Benevolo G, Larocca A, Gentile M, Pregno P, Gay F, Botto B, Frairia C, Evangelista A, Morabito F, Boccadoro M, Vitolo U, Palumbo A. Cancer. 2011 May 1;117(9):1884-90

The treatment of Diffuse Large B Cell Lymphoma with poor prognosis in the Rituximab era - state of the art and future perspectives. Vitolo U, Chiappella A, Frairia C, Botto B. European Haematology. 2010; 4:611-5

Mother tongue	Italian					
Other language(s)						
Self-assessment	Understanding		Speaking		Writing	
European level (*)	Listening	Reading	Spoken interaction	Spoken production		
English	B2 Independent User	C1 Independent User	C1 Independent User	B2 Independent User	B2 Independent User	Independent User
French	A2 Basic User	B1 Independent User	A2 Basic User	A2 Basic User	A1 Basic User	A1 Basic User
Spanish	A2 Basic User	A2 Basic User	A2 Basic User	A2 Basic User	A1 Basic User	A1 Basic User
(*) <i>Common European Framework of Reference for Languages</i>						

Organisational skills and competences	Able to work by its own or in a team, with organized timetables and observing the deadlines. Able to define or organize working objectives by priorities, and to plan timing and mode of execution.
Technical skills and competences	From 2009 till now her clinical activity is focused on acute leukemia, myelodysplastic and myeloproliferative disorders and she's working in the Leukemia Group of our Hematology department, on a leukemia of the elderly's project. Aim of this study was to define clinical criteria of treatment and the best therapeutic regimen for this kind of patients.
Job-related skills	BIOMEDICAL INVESTIGATORS AND KEY PERSONNEL - Basic course. COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI). Passed on 09/06/2013. Expiration data 09/06/2015 CITI GOOD CLINICAL PRACTICE - Basic course. COLLABORATIVE INSTITUTIONAL TRAINING INITIATIVE (CITI). Passed on 09/09/2013.
Computer skills and competences	Good knowledge of Windows OS, Office Suite (Word, Excel, Powerpoint), web browsers (Internet Explorer, Google Chrome, Mozilla Firefox), image management programs (Adobe Photo-Shop, ACDsee). PubMed and MeSh database.



Torino 17/03/2026



ROBERTO FREILONE

Data di nascita: 07/06/1966 | **Nazionalità:** Italiana | **Numero di telefono:**

(+39) 0116335934 (Lavoro) | **Indirizzo e-mail:** rofreilone@cittadellasalute.to.it |

Indirizzo: CORSO BRAMANTE 88, 10126, Torino, Italia (Lavoro)

● ESPERIENZA LAVORATIVA

01/01/2021 – ATTUALE TORINO, Italia

DIRETTORE SC EMATOLOGIA CITTÀ DELLA SALUTE E DELLA SCIENZA DI TORINO

01/02/2020 – 31/12/2020 Ciriè, Chivasso, Ivrea, Italia

DIRETTORE (EX ART 22 CNL) SC MEDICINA TRASFUSIONALE ASLTO4

01/01/2017 – 31/12/2020 Ciriè, Chivasso, Ivrea, Italia

RESPONSABILE STRUTTURA SEMPLICE DIPARTIMENTALE EMATOLOGIA ASLTO4

01/07/2009 – 31/12/2016 Ciriè, Chivasso, Ivrea, Italia

RESPONSABILE STRUTTURA SEMPLICE DI EMATOLOGIA A/B/C ASLTO4

01/01/2004 – 31/12/2007 Ciriè

INCARICO AD ALTA PROFESSIONALITÀ RESPONSABILE PATOLOGIE ONCOEMATOLOGICHE ASL6

07/05/1998 – 31/12/2020 Ciriè

DIRIGENTE MEDICO I LIVELLO EMATOLOGIA ASL6 POI ASLTO4

16/02/1998 – 25/04/1998 TORINO

DIRIGENTE MEDICO I LIVELLO - EMATOLOGIA A TEMPO DETERMINATO AZIENDA OSPEDALIERA S. GIOVANNI BATTISTA

● ISTRUZIONE E FORMAZIONE

1985

MATURITÀ CLASSICA CON IL PUNTEGGIO DI 60/60 Liceo Classico "V Gioberti" - Torino

1992

LAUREA IN MEDICINA E CHIRURGIA CON LA VOTAZIONE DI 110/110 CON LODE E DIGNITÀ DI STAMPA Facoltà di Medicina e Chirurgia dell'Università degli Studi di Torino

1996

SPECIALIZZAZIONE IN EMATOLOGIA (AI SENSI DEL DLGS 257/1991) CON LA VOTAZIONE DI 70/70 E LODE Facoltà di Medicina e Chirurgia dell'Università degli Studi di Torino

1997

CORSO DI PERFEZIONAMENTO IN "DIAGNOSTICA MOLECOLARE IN MEDICINA " Università degli Studi di Torino

1999

CORSO DI PERFEZIONAMENTO IN " CURE PALLIATIVE " Università degli Studi del Piemonte Orientale ' A. Avogadro ' di Novara

COMPETENZE LINGUISTICHE

Lingua madre: ITALIANO

Altre lingue:

	COMPRENSIONE		ESPRESSIONE ORALE		SCRITTURA
	Ascolto	Lettura	Produzione orale	Interazione orale	
INGLESE	B2	B2	B2	B2	B2

Livelli: A1 e A2: Livello elementare B1 e B2: Livello intermedio C1 e C2: Livello avanzato

ULTERIORI INFORMAZIONI

PUBBLICAZIONI

E' autore di numerose pubblicazioni edite su riviste nazionali ed internazionali

COMPETENZE DI GESTIONE E DIRETTIVE

Membro del Tumor Molecular Board Regione Piemonte - Rete Oncologica della Regione Piemonte dal 2021

Componente del Comitato Etico Interaziendale Città della Salute e della Scienza di Torino, AOU Mauriziano di Torino e ASL Torino dal 1/2/2023 al 31/5/2023

Coordinatore gruppo di lavoro sulle patologie linfoproliferative della Rete Oncologica della Regione Piemonte dal 2022

Componente Commissione Farmaceutica Ospedaliera (del 715 del 11 5 2022) - Città della Salute e della Scienza - Torino

Componente Commissione Farmaceutica Interna (CFI) (del 1842 del 29/12/2023) AOU Città della Salute e della Scienza e della Salute - Torino

1. Scrivi qui la descrizione...

Membro Commissione Regionale per valutazione dell'indicazione ai farmaci biosimilari: Rituximab e Eritropoietine

Coordinatore GIC Aziendale ASLT04 Patologie linfoproliferative, mielodisplasie, mieloma dal 2012 al 2020

Membro gruppo di lavoro delle Rete Oncologica Regione Piemonte per Patologie linfoproliferative, mielodisplasie, mieloma fino al 2020

Autorizzo il trattamento dei miei dati personali presenti nel CV ai sensi dell'art. 13 d. lgs. 30 giugno 2003 n. 196 - "Codice in materia di protezione dei dati personali" e dell'art. 13 GDPR 679/16 - "Regolamento europeo sulla protezione dei dati personali".

Torino , 22/02/2024



ROBERTO FREILONE



Curriculum Vitae Europass

Informazioni personali

Nome(i) / Cognome(i)	Gianluca Gaidano
Codice Fiscale	GDNGLC62M22L219A
Indirizzo(i)	Residenza: Via Piazzi 54, 10129 Torino; Domicilio: Via Dolores Bello 8, 28100 Novara
Telefono(i)	+39-0321-660655 +39-339-3322688
E-mail	gianluca.gaidano@uniupo.it gianluca.gaidano@med.uniupo.it
Cittadinanza	Italiana
Data di nascita	22-08-1962
Sesso	M

Occupazione **Professore Ordinario di Malattie del Sangue**

Esperienza professionale

Date	2008-ad oggi
Lavoro o posizione ricoperti	Professore Ordinario di Malattie del Sangue (Settore Scientifico Disciplinare MED/15)
Principali attività e responsabilità	Direzione della Divisione di Ematologia; Prorettore Vicario
Nome e indirizzo del datore di lavoro	Università del Piemonte Orientale, Via Solaroli 17, 28100 Novara
Tipo di attività o settore	Università / Ricerca scientifica / Didattica / Assistenza clinica
Date	2005-ad oggi
Lavoro o posizione ricoperti	Direttore della SCU Ematologia e Direttore del Programma Trapianti di CSE
Principali attività e responsabilità	Direzione della Struttura Complessa a Direzione Universitaria di Ematologia
Nome e indirizzo del datore di lavoro	Azienda Ospedaliero-Universitaria Maggiore della Carità, C. Mazzini 18, 28100 Novara
Tipo di attività o settore	Assistenza clinica / Ricerca scientifica / Didattica / Trapianti di CSE
Date	1998-ad oggi
Lavoro o posizione ricoperti	Direzione del Laboratorio di Ematologia
Principali attività e responsabilità	Direzione del Laboratorio di Ricerca e di Analisi Molecolare di Ematologia nell'ambito del Dipartimento di Medicina Traslazionale
Nome e indirizzo del datore di lavoro	Università del Piemonte Orientale, Via Solaroli 17, 28100 Novara
Tipo di attività o settore	Ricerca scientifica / Didattica / Analisi molecolare
Date	2021-2024
Lavoro o posizione ricoperti	Direzione della Scuola di Specializzazione in Ematologia
Principali attività e responsabilità	Coordinamento delle attività didattiche e cliniche degli specializzandi
Nome e indirizzo del datore di lavoro	Università del Piemonte Orientale, Via Solaroli 17, 28100 Novara
Tipo di attività o settore	Didattica / Assistenza
Date	1998-ad oggi
Lavoro o posizione ricoperti	Componente del Collegio Docenti del Dottorato di Ricerca in Scienze e Biotecnologie Mediche
Principali attività e responsabilità	Formazione dei dottorandi di ricerca
Nome e indirizzo del datore di lavoro	Università del Piemonte Orientale, Via Solaroli 17, 28100 Novara

Pagina /4 - Curriculum vitae di
Cognome/i Nome/i

Per maggiori informazioni su Europass: <http://europass.cedefop.europa.eu>
© Unione europea, 2002-2010 24082010

Tipo di attività o settore	Didattica / Ricerca
Date	2018-2021
Lavoro o posizione ricoperti	Delegato del Rettore all'Internalizzazione; Delegato del Rettore alla Cooperazione Internazionale
Principali attività e responsabilità	Coordinamento delle attività di Ateneo in ambito di Internazionalizzazione e Cooperazione Internazionale
Nome e indirizzo del datore di lavoro	Università del Piemonte Orientale, Via Duomo 6, 13100 Vercelli (sede del Rettorato)
Tipo di attività e settore	Università / Internazionalizzazione
Date	2021-2022
Lavoro o posizione ricoperti	Delegato del Rettore alla Ricerca; Delegato del Rettore alla Cooperazione Internazionale
Principali attività e responsabilità	Coordinamento delle attività di Ateneo in ambito della Ricerca Scientifica e della Cooperazione Internazionale
Nome e indirizzo del datore di lavoro	Università del Piemonte Orientale, Via Duomo 6, 13100 Vercelli (sede del Rettorato)
Tipo di attività e settore	Università / Ricerca scientifica / Cooperazione Internazionale
Date	2022-2024
Lavoro o posizione ricoperti	Presidente della Scuola di Medicina dell'Università del Piemonte Orientale
Principali attività e responsabilità	Coordinamento delle attività delle attività didattiche e assistenziali della Scuola di Medicina
Nome e indirizzo del datore di lavoro	Università del Piemonte Orientale, Via Duomo 6, 13100 Vercelli (sede del Rettorato)
Tipo di attività e settore	Università / Ricerca scientifica / Rapporti con il Sistema Sanitario Regionale
Date	2010-2024
Lavoro o posizione ricoperti	Presidente, Corso di Studi Laurea Magistrale in Medical Biotechnologies (internazionale)
Principali attività e responsabilità	Coordinamento delle attività delle attività didattiche del Corso di Studi
Nome e indirizzo del datore di lavoro	Università del Piemonte Orientale, Via Duomo 6, 13100 Vercelli (sede del Rettorato)
Tipo di attività e settore	Università / Ricerca scientifica / Rapporti con il Sistema Sanitario Regionale
Date	2012-2019
Lavoro o posizione ricoperti	Componente del Senato Accademico dell'Università del Piemonte Orientale
Principali attività e responsabilità	Attività collegiale nel Senato Accademico
Nome e indirizzo del datore di lavoro	Università del Piemonte Orientale, Via Duomo 6, 13100 Vercelli (sede del Rettorato)
Tipo di attività e settore	Università / Organi Collegiali
Date	2015-2019
Posizione ricoperta	Board Member, European Hematology Association (EHA)
Principali attività e responsabilità	Attività di indirizzo e coordinamento delle attività di EHA
Nome e indirizzo del datore di Lavoro	EHA, Koninginnegracht 12b, The Hague/L'Aja, The Netherlands/Paesi Bassi (NL)
Tipo di attività e settore	Ricerca scientifica / Società scientifica
Date	2017-2023
Posizione ricoperta	Chair, European Hematology Association (EHA) Global Outreach Program Committee
Principali attività e responsabilità	Attività di formazione in ambito ematologico
Nome e indirizzo del datore di lavoro	EHA, Koninginnegracht 12b, The Hague/L'Aja, The Netherlands/Paesi Bassi (NL)
Tipo di attività e settore	Formazione clinica e scientifica a livello globale (ASIA, MENA, America Latina)
Date	2015-2024
Posizione ricoperta	Member, European Hematology Association (EHA) Education Committee
Principali attività e responsabilità	Attività di formazione in ambito ematologico
Nome e indirizzo del datore di lavoro	EHA, Koninginnegracht 12b, The Hague/L'Aja, The Netherlands/Paesi Bassi (NL)
Tipo di attività e settore	Formazione clinica e scientifica a livello europeo
Date	2023-2024
Posizione ricoperta	Chair, European Hematology Association (EHA) Community and Stakeholder Committee
Principali attività e responsabilità	Attività di formazione in ambito ematologico
Nome e indirizzo del datore di lavoro	EHA, Koninginnegracht 12b, The Hague/L'Aja, The Netherlands/Paesi Bassi (NL)
Tipo di attività e settore	Relazioni con altre Società Scientifiche in ambito ematologico; attività di formazione
Istruzione e formazione	
Date	1981-1987
Tipo della qualifica rilasciata	Laurea in Medicina e Chirurgia
Principali tematiche / competenze	Competenze relative all'attività di Medico Chirurgo

professionali acquisite
Nome e tipo d'organizzazione erogatrice
dell'istruzione e formazione

Università degli Studi di Torino

Date

1988-1991

Titolo della qualifica rilasciata

Dottorato di Ricerca in Oncologia Umana

Principali tematiche/competenze
professionali acquisite

Tematiche: patologia molecolare dei linfomi non-Hodgkin. Competenze acquisite: competenze di
ricerca scientifica applicate alla ematologia traslazionale

Nome e tipo d'organizzazione
erogatrice dell'istruzione e formazione

Università degli Studi di Torino

Date

1990-1994

Titolo della qualifica rilasciata

Specializzazione in Medicina Interna

Principali tematiche/competenze
professionali acquisite

Tematiche: ricerca sulle malattie linfoproliferative; Medicina Interna. Competenze acquisite:
Competenze di Medico Internista

Nome e tipo d'organizzazione
erogatrice dell'istruzione e formazione

Università degli Studi di Torino

Date

1994-1998

Titolo della qualifica rilasciata

Specializzazione in Ematologia

Principali tematiche/competenze
professionali acquisite

Tematiche: ricerca sulle malattie linfoproliferative; Ematologia. Competenze acquisite: competenze di
Medico Specialista in Ematologia

Nome e tipo d'organizzazione
erogatrice dell'istruzione e formazione

Università degli Studi di Torino

Pubblicazioni scientifiche

Indicatori bibliometrici secondo Scopus (9 Aprile 2025)

Numero di pubblicazioni scientifiche: **742**

h-index (Indice di Hyrsch): **103**

Citazioni ricevute: **41571**

Link all'elenco delle pubblicazioni

Scopus

<https://www.scopus.com/authid/detail.uri?authorId=57203031145>

Orcid

<https://orcid.org/0000-0002-4681-0151>

Iris

https://iris.uniupo.it/browse?type=author&authority=rp02814&sort_by=2&order=DESC

Altri incarichi e competenze personali

Altri incarichi

Componente del Consiglio Direttivo della Fondazione Italiana Linfomi; Componente del
Board del GIMEMA Working Party Sindromi Linfoproliferative Croniche

Madrelingua(e)

Italiano

Altra(e) lingua(e)

Autovalutazione

Livello europeo (*)

Inglese

Francese

Comprensione		Parlato		Scritto	
Ascolto	Lettura	Interazione orale	Produzione orale		
C1	C1	C1	C1	C1	
B2	B2	B2	B2	B2	

(*) [Quadro comune europeo di riferimento per le lingue](#)

Capacità e competenze sociali	- buono spirito di gruppo; - capacità di adeguamento ad ambienti multiculturali; - buone capacità di comunicazione (ad es. scrivere chiaramente o trasmettere efficacemente un'informazione) - buone capacità didattiche
Capacità e competenze organizzative	- leadership (attualmente coordino un gruppo di 30 persone); - senso dell'organizzazione (esperienza logistica); - buona attitudine alla gestione di progetti e di gruppi di ricerca e clinici
Capacità e competenze tecniche	- Esperienza clinica nel settore dell'Oncoematologia - Esperienza di direttore di una Struttura Complessa a Direzione Universitaria di Ematologia - Autore di più di 700 pubblicazioni scientifiche in ambito oncoematologico su riviste e libri internazionali - Principal investigator in più di 100 trial clinici con farmaci innovativi
Capacità e competenze informatiche	Office; altri software per ricerca clinica e molecolare; software di gestione clinica

Firma

Autorizzo il trattamento dei miei dati personali ai sensi del Decreto Legislativo 30 giugno 2003, n. 196 "Codice in materia di protezione dei dati personali".

Gianluca Gaidano



Novara, 9-4-2025

Il/La sottoscritto/a prende visione dell'informativa ai sensi dell'art. 13 del D. Lgs. N. 196/2003 ed esprime il proprio consenso al trattamento ed alla comunicazione dei propri dati personali per le sue finalità istituzionali, connesse o strumentali ai sensi dell'art. 13 del D.Lgs. n. 196/2003 e successive modificazioni.



Novara, 9-4-2025

Firma

CURRICULUM VITAE
Valentina Giai , M.D., PhD

Personal data

Date of birth: January 1, 1980
Place of birth: Pinerolo, Italy
Citizenship: Italian
Mailing address: Hematology Department,
Città della Salute e della Scienza di Torino, Presidio Molinette
Corso Bramante 88, 10125, Torino, Italy
Fax
Phone (work) +39-11-6335551-6335937
(mobile) +39-338-6164075
E-mail: vgiai@cittadellasalute.to.it; valentina.giai02@gmail.com

EDUCATION

1994 – 1999 High School at “Liceo Scientifico Marie Curie”, Pinerolo (To), Italy

1999 – 2005 School of Medicine and Surgery, University of Torino, Italy: MD, degree with the highest score (110/110). Italian Board Examination for M.D.

2006- 2010 Post-graduated School of Hematology; University of Torino

2011-2014 PhD Programme in "Medicina e Terapia Sperimentale" - University of Torino and grant winner ("Fondazione Bossolasco")

Professional records:

2005 Internship in Internal Medicine and in the Department of Hematology, University of Torino, Italy.

2006-2010 Residency and Fellowship as post-graduated student in Hematology, University of Torino, Italy

2010 Licensed in hematology (specialist)

2010-2012 Guest researcher at Karolinska Institutet (Stockholm, Sweden), Laboratory of Hematology, headed by Professor Eva Hellström Lindberg

2011-2014 PhD Programme in "Medicina e Terapia Sperimentale" - University of Torino and grant winner ("Fondazione Bossolasco")

2011-2014 PhD/Licentiate Program at Karolinska Institutet, Laboratory of Hematology and Regenerative Medicine (HERM), headed by Professor Eva Hellström Lindberg.

2012-2015 Residency as Hematologist at Azienda Ospedaliera Città della Salute e della Scienza, presidio Molinette, Department of Hematology, University of Torino, Italy

2015-2016 Hematology Consultant at Ospedale Cardinal Massaia, Asti, Italy

2015-2019 Attending physician in Haematology, Division of Hematology, Alessandria, Italy

2019-present Attending physician in Haematology, Department of Oncology and Hematology, Città della Salute e della Scienza, Torino, Italy

Scientific interests:

Basic research:

- **Studies on ROS levels in MDS hematopoietic stem and progenitor cells**
- In vitro studies of del(5q) Syndrome pathogenesis: FACS analysis of stem cell compartment, characterisation of stem and progenitor cells and their proliferative potential. Adhesion experiments of CD34+ cells from del(5q) patients on different kind of substrates*
- Characterisation of healthy CD34+ cells adhesion to different kind of substrates and FACS analysis of CD34+ cells subpopulations after the adhesion assay; study of adhesion molecules inhibition, using drugs already available commercially.*
- Imaging of human AML CD34+ cells with confocal microscope: cytoplasmatic or nuclear localisation of β -catenin, a protein involved in cancer pathogenesis and seemingly in resistance to chemotherapy.*
- In vitro studies of ABCB7 gene in RARS development, using retroviral vectors, qRT-PCR and Colony forming units (CFU)*
- In vitro studies of AML CD34+ cells and their phenotypical characterisation in correlation with CXCR4 expression and their susceptibility to chemotherapy.
- In vitro cultures of hematopoietic progenitors in the pre-clinical workup of a novel, orally active, proteasome inhibitor (CEP-18770).
- In vitro characterization of a new cell line from a case of Acute Monoblastic Leukemia.

**in collaboration with Karolinska Institutet*

Clinical research:

- Clinical protocols on new drugs in Paroxysmal Nocturnal Haemoglobinuria (*Principal Investigator*)
- Clinical protocols on Luspatercept in low risk RS MDS (*Principal Investigator*).
- Clinical protocols on oral Azacitidine as a maintenance therapy on AML and as front line therapy in low-risk MDS with thrombocytopenia (*Principal Investigator*).
- Clinical protocols on new tyrosine-kinase inhibitors (Nilotinib, Dasatinib and Pomatinib) in Chronic Myeloid Leukemia (*Principal Investigator*).
- Clinical protocols on high-dose erythropoietin versus placebo for the treatment of anaemia in low risk MDS patients.
- Observational studies on del(5q) patients treated with Lenalidomide.
- Clinical protocols of maintenance low-dose chemotherapy + differentiating agents in high-risk MDS and AML.
- Graduation thesis on treatment of symptomatic / transfusion dependent anemia in patients with myelodysplastic syndromes with high-dose erythropoietin + differentiating agents (13-cis-retinoic acid and dihydroxylated vitamin D3).

Clinical practice:

- Outpatient and inpatient care of neoplastic and non neoplastic hematological patients, in particular of patients affected by myelodysplastic syndromes, acute myeloid leukemias and myeloproliferative disorders.
- Routine in vitro cultures of erythroid progenitors in the diagnostic procedures for polyclonal patients.

Courses:

- Functional Fluorescence Microscopy Imaging (fFMI) in Biomedical research (05-27-2011)
- Flow Cytometry: from Theory to Application (09-30-2011)
- Live Cell Imaging (10-14-2011)
- Basic Course in Medical Statistics (04-02-2012)
- GCP Training at 07/02/2022

PUBLICATIONS:

Chronic myeloid leukemia outcomes according to baseline risk and first-line treatment in real-world settings: Data from the Italian Network/CML Campus.

Giai V, Rosso T, Castagnetti F, Pregno P, Bonifacio M, Capodanno I, Tiribelli M, Stagno F, Caocci G, Gozzini A, Luciano L, Galimberti S, Bocchia M, Patriarca A, Lanzarone G, Martino B, Guella A, Scortechini AR, Fava C, Fozza C, Sica S, Di Renzo N,

Musto P, Pastore D, Maggi A, Pizzuti M, Antonia Melillo LM, Carella AM, Tarantini G, Mele A, Calistri E, Coppi MR, Saccona F, Scalzulli E, Battaglio B, Iezza M, Bitetti C, Freilone R, Rosti G, Albano F, Pane F, Specchia G, Ciccone G, Saglio G, Breccia M. **Cancer**. 2025 Jul 1;131(13):e35963. doi: 10.1002/cncr.35963.

Phase 3 randomized COMMODORE 1 trial: Crovalimab versus eculizumab in complement inhibitor-experienced patients with paroxysmal nocturnal hemoglobinuria.

Scheinberg P, Clé DV, Kim JS, Nur E, Yenerel MN, Barcellini W, Bonito D, Giai V, Hus M, Lee Y, Lekue CB, Panse J, Ueda Y, Buatois S, Gentile B, Kiialainen A, Patel H, Sreckovic S, Uguen M, Edwards J, Nagy Z, Kulasekararaj AG. **Am J Hematol**. 2024 Sep;99(9):1757-1767.

Real-World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi-Resistant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patient Population.

Breccia M, Rossi AR, Giai V, Martino B, Fava C, Annunziata M, Abruzzese E, Binotto G, Baratè C, Nardoza AP, Misto A, Coco P, Calafiore V, Carraro MC, Cattina F, Cavazzini F, Corsetti MT, Crucitti L, Crugnola M, Di Veroli A, Dittono P, Ermacora A, Ferrara F, Genua A, Gozzini A, Impera S, Iurlo A, Levato L, Luciano L, Miggiano MC, De Gobbi M, Santoro M, Scappini B, Scortechini AR, Patriarca A, Rosati S, Russo S, Sancetta R, Sanpaolo G, Santeramo TM, Sibilla S, Sorà F, Sportoletti P, Stagno F, Trabacchi E, Castagnetti F. **Hematol Oncol**. 2025 May;43(3):e70101. doi: 10.1002/hon.70101.

Sorafenib in combination with intensive chemotherapy for relapsed or refractory FLT3-ITD positive acute myeloid leukemia: A two centers experience.

Urbino I, Secreto C, Apolito V, Olivi M, Arrigo G, Boscaro E, Catania FM, D'Ardia S, Frairia C, Giai V, Freilone R, Bruno B, Lanzarone G, Giaccone L, Busca A, Dellacasa CM, Ferrero D, Audisio E, Cerrano M. **Leuk Res**. 2024 Jan;136:107421.

The new Systematic Coronary Risk Evaluation (SCORE2 and SCORE2-OP) estimates the risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib or ponatinib.

Mulas O, Abruzzese E, Luciano L, Iurlo A, Attolico I, Castagnetti F, Galimberti S, Bonifacio M, Annunziata M, Gozzini A, Orlandi EM, Stagno F, Binotto G, Pregno P, Fozza C, Loi M, Trawinska MM, De Gregorio F, Cattaneo D, Albano F, Iezza M, Baratè C, Scaffidi L, Elena C, Giai V, Scalzulli E, Breccia M, La Nasa G, Caocci G. **Ann Hematol**. 2024 Feb;103(2):427-436.

Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia.

Efficace F, Cottone F, Yanez B, Kota V, Castagnetti F, Caocci G, Bonifacio M, Patriarca A, Capodanno I, Miggiano MC, Tiribelli M, Breccia M, Luciano L, Giai V, Iurlo A, Abruzzese E, Fava C, Dinner S, Altman JK, Rosti G, Cortes J, Vignetti M, Cella D. **Cancer**. 2024 Jan;130(2):287-299.

Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts.

Lanino L, Restuccia F, Perego A, Ubezio M, Fattizzo B, Riva M, Consagra A, Musto P, Cilloni D, Oliva EN, Palmieri R, Poloni A, Califano C, Capodanno I, Itri F, Elena C, Fozza C, Pane F, Pelizzari AM, Breccia M, Di Bassiano F, Crisà E, Ferrero D, Giai V, Barraco D, Vaccarino A, Griguolo D, Minetto P, Quintini M, Paolini S, Sanpaolo G, Sessa M, Bocchia M, Di Renzo N, Diral E, Leuzzi L, Genua A, Guarini A, Molteni A, Nicolino B, Occhini U, Rivoli G, Bono R, Calvisi A, Castelli A, Di Bona E, Di Veroli A, Ferrara F, Fianchi L, Galimberti S, Grimaldi D, Marchetti M, Norata M, Frigeni M, Sancetta R, Selleri C, Tanasi I, Tosi P, Turrini M, Giordano L, Finelli C, Pasini P, Naldi I, Santini V, Della Porta MG; Fondazione Italiana Sindromi Mielodisplastiche (FISiM) Clinical network (<https://www.fisimematologia.it/>). **Am J Hematol**. 2023 May 24. doi: 10.1002/ajh.26960.

Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS).

Oliva EN, Riva M, Niscola P, Santini V, Breccia M, Giai V, Poloni A, Patriarca A, Crisà E, Capodanno I, Salutati P, Reda G, Cascavilla N, Ferrero D, Guarini A, Tripepi G, Ianni G, Russo E, Castelli A, Fattizzo B, Beltrami G, Bocchia M, Molteni A, Fenaux P, Germing U, Ricco A, Palumbo GA, Impera S, Di Renzo N, Rivellini F, Buccisano F, Stamatoullas-Bastard A, Liberati AM, Candoni A, Delfino IM, Arcadi MT, Cufari P, Rizzo L, Bova I, D'Errigo MG, Zini G, Latagliata R. **J Clin Oncol**. 2023 Jun 9;JCO2202699. doi: 10.1200/JCO.22.02699.

Validation of SIE/SIES/GITMO consensus criteria for unfitnes to predict early mortality and survival in acute myeloid leukaemia patients treated with hypomethylating agents and venetoclax.

Apolito V, Arrigo G, Vasseur L, Olivi M, Perrone S, Giai V, Secreto C, Di Biase F, De Simone MC, Copia C, Gravetti A, Freilone R, Bruno B, Lanzarone G, Beggiato E, Frairia C, Audisio E, D'Ardia S, Ferrero D, Cerrano M, Ferrara F. **Br J Haematol**. 2023 Nov;203(4):e98-e101

Prospective monitoring of chronic myeloid leukemia patients from the time of TKI discontinuation: the fate of peripheral blood CD26⁺ leukemia stem cells.

Pacelli P, Santoni A, Sicuranza A, Abruzzese E, **Giai V**, Crugnola M, Annunziata M, Galimberti S, Iurlo A, Luciano L, Sorà F, Fava C, Bestoso E, Marzano C, Cartocci A, Defina M, Sammartano V, Cencini E, Raspadori D, Bocchia M. **Front Pharmacol.** 2023 May 26;14:1194712. doi: 10.3389/fphar.2023.1194712.

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes.

Garcia-Manero G, Santini V, Almeida A, Platzbecker U, Jonasova A, Silverman LR, Falantes J, Reda G, Buccisano F, Fenaux P, Buckstein R, Díez Campelo M, Larsen S, Valcarcel D, Vyas P, Giai V, Oliva EN, Shortt J, Niederwieser D, Mittelman M, Fianchi L, La Torre I, Zhong J, Laille E, Lopes de Menezes D, Skikne B, Beach CL, Giagounidis A. **J Clin Oncol.** 2021 May 1;39(13):1426-1436.

Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.

Wei AH, Döhner H, Pocock C, Montesinos P, Afanasyev B, Dombret H, Ravandi F, Sayar H, Jang JH, Porkka K, Selleslag D, Sandhu I, Turgut M, **Giai V**, Ofra Y, Kizil Çakar M, Botelho de Sousa A, Rybka J, Frairia C, Borin L, Beltrami G, Čermák J, Ossenkoppele GJ, La Torre I, Skikne B, Kumar K, Dong Q, Beach CL, Roboz GJ; QUAZAR AML-001 Trial Investigators. **N Engl J Med.** 2020 Dec 24;383(26):2526-2537.

SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience

Sandra Mossuto, Enrico Attardi, Francesco Alesiani, Emanuele Angelucci, Enrico Balleari, Massimo Bernardi, Gianni Binotto, Costanza Bosi, Anna Calvisi, Isabella Capodanno, Antonella Carbone, Andrea Castelli, Marco Cerrano, Rosanna Ciancia, Daniela Cilloni, Marino Clavio, Cristina Clissa, Elena Crisà, Monica Crugnola, Matteo G. Della Porta, Nicola Di Renzo, Ambra Di Veroli, Roberto Fattizzo, Carmen Fava, Susanna Fenu, Ida L. Ferrara, Luana Fianchi, Carla Filì, Carlo Finelli, **Valentina Giai**, Francesco Frattini, Valentina Gaidano, Gianluca Guaragna, Svitlana Gumenyuk, Roberto Latagliata, Stefano Mancini, Emanuela Messa, Alfredo Molteni, Pellegrino Musto, Pasquale Niscola, Esther Oliva, Giuseppe A. Palumbo, Annamaria Pelizzari, Federica Pilo, Antonella Poloni, Marta Riva, Flavia Rivellini, Chiara Sarlo, Mariarita Sciumé, Roberto Secchi, Carmine Selli, Agostino Tafuri, Valeria Santini. **HEMASPHERE** 2020

Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.

Fenaux P, Platzbecker U, Mufti GJ, Garcia-Manero G, Buckstein R, Santini V, Díez-Campelo M, Finelli C, Cazzola M, İlhan O, Sekeres MA, Falantes JF, Arrizabalaga B, Salvi F, **Giai V**, Vyas P, Bowen D, Selleslag D, DeZern AE, Jurcic JG, Germing U, Götze KS, Quesnel B, Beyne-Rauzy O, Cluzeau T, Voso MT, Mazure D, Vellenga E, Greenberg PL, Hellström-Lindberg E, Zeidan AM, Adès L, Verma A, Savona MR, Laadem A, Benzohra A, Zhang J, Rampersad A, Dunshee DR, Linde PG, Sherman ML, Komrokji RS, List AF.

N Engl J Med. 2020 Jan 9;382(2):140-151. doi: 10.1056/NEJMoa1908892.

PMID: 31914241

SARS-CoV-2 vaccination in patients with paroxysmal nocturnal hemoglobinuria: An Italian multicenter survey.

Giannotta JA, Fattizzo B, Bortolotti M, Girmenia C, Ielo C, Metafuni E, Visentin A, Apolito V, Lucchesi A, **Giai V**, Beggiato E, Di Bona E, Giglio F, Sica S, Iori AP, Barcellini W. **Am J Hematol.** 2022 Mar 23;10.1002/ajh.26545. doi: 10.1002/ajh.26545

Hypocellular myelodysplastic syndromes (h-MDS): from clinical description to immunological characterization in the Italian multi-center experience.

Calabretto G, Attardi E, Teramo A, Trimarco V, Carraro S, Mossuto S, Barilà G, Vicenzetto C, Gasparini VR, Crugnola M, Niscola P, Poloni A, **Giai V**, Gaidano V, Finelli C, Bertorelle R, Candiotti C, Pizzi M, Binotto G, Facco M, Vianello F, Trentin L, Semenzato G, Zambello R, Santini V. **Leukemia.** 2022 Jul;36(7):1947-1950. doi: 10.1038/s41375-022-01592-3. Epub 2022 May 21. PMID: 35597805

Hematopoietic Stem Cells (HSC) and Granulocyte Macrophage Progenitors (GMP) are the Oxidative Stress Targets in Low/Intermediate-1 Risk Myelodysplastic Syndromes.

Giai V, Bensi T, Bertassello C, Savio M, Ferrero D, Ciriello MM, Ladetto M.

J Biotechnol Biomed. 2022;5(4):226-235. doi: 10.26502/jbb.2642-91280063. Epub 2022 Nov 9. PMID: 36644527

Gilteritinib in Isolated Breast Relapse of FLT3 Positive Acute Myeloid Leukemia: A Case Report and Review of Literature.

Arrigo G, D'Ardia S, Audisio E, Cerrano M, Freilone R, **Giai V**, Secreto C, Urbino I, Frairia C. **Acta Haematol.** 2022;145(5):566-570. doi: 10.1159/000524878. Epub 2022 May 17.

Arsenic trioxide neurotoxicity in acute promyelocytic leukemia patients: a single center experience.

Arrigo G, Scaldaferri M, Audisio E, Boscaro E, Catania F, Cattel F, Celona L, Cerrano M, Freilone R, Giai V, Urbino I, D'Ardia S, Frairia C. **Leuk Lymphoma**. 2025 Mar;66(3):567-568. doi: 10.1080/10428194.2024.2427266. Epub 2024 Nov 8.

Philadelphia-Negative MPN: A Molecular Journey, from Hematopoietic Stem Cell to Clinical Features.

Giai V, Secreto C, Freilone R, Pregno P.

Medicina (Kaunas). 2021 Sep 30;57(10):1043. doi: 10.3390/medicina57101043. PMID: 34684081

Polycythemia Vera (PV): Update on Emerging Treatment Options.

Benevolo G, Vassallo F, Urbino I, Giai V. *Ther Clin Risk Manag*. 2021 Mar 16;17:209-221.

Validation of National Early Warning Score and Quick Sequential (sepsis-related) Organ Failure Assessment in acute myeloid leukaemia patients treated with intensive chemotherapy.

Frairia C, Nicolino B, Secreto C, Messa E, Arrigo G, Busca A, Cerrano M, D'Ardia S, Dellacasa C, Evangelista A, Freilone R, Giai V, Priolo G, Urbino I, Audisio E. *Eur J Haematol*. 2023 Jun;110(6):696-705. doi: 10.1111/ejh.13952. Epub 2023 Mar 24. PMID: 36919878

Levofloxacin Prophylaxis Versus no Prophylaxis in Acute Myeloid Leukemia During Post-Induction Aplasia: a Single Center Study.

Urbino I, Frairia C, Busca A, Corcione S, D'Ardia S, Dellacasa CM, Giai V, Secreto C, Freilone R, De Rosa FG, Aydin S, Ciccone G, Rosato R, Cerrano M, Audisio E. *Mediterr J Hematol Infect Dis*. 2023 Mar 1;15(1):e2023022. doi: 10.4084/MJHID.2023.022. eCollection 2023. PMID: 36

Combining the HCT-CI, G8, and AML-Score for Fitness Evaluation of Elderly Patients with Acute Myeloid Leukemia: A Single Center Analysis.

Aydin S, Passera R, Cerrano M, Giai V, D'Ardia S, Iovino G, Dellacasa CM, Audisio E, Busca A. *Cancers* (Basel). 2023 Feb 4;15(4):1002. doi: 10.3390/cancers15041002.

Frequency and risk factors for thrombosis in acute myeloid leukemia and high-risk myelodysplastic syndromes treated with intensive chemotherapy: a two centers observational study.

Martella F, Cerrano M, Di Cuonzo D, Secreto C, Olivi M, Apolito V, D'Ardia S, Frairia C, Giai V, Lanzarone G, Urbino I, Freilone R, Giaccone L, Busca A, Dellacasa CM, Audisio E, Ferrero D, Beggiato E. *Ann Hematol*. 2022 Apr;101(4):855-867. doi: 10.1007/s00277-022-04770-6. Epub 2022 Feb 7. PMID: 35128571

Glitteritinib in isolated breast relapse of FLT3positive acute myeloid leukemia: a case report and review of literature.

Arrigo G, D'Ardia S, Audisio E, Cerrano M, Freilone R, Giai V, Secreto C, Urbino I, Frairia C. *Acta Haematol*. 2022 May 17. doi: 10.1159/000524878.

Evolving Therapeutic Approaches for Older Patients with Acute Myeloid Leukemia in 2021.

Urbino I, Secreto C, Olivi M, Apolito V, D'Ardia S, Frairia C, Giai V, Aydin S, Freilone R, Dellacasa C, Giaccone L, Ferrero D, Audisio E, Busca A, Cerrano M. *Cancers* (Basel). 2021 Oct 11;13(20):5075. doi: 10.3390/cancers13205075.

Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network.

Specchia G, Pregno P, Breccia M, Castagnetti F, Monagheddu C, Bonifacio M, Tiribelli M, Stagno F, Caocci G, Martino B, Luciano L, Pizzuti M, Gozzini A, Scortechini AR, Albano F, Bergamaschi M, Capodanno I, Patriarca A, Fava C, Rege-Cambrin G, Sorà F, Galimberti S, Bocchia M, Binotto G, Reddicono G, DiTonno P, Maggi A, Sanpaolo G, De Candia MS, Giai V, Abruzzese E, Miggiano MC, La Barba G, Pietrantuono G, Guella A, Levato L, Mulas O, Saccona F, Rosti G, Musto P, Di Raimondo F, Pane F, Baccarani M, Saglio G, Ciccone G. *Front Oncol*. 2021 Aug 26;11:739171. doi: 10.3389/fonc.2021.739171. eCollection 2021. PMID: 34513714

A Retrospective Analysis about Frequency of Monitoring in Italian Chronic Myeloid Leukemia Patients after Discontinuation.

Dragani M, Rege Cambrin G, Berchiolla P, Dogliotti I, Rosti G, Castagnetti F, Capodanno I, Martino B, Cerrano M, Ferrero D, Gambacorti-Passerini C, Crugnola M, Elena C, Breccia M, Iurlo A, Cattaneo D, Galimberti S, Gozzini A, Bocchia M, Lunghi F, Cedrone M, Sgherza N, Luciano L, Russo S, Santoro M, Giai V, Caocci G, Levato L, Abruzzese E, Sora F, Saglio G, Fava C. *J Clin Med*. 2020 Nov 17;9(11):3692. doi: 10.3390/jcm9113692.

Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP.

Baccarani M, Abruzzese E, Accurso V, Albano F, Annunziata M, Barulli S, Beltrami G, Bergamaschi M, Binotto G, Bocchia M, Caocci G, Capodanno I, Cavazzini F, Cedrone M, Cerrano M, Crugnola M, D'Adda M, Elena C, Fava C, Fazi P, Foza C, Galimberti S, Giai V, Gozzini A, Gugliotta G, Iurlo A, La Barba G, Levato L, Lucchesi A, Luciano L, Lunghi F, Lunghi M, Malagola M, Marasca R, Martino B, Melpignano A, Miggiano MC, Montefusco E, Musolino C, Palmieri F, Pregno P, Rapezzi D, Rege-

Cambrin G, Rupoli S, Salvucci M, Sancetta R, Sica S, Spadano R, Stagno F, Tiribelli M, Tomassetti S, Trabacchi E, Bonifacio M, Breccia M, Castagnetti F, Pane F, Russo D, Saglio G, Soverini S, Vigneri P, Rosti G.
Blood Adv. 2019 Dec 23;3(24):4280-4290. doi: 10.1182/bloodadvances.2019000865.
PMID: 31869412

Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice.

Fava C, Rege-Cambrin G, Dogliotti I, Cerrano M, Berchialla P, Dragani M, Rosti G, Castagnetti F, Gugliotta G, Martino B, Gambacorti-Passerini C, Abruzzese E, Elena C, Pregno P, Gozzini A, Capodanno I, Bergamaschi M, Crugnola M, Bocchia M, Galimberti S, Rapezzi D, Iurlo A, Cattaneo D, Latagliata R, Breccia M, Cedrone M, Santoro M, Annunziata M, Levato L, Stagno F, Cavazzini F, Sgherza N, [Giai V](#), Luciano L, Russo S, Musto P, Caocci G, Sorà F, Iuliano F, Lunghi F, Specchia G, Pane F, Ferrero D, Baccarani M, Saglio G.
Haematologica. 2019 Aug;104(8):1589-1596. doi: 10.3324/haematol.2018.205054. Epub 2019 Feb 28.
PMID: 30819917

Progression in Patients With Low- And intermediate-1-risk del(5q) Myelodysplastic Syndromes Is Predicted by a Limited Subset of Mutations

Christian Scharenberg, [Valentina Giai](#), Andrea Pellagatti, Leonie Saft, Marios Dimitriou, Monika Jansson, Martin Jädersten, Alf Grandien, Iyadh Douagi, Donna Neuberg, Katarina LeBlanc, Jacqueline Boulwood, Mohsen Karimi, Sten Eirik W Jacobsen, Petter S Woll, Eva Hellström-Lindberg.
Haematologica. 2017 Mar;102(3):498-508. doi: 10.3324/haematol.2016.152025.

The transporter ABCB7 is implicated in the phenotype of acquired refractory anemia with ring sideroblasts. Nikpour M, Scharenberg C, Liu A, Conte S, Karimi M, Mortera-Blanco T, [Giai V](#), Fernandez-Mercado M, Papaemmanuil E, Högstrand K, Jansson M, Vedin I, Wainscoat JS, Campbell P, Cazzola M, Boulwood J, Grandien A and Hellström-Lindberg E *Leukemia* 2013 Apr;27(4):889-96

CEP-18770: A novel, orally active proteasome inhibitor with a tumor- selective pharmacologic profile competitive with bortezomib.

Piva R, Ruggeri B, Williams M, Costa G, Tamagno I, Ferrero D, [Giai V](#), Coscia M, Peola S, Massaia M, Pezzoni G, Allievi C, Pescalli N, Cassin M, di Giovine S, Nicoli P, de Feudis P, Strepponi I, Roato I, Ferracini R, Bussolati B, Camussi G, Jones- Bolin S, Hunter K, Zhao H, Neri A, Palumbo A, Berkers C, Ovaa H, Bernareggi A, Inghirami G. *Blood.* 2008 Mar 1;111(5):2765-75.

• **Efficacy of a combination of human recombinant erythropoietin + 13- cis-retinoic acid and dihydroxylated vitamin D3 to improve moderate to severe anaemia in low/intermediate risk myelodysplastic syndromes.** Ferrero D, Darbesio A, [Giai V](#), Genuardi M, Dellacasa CM, Sorasio R, Bertini M, Boccadoro M. *Br J Haematol.* 2009 Feb;144(3):342-9

• **A retrospective study on 226 Polycythemia Vera patiens: impact of median haematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs** Crisà E, Venturino E, Passera R, Prina M, Schinco PC, Borchellini A, [Giai V](#), Ciocca Vasino MA, Bazzan M, Vaccarino A, Boccadoro M and Ferrero D. *Ann Hematology* 2010 Jul;89(7):691-9.

• **Telomere loss in Philadelphia-negative hematopoiesis after successful treatment of chronic myeloid leukemia: evidence for premature aging of the myeloid compartment.** Lobetti-Bodoni C, Ferrero D, Genuardi E, Passera R, Bernocco E, Sia D, Grignani G, Crisà E, Monitillo L, Rocci A, Drandi D, [Giai V](#), Zanni M, Boi M, Isaia G, Barbero D, Lunghi M, Abruzzese E, Radaelli F, Pini M, Pregno P, Carlo-Stella C, Gaidano G, Boccadoro M, Ladetto M. *Mech Ageing Dev.* 2012 Jul;133(7):479-88.

• **Survival improvement of poor- prognosis AML/MDS patients by maintenance treatment with low-dose chemotherapy and differentiating agents.** Ferrero D, Crisà E, Marmont F, Audisio E, Frairia C, [Giai V](#), Gatti T, Festuccia M, Bruno B, Riera L, Passera R, Boccadoro M. *Ann Hematol.* 2014 Apr 6.

• **How many patients can proceed from chronic myeloid leukaemia diagnosis to deep molecular response and long-lasting imatinib discontinuation? A real life experience.** Ferrero D, Cerrano M, Crisà E, Aguzzi C, [Giai V](#), Boccadoro M. *Br J Haematol.* 2016 Feb 23

• **Anemia in the Elderly: not Always what it Seems.** Cerrano M, Crisà E, [Giai V](#), Boccadoro M, Ferrero D. *Mediterr J Hematol Infect Dis.* 2016 Feb 25;8(1)

ORAL COMMUNICATIONS AT NATIONAL and INTERNATIONAL CONFERENCES:

- “Adhesion of hematopoietic stem and progenitor cells to surrogate microenvironments” First Nordic Conference on the Biology of Myelodysplastic Syndromes, November 16th-17th 2011, Rosersbergs Palace, Sweden.
- “Clinical aspects of Myelodysplastic Syndromes”, Erasmus students Lecture, May 22nd 2012, Dept of Medicine, HERM, Karolinska Institutet, Stockholm, Sweden.
- “Analisi immunofenotipica di sottopopolazioni di cellule staminali e progenitori di Leucemia Acuta Mieloide e loro interazione con molecole di adesione del microambiente midollare” Under 40 in Hematology, November 15th-16th 2012, Napoli, Italy
- “A case of AML in the elderly”, Rapid Fire in Hematology, Esperienze cliniche a confronto sulle Sindromi Mielodisplastiche e sulla Leucemia Acuta Mieloide, November 27th 2012, Milan, Italy.
- “Adhesion of hematopoietic stem and progenitor cells to surrogate microenvironments” Società Italiana di Ematologia, Verona 2013
- “Investigating basal and mobilized peripheral CD34+ cells: differences among the same entity “ Under 40 in Hematology, November 13th-14th 2014, Roma, Italy
- “Different composition of hematopoietic stem and progenitor cells between peripheral blood and bone marrow: biological and clinical implications” Società Italiana di Ematologia Sperimentale, Rimini, Ottobre 2016
- **PREMI**

EHA 2012 Travel Grant winner con l’abstract “Characterization of hematopoietic stem and progenitor cells adhesion to surrogate microenvironments”

Dr. Valentina Giai authorizes the treatment of own personal data as D. Lgs. 196/03 in order to comply with how much requested from D.M. 21.12.2007 and in accordance with EU General Data Protection Regulation (GDPR) (EU) 2016/679.

Torino, august 12 2025



	MARCHETTI MONIA Birth date: 31-07-1971 Email: monia.marchetti@uniupo.it PEC: monia.marchetti.yjw7@pec.al.omceo.it National board number: 5235 (Alessandria)
BIBLIOMETRIC INDEXES	ORCID: /0000-0001-7615-0572 Web of Science ResearcherID AAH-9505-2019 Number of citations: 7800 (Scopus 05.02.2026) Google Scholar 9469 (Feb 2024) h-index: 43 (Scopus 04.06.2025) 49 (Google Scholar Feb 2024) Peer-reviewed international papers published: 172 [#40 as 1st author] Book chapters (or ASH educational): 4
POSITIONS Since 2020 – (current position) Prior positions: 2006-2019 2005-2019	Senior Haematologist – Outpatient Care of High-Risk Myeloid Neoplasms - Azienda Ospedaliera Universitaria SS Antonio e Biagio e Cesare Arrigo, Alessandria, Italy Contract professor – University of Eastern Piedmont Guideline Committee of the European Hematology Association (June 2025-) Guideline Committee of the Italian Society of Hematology Visiting professor at Siset Master Teaching Professor- Resident School Hematology - University of Eastern Piedmont Senior Hematologist – Outpatient Care for Blood neoplasms- Community Hospital Cardinal Massaia, Asti, Italy Senior Researcher – Myelofibrosis Unit – IRCCS Policlinico San Matteo Foundation – Pavia, Italy
PROJECT LEADERSHIP	Member of the EHA Guidelines Board Methodology Chair of 25 clinical practice guidelines (6 national guidelines in the SNLG ISS national repository, 3 EBMT guidelines, 4 ELN guidelines, 14 guidelines by the Italian Society of Hematology) and 2 international consensus papers (Evans syndrome and MDS diagnostic classification) Current Methodology Chair of selected LeukemiaNet and EBMT (European Bone Marrow Transplant society) guidelines. Current Methodology Chair of the Guideline Program of the Italian Society of Hematology, the Italian Group for Bone Marrow Transplantation, the Italian Society for Experimental Hematology, the Italian Society of Hemapheresis and Cellular Therapy, the Italian Society of Thalassemia and Hemoglobinopathies.

	<i>Chair of a Specific Aim 3b in 2021 research project funded by the Italian Ministry of Health “ MINIMAL RESIDUAL DISEASE IN FOLLICULAR AND MANTLE CELL LYMPHOMA: DEVELOPMENT AND VALIDATION OF NOVEL TOOLS AND PREDICTIVE. Specific Aim 3b. Cost-benefit analysis of hypothetical use of MRD analysis in clinical trials and practice.</i> <i>Founder and manager of the Italian Registry of Myelofibrosis from 2011 to 2006.</i>
INSTRUCTION	<i>MD achieved in 1995 at University of Pavia. Board Certification achieved in 2001 at University of Pavia. PhD achieved in 2007 at University of Pavia.</i> <i>Highest scores cum laude at all the 3 certifications.</i>
TEACHING	<i>National Teaching Board Certification 9.7.2020 (holds for 9 years) of Assistant Professor in Hematology.</i>
EDITORIAL & REVIEWER ACTIVITIES	<i>Academic Editor PLOS-ONE</i> <i>Associate Editor FRONTIERS in ONCOLOGY (Hematology section) since 18.7.25</i> <i>Editor-in-chief INTERNATIONAL JOURNAL of HEMATOLOGY</i> <i>Editorial Board for 6 journals: CANCER VACCINES and IMMUNOTHERAPY, ACADEMIA ONCOLOGY, JOURNAL OF INTERNATIONAL MEDICAL RESEARCH, ACADEMIA MEDICINE, GLOBAL TRANSLATIONAL MEDICINE, TECHNOLOGY in CANCER RESEARCH & TREATMENT</i> <i>Guest Editor special issue “Immunotherapy against Myeloma” in Vaccine (2022), “Advanced therapies for Chronic Lymphocytic leukemia and related diseases” in the Journal of Clinical Medicine (2021), “Chronic Lymphocytic Leukemia and COVID19: what are we facing?” in the Journal of Clinical Medicine (2022)</i> <i>Referee for several peer-reviewed journals: American Journal of Hematology, Annals of Hematology, Haematologica, Journal of Medical Economics, Medical Oncology, Pharmacoeconomics, Blood Advances, Annals of Hematology, Circulation, Expert Reviews on Pharmacoeconomics and Outcomes Research, Mediterranean Journal of Hematology and Infectious Diseases.</i> <i>Reviewer of applications to the Carreras Leaders program 2024 –Josep Carreras Leukaemia research institute - Agency for Management of University and Research Grants (AGAUR)</i>
EXTERNAL REVIEWER	<i>1. Deutsche José Carreras Leukämie-Stiftung</i> <i>2. Spanish Josep Carreras Laeukemia Research Institute - CarrerasLeaders</i>
CLINICAL RESEARCH	<i>PI of more than 40 phase 2 or phase 3 trials and of several observational studies.</i>
MEETING	<i>8th November 2025 –Alessandria - MyMyelo – Sharing MPN experience is possible</i>

ORGANIZER	
MEMBERSHIPS	<i>European Hematology Association, Italian Society of Hematology, Italian GRADE Network</i>
KNOW-HOW	<i>High-level practice of English (spoken, written, comprehension)</i> <i>High-complexity SW user and developer: Office, Excel, Access, FileMakerPro, Tree-Age, Laser-AI, SPSS, Orange</i> <i>Management and planning of outpatient care units</i> <i>Management and planning of international Expert Panels developing clinical practice guidelines and consensus recommendations</i> <i>Fund raising – application wrtining and finalization</i>
PRIZES and AWARDS ORAL PRESENTATIONS at INTERNATIONAL MEETINGS	<i>Biannual Prize Gaetano Fichera for Oncology Research received on 13.12.2004</i> <i>GILEAD COMMUNITY AWARD 2016 for the project “P-to-P (Patients for Patients)”</i> ■ <i>Global Evidence Summit 2024: oral short communication</i> ■ <i>EBMT 2024: GVHD session chair</i> ■ <i>EHA 2024: sponsored symposium talk</i> ■ <i>EHA 2022 and 2023: 3 oral presentations</i> ■ <i>ELN annual meeting (Mannheim) 2021: 2 presentations</i> ■ <i>ELN annual meeting 2022: 1 presentation</i> ■ <i>ESH-MPN 2022: 1 presentation</i> ■ <i>ASH 2021 SCIENTIFIC WORKSHOP : 1 presentation</i> ■ <i>ASH 2014: 1 presentation</i> ■ <i>Member of the Scientific Faculty of the Annual EBMT Meeting 2024 (Glasgow)—Chair of GVHD session</i> ■ <i>ELN meeting – San Diego 8 Dec 2024</i> ■ <i>Keynote Speaker at MSD Investigator meeting MK006 – Rome 30 Jan 2025</i> ■ <i>Key Lecturer at National GITMO meeting (Turin, 5 th May 2025)</i> ■ <i>International GIN (Guideline International Network) meeting at Geneva, 16-19 September 2025: 2 long oral presentations</i> ■ <i>Plenary Session Speaker at National Meeting of the Italian Society of Hematology, 2025 October 21st, Milan.</i> ■ <i>EBMT Annual Meeting – March 24th 2026, Madrid</i>

PUBLISHED PAPERS

Legend: AU* = MM first, second or last author

N	First author	Title	Journal	Yr	Full reference	AU*	Impact factor
172		Phase 2 study of the lysine-specific demethylase 1 (LSD1) inhibitor bomedemstat for essential thrombocythemia	Blood Adv	2026	Blood Advances (in press) ADV-2025-017575R2:		
171	Corso A	Imaging in plasma-cell neoplasms: Italian experts' recommendations	EJH	2026	European Journal of Haematology	2 nd AU	1.97
170	Marchetti M	European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis	BCJ	2025	Blood Cancer Journal 2025;15(1): article n 207	1 st AU	11.6
169	Salamanton-Garcia J	Beyond the Usual Suspects: RSV Infection in Patients With Hematological Malignancies Compared to Influenza and SARS-COV-2—A Report From the EPICOVIDEHA/EPIRESEHA Registry in	Am J Hematol	2025	American Journal of Hematology 2025;101(1):95-109		9.9
168	Marchetti M	Key indications of passive immune prophylaxis against SARS-CoV-2 infection in malignant hematological disorders: An evidence-based analytic hierarchy process by an ad hoc Italian expert panel.	Vaccines	2025	In press	1 st AU	5.4
167	Vannucchi A	A novel ruxolitinib-sensitive CCDC6::JAK2 fusion gene in a patient with atypical JAK2 unmutated PV-like MPN	American Journal of Hematology	2026	Am J Hematol (in press)		9.9
166	Pinto A	Defining and Addressing the Current Unmet Medical Needs for the Frontline Treatment of Advanced Stage Aggressive Large B-Cell Lymphoma: A Consensus Opinion from an Ad Hoc Panel of Experts	Hematologica I Oncology	2025	Hematol Oncol 2025; 43:e70152		3.3
165	Efficace	Health-Related Quality of Life and Symptom Profile of Patients with BCR::ABL1-negative Myeloproliferative Neoplasms: Real-World Evidence from the GIMEMA-PROPHCY Observational Study	HemaSphere	2025	HEM-2025-0661.R1		
164	Tripodi A	Facts and Misfacts on D-dimer Testing. Consensus Guidance from the Italian Society on Thrombosis and Hemostasis (SISET)	Am J Hematol	2026	American Journal of Hematology 2026;101(1):97-109		10.0
163	Marchetti M	European LeukemiaNet criteria for safety and efficacy evaluation of new drugs for myelofibrosis.	Blood Cancer J	2025	Blood Cancer Journal (in press)	1 st AU	11.0
162	Marchetti M	A SWOT-consensus for CAR-T in follicular lymphoma: fine tuning of patient journey and selection	Hematologica I Oncology	2025	Hematological Oncology 2025;43(5): article n e70125	1 st AU	3.3
161	Serafin A	Venetoclax-based regimens in octogenarian patients with CLL: efficacy, safety, and comparison to BTKi in a multicenter cohort.	Blood Adv	2025	Blood Advances 2025; 14: 3576-84		
160	De Stefano V	Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design	Ann Hematol	2025	Annals of Hematology 2025;104:3553-66		3.0
159	Kittai A, Marchetti M	International Consensus Statement on Diagnosis, Evaluation, and Research of Richter Transformation: ERIC Recommendations	Blood	2025	Blood 2025;146:291-303	1 st AU	21.0
158	Salamanton-Garcia J	Respiratory Viruses in Patients With Hematological Malignancy in Boreal Autumn/Winter 2023–2024: EPICOVIDEHA-EPIFLUEHA Report	Am J Hematol	2025	American Journal of Hematology 2025;100:35874		10.0
157	Marchetti M	Should we target demethylation in acute myeloid leukemia?	ACTR	2025	AME Clinical Trials Reviews	1 st AU	
156	Marchetti M	Ph-Negative Chronic Myeloproliferative Neoplasms	Comprehensive Hematology and Stem Cell Research	2024	Comprehensive Hematology and Stem Cell Research: Volume 1-5, 2024, 2, pp. V2:120–V2:143	1 st AU	

155	Belosillo B	JAK2 mutations in polycythemia vera: from molecular origins to inflammatory pathways and clinical implications	Magazine of European medical Oncology	2025	Mag Eur Med Oncol 2025, 17(Suppl 4), pp. 79–93		
154	Fattizzo B	Clonal hematopoiesis in patients with autoimmune thrombocytopenia: an international multicenter study	Blood Advances	2024	Blood Advances 2025;9(3):488-95	2 nd AU	7.4
153	Komrokji RS	Data-driven harmonized classification system of myelodysplastic syndromes to improve patients' management in a real-world clinical setting. A study from the International Consortium for Myelodysplastic Syndromes (icMDS).	Lancet Haematology	2024	Lancet Haematol 2024, 11(11), pp. e862–e872		15.4
152	Lahmer T	Need for ICU and outcome of critically ill patients with COVID-19 and haematological malignancies: results from the EPICOVIDEHA survey	Infection	2024	Infection, 2024, 52(3), pp. 1125–1141		
151	Aiello TF	Dexamethasone treatment for COVID-19 is related to increased mortality in hematologic malignancy patients: results from the EPICOVIDEHA registry	Haematologica	2024	Haematologica, 2024, 109(8), pp. 2693–2700		
150	Colpo A	Treatment of acute and chronic graft-versus-host disease with extracorporeal photopheresis: update of best practice recommendations from Italian Society of Hemapheresis and Cell Manipulation (SidEM) and the Italian Transplant Group for Bone Marrow Transplantation, Hematopoietic Stem Cells and Cell Therapy (GITMO)	Transfusion and Apheresis Science	2024	Transfus Apher Sci 2024, 63(5), 103990	2 nd AU	
149	Fattizzo B	Evans syndrome: disease awareness and clinical management in a nation-wide ITP-NET survey	European Journal of Haematology	2024	Eur J Haematol., 2024, 113(4), pp. 472–476		
148	Fattizzo B	Diagnosis and management of Evans Syndrome in adults: first consensus recommendations	Lancet Haematol	2024	thelancethaematology-D-23-00565R1		
147	Salmanton-García J	Decoding the historical tale: COVID-19 impact on haematological malignancy patients – EPICOVIDEHA insights from 2020 to 2022	eClinicalMedicine	2024	eClinicalMedicine ; 71: 102553		
146	El-Ashwah S	The mortality of COVID-19 in CML patients from 2020 to 2022: results from the EPICOVIDEHA survey.	Leukemia and Lymphoma	2024	Leuk Lymph 2024;65(2):199-208		
145	Musto P	Survival in multiple myeloma and SARS-COV-2 infection through the COVID-19 pandemic: results from the epicovideha REGISTRY.	Hematologica Oncology	2024	Hematol Oncol 2024;42(1): e3240		
144	Visentin A	Continuous venetoclax in treatment-naïve TP53 disrupted patients with chronic lymphocytic leukemia: a chronic lymphocytic leukemia campus study.	American Journal of Hematology	2024	Am J Hematol 2023;99(9):E237-40		
143	Bos S	ERS/EBMT clinical practice guideline on treatment of pulmonary chronic graft-versus-host disease in adults	European Respiratory Journal	2024	European Respiratory Journal 2024;23:2301727	3 rd AU	
142	Benevolo G	Diagnosis and management of cardiovascular risk factors in patients with polycythemia vera	Vasc Health Risk Manag	2023	Vascular Health and Risk Management 2023;19:765-778	2 nd AU	
141	Ruffo	Nephrological Complications in Hemoglobinopathies: SITE Good Practice" has been published in JCM as part of the Special Issue Care and Management of Hemoglobinopathies, a Changing Global Health Problem: Guidelines and Recommendations from the Italian Society of Thalassemia and Hemoglobinopathies (SITE)	Journal of Clinical Medicine	2023	J Clin Med 2023 . doi: 10.3390/jcm12237476		
140	Busca	Outcome of COVID-19 in allogeneic stem cell transplant recipients: results from the EPICOVIDEHA registry.	Frontiers in Immunology	2023	Front Immunol		
139	Pennack O, Marchetti M	Prophylaxis and management of graft-versus-host disease after stem cell transplantation for haematological malignancies: updated consensus	Lancet Haematology	2023	Lancet Haematol 2023; 11(2): e147-159	1 st AU	26

		recommendations of the European Society for Blood and Marrow Transplantation					
138	Rossi G	Age, successive waves, immunization, and mortality in elderly COVID-19 haematological patients: EPICOCIDEHA findings.	International Journal of Infective Diseases	2023	Int J Infect Dis 2023; 137:98-110		
137	Salmanton-García J	Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-pair analysis from the EPICOCIDEHA registry.	International J Antimicrobial Agents	2023	Int J Antimicrob Agents 2023; 62(4):106952		
136	Visentin A	The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia: a study by ERIC, the European Research Initiative on CLL	American Journal of Hematology	2023	American Journal of Hematology, 2023, 98(12), 1856-68		
135	Marchetti M	Cost-effectiveness of KTE-X19 for relapsed-refractory mantle cell lymphoma	Leukemia and Lymphoma	2023	Leuk Lymphoma 2023;64(8):1442-50	1 st AU	
134	Lanino L	Real-world Efficacy and Safety of Luspatercept and Predictive Factors of Response in Patients with Lower-risk Myelodysplastic Syndromes with Ring Sideroblasts	American Journal of Hematology	2023	American Journal of Hematology, 2023, 98(8), pp. E204-E208		
133	Salmanton-García J	Molnupiravir compared wto nirmatrelvir/ritonavir for COVID1-19 in high-risk patients with haematological malignancy in Europe: a matched-pair analysis from the EPICOCIDEHA registry	eClinicalMedicine	2023	eClinicalMedicine 2023, 58, 101939		
132	Merli M	SARS-CoV-2 infection in patients with chronic lymphocytic leukemia: The Italian Hematology Alliance on COVID-19 cohort	Hematological Oncology	2023	Hematological Oncology, 2023, 41(1), pp. 128-138		
131	Van Doesum JA	Impact of SARS-CoV-2 vaccination and monoclonal antibodies on outcome post-CD19-directed CAR T-cell therapy: an EPICOCIDEHA survey.	Blood Advances	2023	Blood Adv 2023;7(11):2645-2655		
130	Marchetti M	Outcomes of SARS-CoV-2 infection in Ph-neg chronic myeloproliferative neoplasms: results from the EPICOCIDEHA registry	Therapeutic Advanced Hematology	2023	Ther Adv Hematol. 2023 Mar 11;14:20406207231154706. doi: 10.1177/20406207231154706	1 st AU	IF 5.4 (2021)
129	Marchesi F	COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOCIDEHA)	Haematologica	2023	Haematologica 2023 108:1 (22-33)		
128	Mauro FR	High rate of durable responses with undetectable minimal residual disease with frontline venetoclax and rituximab in young and fit patients with chronic lymphocytic leukemia and an adverse biologic profile: results of the GIMEMA phase II LLC 1518 'Veritas' study	Haematologica	2023	Haematologica 2023, 108(8), pp. 2091-2100		
127	Barbui T	Breakthrough infections in MPN-COVID vaccinated patients.	Blood Cancer Journal	2022	BCJ 2022;12:11, article number 154		IF 9.8 (2021)
126	Tiacci E	SARS-CoV-2 infection and vaccination in patients with hairy cell leukemia.	British Journal of Haematology	2022			IF >8 (2021)
125	Antic D	Thrombotic and bleeding complications in patients with chronic lymphocytic leukemia and severe COVID-19: a study of ERIC, the European Research Initiative on CLL.	Journal of Hematology Oncology	2022	J Hematol Oncol 2022;15: article number 116		
126	Salamanton-Garcia J	Improved outcome of COVID-19 in hematologic malignancy patients receiving a fourth dose of anti-SARS-CoV-2 vaccine.	HemaSphere	2022			
125	Cattaneo C	Simultaneous onset of haematological malignancy and COVID19: an EPICOCIDEHA survey	Cancers	2022			
124	Visentin A	Obinutuzumab plus chlorambucil versus ibrutinib in previously untreated chronic lymphocytic leukemia without TP53 disruption. A real-life CLL Campus study.	Frontiers in Oncology	2022			

123	Pagano L	Breakthrough COVID-19 in vaccinated patients with haematologic malignancies: results from EPICOVIDEHA survey.	Blood	2022	Blood 2022;140(26):2773-87		
122	Infante MS	B-cell malignancies treated with targeted drugs and SARS-CoV-2 infection: a European Haematology Association Survey (EPICOVIDEHA).	Frontiers in Oncology	2022	Front Oncol 2022;12:992137		
121	Lanza F	Lack of efficacy of convalescent plasma in COVID-19 patients with concomitant haematological malignancies: an Italian retrospective study	Haematologic al Oncology	2022	Hematol Oncol 2022;40(5):857-63		
120	Marchetti M	Old and new drugs for chronic lymphocytic leukemia: lights and shadows of real world evidence.	Journal of Clinical Medicine	2022		1 st AU	
119	Marchetti M	Appropriate management of polycythemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations.	Lancet Haematology	2022		1 st AU	>30
118	Marchetti M	Comparative clinical value of pharmacologic therapies for B-cell chronic lymphocytic leukemia: an umbrella analysis.	Journal of Clinical Medicine	2022		1 st AU	
117	Barbui T	Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients	American Journal of Hematology	2022	Am J Hematol 97(12):E470-473		
116	Casale M	Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE) for the management of endocrine complications in patients with haemoglobinopathies	Journal of Clinical Medicine	2022	J Clin Med 2022;11:1826		
115	Borgogna	Induction of robust humoral immunity against SARS-CoV-2 after vaccine administration in previously infected haematological cancer patients	British Journal of haematology	2022	Br J Haematol 202;199:463-7		
114	Lamure S	COVID-19 and hairy-cell leukemia: an EPICOVIDEHA survey.	Blood Advances	2022	Blood Adv 2022;6:3870-4		
113	Casale M	Good Clinical Practice of the Italian Society of Thalassemia and Haemoglobinopathies (SITE) for the management of endocrine complications in patients with haemoglobinopathies.	Journal of Clinical Medicine	2022			
112	Barbui T	Second versus first wave of COVID-19 in patients with MPN.	Leukemia	2022	Leukemia 2022;36:897-900		
111	Mauro FR	Efficacy of front-line ibrutinib and rituximab combination and impact of treatment discontinuation in unfit patients with chronic lymphocytic leukemia: results of the GIMEMA LLC1114 study.	Cancers	2022	Cancers 2022;14(1): art n 207		
110	Marchetti M	Pharmacoeconomic consideration for acute myeloid leukemia pharmacotherapy.	Expert Opinion on Pharmacotherapy	2021	Exp Opin Pharmacother 2021;23(2):263-272	1 st AU	
109	Visentin A	Continuous treatment with ibrutinib in 100 untreated patients with TP53 disrupted chronic lymphocytic leukemia. A real-life Campus CLL study	American Journal of Hematology	2021	Am J Haematol 2021: E95-99		13
108	Borgogna C	Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naïve patients	Blood Cancer Journal	2022	Blood Cancer J 2022;12(1):art n 8		9.8 (2021)
107	Pagano L	COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)	Journal of Hematologica l Oncology	2021	J Hematol Oncol 2021;14:168		13 (2021)
108	Chatzikonstantinou T	COVID-19 severity and mortality in patients with Chronic Lymphocytic Leukemia: an update of the international ERIC study	Leukemia	2021	Leukemia 2021;35:3444-54 doi: 10.1038/s41375-021-01450-8.		
107	Rigolin GM	Complex karyotype in unfit patients with CLL treated with ibrutinib and rituximab. The GIMEMA LLC1114 phase 2 study.	Blood	2021	Blood 2021; 138(25):2727-2730		
106	Visco C	A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study	Blood Advances	2022	Blood Adv 2022;6(1):327-338		4.84
105	Vitale C	Pre-existing and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs	Blood	2021	Blood 2021;137:3507-17.		

104	Passamonti F	Covid-19 elicits an impaired antibody response against SARS-CoV-2 in patients with hematological malignancies	British Journal of Haematology	2021	British Journal of Haematology 2021;195:371-77. Doi: 10.1111/bjh.17704		
103	Marchetti M	Cost-effectiveness of post-autotransplant lenalidomide in persons with plasma cell myeloma	Mediterranean Journal of Hematology and Infective Diseases	2021	Mediterranean J Hematol and Infect Dis. 2021;13: e2021034. Doi: 10.4084/MJHID.2021.034	1 st AU	
102	Rigolin GM	Efficacy of idelalisib and Rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the GIMEMA Working Group		2021	Hematol Oncol 2021; 39:326-335. Doi: 10.1002/hon.2861		
101	Baronciani D	Selecting β -thalassemia Patients for Gene Therapy: A Decision-making Algorithm	HemaSphere	2021	HemaSphere 2021;5:e622 doi: 10.1097/HS9.0000000000000622		
100	Scarfò L	COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.	Leukemia	2020	Leukemia 2020;34(9):2354-2363		
99	Cuneo A	Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and U.S. study.	Cancer Medicine	2020	Cancer Med 2020;9(22):8468-8479 DOI: 10.1002/cam4.3470		
98	Passamonti F	Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with hematological malignancies in Italy: a multicentre, cohort study.	The Lancet Haematology	2020	Lancet Haem 2020;7(10):e737-e745		24 (2022)
97	Cuneo A	Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a campus CLL report.	Blood	2020	doi: 10.1182/blood.202006854		
96	Marchetti M	Frontline Siltuximab and Rituximab in TAFRO syndrome: a case report.		2020	Eur J Haematol 2020;105:505-507. doi: 10.1111/ejh.13473	1 st AU	
95	Marchetti M	COVID-19-driven endothelial damage: complement, HIF-1 and ABL2 are potential pathways of damage and targets for cure.		2020	Ann Hematol 2020 2020;99(8):1701-1707.		
94	Barbui T	Reply to: Second primary malignancies in myeloproliferative neoplasms and the role of aspirin.	Leukemia	2020	Leukemia 2020;34(8):1208-1209. doi: 10.1038/s41375-019-0616-4		
93	Visentin A	Clinical characteristics and outcome of West Nile Virus infection in patients with lymphoid neoplasms: an Italian multicenter study.	HemaSphere	2020			
92	Mina R	Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study.	Blood Cancer Journal		Blood Cancer J. 2020 May 18;10(5):58. doi: 10.1038/s41408-020-0326-1.		
91	Marchetti M	Second cancers in MPN: a survival analysis from an international study.	American Journal of Hematology	2020	Am J Hematol 2020;95(3):295-301. doi: 10.1002/ajh.25700.	1 st AU	
90	Griggio V	HIF-1 α is overexpressed in leukemic cells from TP53-disrupted patients and is a promising therapeutic target in chronic lymphocytic leukemia.		2020	Haematologica 2020;105(4):1042-1054. doi: 10.3324/haematol.2019.217430		

89	De Stefano V	Arterial thrombosis in myeloproliferative neoplasms predicts second cancer. Clinical observations in a case-control study.	Blood	2020	Blood 2020;135(5):381-386. doi: 10.1182/blood.2019002614.		
88	Pennack O	Prophylaxis and management of graft versus host disease after stem cell transplantation for malignant haematologic malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation		2020	Lancet Hematology 2020;7(2):e157-e167. doi: 10.1016/S2352-3026(19)30256-X.	2 nd AU	24 (2022)
87	Barbui T	Second cancer in Philadelphia negative Myeloproliferative neoplasms (MPN-K). A nested case-control study		2019	Leukemia 2019;33:1996-2005		
86	Zinzani PL	Infection control in patients candidate to treatment with ibrutinib or idelalisib in chronic lymphocytic leukemia: recommendations from Italian Society of Hematology		2019	Leuk Res 2019;81:88-94.		
85	Cuneo A	Efficacy of bendamustine and rituximab as first salvage treatment in chronic lymphocytic leukemia and indirect comparison with ibrutinib: a GIMEMA, ERIC and UK CLL FORUM study	Haematologica	2018	Haematologica 2018 Jul;103(7):1209-1217.		
84	Rossi G	Short course of bortezomib in anemic patients with relapsed cold agglutinin disease. A phase II prospective GIMEMA study	Blood	2018	Blood 2018 Aug 2;132(5):547-550.		
83	Crisa E	The use of erythropoiesis-stimulating agents is safe and effective in the management of anemia in myelofibrosis patients treated with ruxolitinib.		2018	Br J Haematol. 2018 Sep;182(5):701-704		
83	Barbui A	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet	Leukemia	2018	Leukemia 2018; 32(5):1057-1069. doi: 10.1038/s41375-018-0077-1.		
81	Marchetti M	Lymphoproliferative disorders in patients with chronic myeloproliferative neoplasms: a systematic review		2018	Am J Hematol 2018;93:698-703 doi: 10.1002/ajh.25049	1 st AU	
80	Marchetti M	Cost-effectiveness of kinase inhibitors for hematologic malignancies: a systematic and critical review		2017	Expert Rev Pharmacoecon Outcomes Res 2017;17:469-80	1 st AU	
79	Marchetti M	Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations	Leukemia	2017	Leukemia 2017;31:882-8.	1 st AU	
78	Piubelli C	Identification of new BMP6 pro-peptide mutations in patients with iron overload	American Journal of Hematology	2017	Am J Hematol 2017;92:562-8		
77	Marchetti M	Value of innovation for hematologic malignancies	Journal of Medical Economics	2016	J Med Econ 2016;19:487-9.	1 st AU	
76	Liberato NL	Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in non-valvular atrial fibrillation: a systematic and qualitative review.		2016	Expert Rev Pharmacoecon Outcomes Res 2016;16:221-35.	2 nd AU	
75	Tarella C	. Italian Society of Hematology, Italian Society of Experimental Hematology, and Italian Group for Bone Marrow Transplantation guidelines for the management of indolent, nonfollicular B-cell lymphoma (marginal zone, lymphoplasmacytic, and small lymphocytic lymphoma)		2015	Clin Lymphoma Myeloma Leuk. 2015 Feb;15(2):75-85		
74	Rognoni C	Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis		2015	J Thromb Thrombolysis. 2015 Feb;39(2):149-54.		
73	Cuneo A	Appropriate use of bendamustine in first-line therapy of chronic lymphocytic leukemia. Recommendations from SIE, SIES, GITMO Group.		2014	Leuk Res 2014;38:1269-77		

72	Marchetti M	Biological therapies in Crohn's disease: are they cost-effective? A critical appraisal of model-based analyses		2014	Expert Rev Pharmacoecon Outcomes Res. 2014 Dec;14(6):815-24.	1 st AU	
71	Corradini P	SIE-SIES-GITMO guidelines for the management of adult peripheral T- and NK-cell lymphomas, excluding mature T-cell leukemias		2014	Ann Oncol 2014;25(12):2339-50	2 nd AU	
70	Perseghin P	A policy for the disposal of autologous hematopoietic progenitor cells: report from an Italian consensus panel.		2014	Transfusion 2014;54:2353-60	2 nd AU	
69	Olivieri J	Kinetics of the use of cryopreserved autologous stem cell grafts: a GITMO-SIEDM survey		2014	Cytotherapy 2014;16:101-10.		
68	Rognoni C	Apixaban, Dabigatran, and Rivaroxaban versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: a Cost-Effectiveness Analysis		2014	Clinical Drug Investigation 2014;34(1):9-17.	2 nd AU	
67	Perseghin P	Best practice recommendations in (1) peripheral blood stem cell mobilization and collection and (2) acute and chronic GvHD treatment using extracorporeal photopheresis. A joint effort from SIdEM (Società Italiana di Emaferesi e Manipolazione Cellulare) and GITMO (Gruppo Italiano Trapianto di Midollo Osseo).		2013	Transfus Apher Sci 2013;48(2):195-6.	2 nd AU	
66	Bassetti M	A research agenda on the management of intra-abdominal candidiasis: results from a consensus of multinational experts		2013	Intensive Care Med 2013;39:2092-106	2 nd AU	
65	Zinzani PL	SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma		2013	Am J Hematol 2013 Mar;88(3):185-92	2 nd AU	6.862
64	Catania G	Cancer-related fatigue in Italian cancer patients: validation of the Italian version of the Brief Fatigue Inventory (BFI)		2013	Support Care Cancer 2013 Feb;21(2):413-9.		
63	Pierelli L	Extracorporeal photopheresis for the treatment of acute and chronic GvHD in adults and children – best practice recommendations from a SIdEM (Società Italiana di Emaferesi e Manipolazione cellulare) and GITMO (Gruppo Italiano Trapianto Midollo Osseo) consensus process.		2013	Transfusion 2013 ;53:2340-52.		3.2
62	Marchetti M	Cost-effectiveness of top-down versus step-up strategies in patients with newly diagnosed active luminal Crohn's disease.		2013	Eur J Health Econ 2013 Dec;14(6):853-61	1 st AU	1.5 (2011)
61	Barosi G	SIE, SIES, GITMO evidence-based guidelines on novel agent (thalidomide, bortezomib and lenalidomide) in the treatment of multiple myeloma		2012	Ann Hematol 2012;91:875-88		2.61
60	Liberato NL	Adding docetaxel to cisplatin and fluorouracil in patients with unresectable head and neck cancer: a cost-utility analysis		2012	Annals of Oncology 2012;23:1825-32		6.42
59	Di Sabatino A	Optimal use and cost-effectiveness of biologic therapies in inflammatory bowel disease		2011	Intern Emerg Med. 2011 Oct;6 Suppl 1:17-27		2.05
58	Zinzani PL	Overview of alemtuzumab therapy for the treatment of T-cell lymphomas		2011	Leuk Lymphoma. 2011;53:789-95		2.58
57	Mauro FR	SIE, SIES, GITMO updated clinical recommendations for the management of chronic lymphocytic leukemia		2011	Leuk Res. 2011; 36(4):459-66		2.92
56	Olivieri A	Proposed definition of "poor mobilizer" in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo Italiano Trapianto di Midollo Osseo.		2011	Bone Marrow Transplantation 2011 47(3):342-51	2 nd AU	3.74
55	Pierelli L	Best practice for peripheral blood progenitor cell mobilization and collection in adults and children: results of a SIdEM and GITMO consensus process		2011	Transfusion 2011;52:893-905.		3.2
54	Casabianca A	Seronegative visceral leishmaniasis with relapsing and fatal course following rituximab treatment		2011	Infection 2011 Aug;39(4):375-8	2 nd AU	2.66
53	Santini V	Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines.		2010	Leuk Res 2010;34(12):1576-88.		2.55

52	Brusamolino E	Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up.		2009	Haematologica 2009 Apr;94(4):550-65		6.41
51	Morra E	Clinical management of primary non-APL Acute Myeloid Leukemia: practice guidelines by the Italian Society of Haematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.		2009	Haematologica 2009 Jan;94(1):102-12.		6.41
50	Tosi P	Consensus conference on the management of tumor lysis syndrome		2008	Haematologica 2008;93:1877-85		5.98
49	Zinzani PL	Practice guidelines for the management of extranodal non-Hodgkin's lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation		2008	Haematologica.2008;93:1364-71.		5.98
48	Angelucci E	Italian Society Haematology Practice Guidelines for the management of iron overload in thalassemia major and related disorders		2008	Haematologica 2008; 93: 741-52		5.98
47	Maserati E	Constitutional trisomy 8 mosaicism in primary myelofibrosis: relevance to clinical practice and warning for trisomy 8 studies.		2007	Cancer Genetics and Cytogenetics 2007; 179: 79-81		1.55
46	Barosi G	JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis		2007	Blood 2007;110:4030-		10.89
45	Rosti V	The expression of CXCR4 is down-regulated on the CD34+ cells of patients with myelofibrosis with myeloid metaplasia.		2007	Blood Cells Molecules and Diseases 2007;38:280-6		2.55
44	Liberato NL	Cost-effectiveness of adjuvant trastuzumab in human epidermal growth factor 2 – positive breast cancer		2007	Journal of Clinical Oncology 2007;25:625-33	2 nd AU	15.48
43	Marchetti M	Cost-effectiveness of adjuvanted influenza vaccination of healthy children 6 to 60 months of age.		2007	Human Vaccines 2007;3:14-22	1 st AU	
42	Brugiatelli M	Management of chronic lymphocytic leukemia: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.		2006	Haematologica 2006 Dec;91(12):1662-73.		5.03
41	Barosi G	Management of nodal diffuse-large-B-cell lymphomas: practice guidelines from the Italian Society of Haematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation.		2006	Haematologica 2006 Jan;91(1):96-103.		5.03
40	Barosi g	Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphoma: practice guidelines from the Italian Society of Haematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation		2005	Haematologica 2005;90:1237-1257		4.575
39	Barosi G	Response criteria for Myelofibrosis with Myeloid Metaplasia: Results of an Initiative of the European Myelofibrosis Network (EUMNET).		2005	Blood 2005;106:2849-53		10.131
38	Massa M	Circulating CD34+, CD133+, and Vascular Endothelial Growth Factor Receptor 2-positive endothelial progenitor cells in myelofibrosis with myeloid metaplasia		2005	Journal of Clinical Oncology 2005;23:5688-5695		11.310
37	Marchetti M	Cost-effectiveness of universal pneumococcal vaccination for infants in Italy		2005	Vaccine 2005; 23:4565-76	1 st AU	3.00
36	Huges DA	Cost minimization of on-demand maintenance therapy with proton pump inhibitors in patients with non-erosive gastroesophageal reflux disease – a Monte Carlo analysis for Italy.		2005	Expert Reviews in Pharmacoeconomics and Outcomes Research 2005;5:29-38.	2 nd AU	

35	Marchetti M	Low-dose thalidomide ameliorates cytopenias and splenomegaly in myelofibrosis with myeloid metaplasia: a phase II trial of 63 patients.		2004	Journal of Clinical Oncology 2004;22: 424-31.	1 st AU	9.8
34	Marchetti M	Cost-utility of inhaled corticosteroids in patients with moderate-to-severe asthma.		2004	Expert Review in Pharmacoeconomics and Outcomes Research 2004;4:549-564.	1 st AU	
33	Marchetti M	Drug-eluting stents: from evidence to policy		2004	Expert Review in Medical Device 2004;1:49-63	1 st AU	
32	Barosi G	Spleen neoangiogenesis in patients with myelofibrosis with myeloid metaplasia.		2004	Br J Haematol 2004;124:618-625		3.19
31	Barbui T	Evidence- and Consensus-Based Practice Guidelines for the Therapy of Essential Thrombocythemia. A statement from SIE, SIES and GITMO (Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation).	Haematologica	2004	Haematologica 2004;89:215-32		4.19
30	Tarricone R	What reimbursement for coronary revascularization with drug-eluting stents?	European Journal of Health Economics	2004	Eur J Health Econ 2004;5:309-16	2 nd AU	
29	Barosi G	Management of multiple myeloma and related disorders: guidelines from the Italian Society of Hematology (SIE), Italian Society of Experimental Hematology (SIES) and Italian Group for Bone Marrow Transplantation (GITMO).	Haematologica	2004	Haematologica 2004;89:717-741		4.10
28	Marchetti M	Clinical and economic impact of epoetins in cancer care: a review	Pharmacoeconomics	2004	Pharmacoeconomics 2004;22:1029-45	1 st AU	1.95
27	Marchetti M	Cost-utility and budget impact of third-generation aromatase inhibitors for advanced breast cancer.	Clinical Therapeutic	2004	Clin Ther 2004; 26:1546-1561.	1 st AU	3.01
26	Liberato NL	Clinical and economic issues in bisphosphonates treatment of advanced breast cancer	Drugs and Aging	2003	Drugs and Aging 2003; 20: 631-642	2 nd AU	2.79
25	Spivak JL	Chronic myeloproliferative disorders.	Hematology	2003	Hematology 2003:199-223.		
24	Marchetti M	Screening for factor V Leiden mutation in pregnant women	The Lancet	2002	Lancet 2002;360:1518.	1 st AU	15.39
23	Barosi G	High prevalence of a screening-detected, HFE-unrelated, mild idiopathic iron overload in Northern Italy		2002	Haematologica 2002;87:472-478		3.22
22	Alessandrino EP	Evidence- and consensus-based guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.		2002	Haematologica 2002;87:1286-1306.		3.22
21	Barosi G	Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of individual patient data from 5 studies		2002	Leuk Lymph 2002; 43 : 2301-2307		1.33
20	Barosi G	Diagnostic and clinical relevance of the number of circulating CD34-positive cells in myelofibrosis with myeloid metaplasia		2001	Blood 2001;98:3249-55		9.27
19	Marchetti M	Cost-effectiveness of screening and extended anticoagulation for carriers of both factor V Leiden and prothrombin G20210A.		2001	Quarterly Journal of Medicine 2001; 94:365-372	1 st AU	2.6
18	Marchetti M	Low-molecular-weight heparin versus warfarin for secondary prophylaxis of venous thromboembolism: cost-effectiveness analysis		2001	Am J Med 2001; 111:130-139.	1 st AU	6.1
17	Marchetti M	Pharmacoeconomics of fludarabine as first-line therapy for CLL.	New England Journal of Medicine	2001	N Engl J Med 2001;344:1166-7	1 st AU	29.06
16	Barosi G	Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia		2001	Haematol 2001;114:78-83		2.81
15	Cervantes F	Myelofibrosis with myeloid metaplasia in individuals 30 years old or younger individuals: presenting features, evolution and survival.		2001	Eur J Haematology 2001; 66:423-427		1.67

14	Gerli GC	Myelofibrosis with myeloid metaplasia with fatty bone marrow: report of a new case		2001	Haematologica 2001 Aug;86:885-6		3.21
13	Marchetti M	Cost-effectiveness of epoetin for reducing allogeneic blood transfusions in coronary artery by-pass		2001	Transfusion 2000;40:673-81	1 st AU	3.04
12	Magni P	Deciding when to intervene: the Markov decision planning approach for managing uncertainty about intervention-time		2000	International Journal of Medical Informatics 2000;60:237-53.		0.69
11	Marchetti M	Extended anticoagulation for prevention of recurrent venous thromboembolism in carriers of factor V Leiden: cost-effectiveness analysis.		2000	Thrombosis and Haemostasis 2000;84:752-7	1 st AU	4.37
10	Barosi G	The Italian Registry of Myelofibrosis is one year old.		2000	Haematologica 2000;85:1121-2.	2 nd AU	2.53
9	Barosi G	The clinical utility of epoetin in cancer patients: a matter of perspective.		2000	Haematologica 2000;85:449-50.	2 nd AU Last AU	2.53
8	Marchetti M	Long term cost-effectiveness of low-molecular weight heparin versus unfractionated heparin for the prophylaxis of venous thromboembolism in elective hip replacement		1999	Haematologica 1999;84(8):730-7	1 st AU	2.07
7	Barosi G	A model for analyzing the costs of autologous peripheral blood progenitor cells (PBPC) transplantation.		1999	Bone Marrow Transplantation 1999;23:719-25.	2 nd AU	2.27
6	Quaglini S	Decision support systems in health economics		1999	Top Health Inf Manage 1999;20:16-30.	Last AU	
5	Marchetti M	Prophylactic splenectomy and cholecystectomy in mild hereditary spherocytosis. Analyzing the decision in different clinical scenarios.		1998	Journal of Internal Medicine 1998;244:217-26.	1 st AU	1.53
4	Barosi G	Cost-effectiveness of recombinant human erythropoietin in the prevention of chemotherapy-induced anemia.		1998	British Journal of Cancer 1998;78:781-787.	2 nd AU	3.03
3	Barosi G	Testing for occult cancer in patients with idiopathic deep vein thrombosis – A decision analysis.		1997	Thrombosis and Haemostasis 1997;78:1319-1326	2 nd AU	4.58
2	Marchetti M	Beyond Bayes..		1996	Haematologica 1996;81:253-7	1 st AU	1.4
1	Barosi G	Cost-effectiveness of post-routine screening for an occult cancer in patients with idiopathic venous thromboembolism.		1995	Haematologica 1995;80 (Suppl. issue n.2): 61-65	1 st AU	1.2

ITALIAN-LANGUAGE PAPERS or NOT INDEXED JOURNALS

1. Marchetti M, Montillo M, Cuneo A, Mauro FR, Martelli E, Pedone MP. *Cost-effectiveness of idelalisib-rituximab for the treatment of relapsed-refractory chronic lymphocytic leukemia*. **Hematology International Journal** 2017;1(1):000106 (ISSN: 2578-501X indexed ResearchBib. doi: 10.23880/hij-16000106
2. Marchetti M.. *Clinical practice guidelines in hematology* **Haematologica** 2021 (suppl)
3. Marchetti M, et al. *Primary prophylaxis of venous thromboembolism in patients affected by hematologic malignancies (lymphoma, myeloma, acute leukemia). Guidelines from the Italian Society of Hematology*. **Haematologica** 2021 (suppl).
4. Marchetti M. *Clinical practice guidelines in hematology*. **Haematologica** 2020;105 (suppl 2): S7-S8
5. Barosi G, Marchetti M, Liberato NL. *La terapia delle sindromi mielodisplastiche- Linee-guida su evidenza e consenso – La metodologia dell’evidenza e del consenso per le linee-guida*. **Haematologica** 2002; 87 (suppl 3):2-4. [IF year 2002: 3.22]
6. Barosi G, Marchetti M, Longo G. *La terapia del mieloma multiplo - La metodologia dell’evidenza e del consenso per le linee guida*. **Haematologica** 2003;87:2-4. [IF year 2003: 3.45]
7. Barosi G, Marchetti M, Liberato LN. *La terapia della trombocitemia essenziale - Metodologia dell’evidenza e del consenso per le linee-guida*. **Haematologica** 2003;88 (suppl 11): 2-4. [IF year 2003: 3.45]
8. Di Michele D, Marchetti M, Magrini U, Di Pietro E, Pomante R, Barosi G. *Metaplasia mieloide: un criterio necessario per la diagnosi di mielofibrosi in pazienti asplenic*. **Giornale Italiano di Medicina Interna** 2006;5:112-114.
9. Marchetti M, Colombo GL. *Considerazioni cliniche ed economiche nel trattamento del cancro alla prostata: analisi costo-efficacia di bicalutamide vs flutamide in combinazione con LHRH*. **Farmacoeconomia e Percorsi Terapeutici** 2003; 4 (3): 153-168.
10. Casale M, Baldini M, Del Monte P, Gigante A, Grandone A, Origa R, Poggi M, Gadda F, Lai R, Marchetti M, Forni GL. *Le principali complicanze endocrinologiche nelle emoglobinopatie: buone pratiche cliniche della Società Italiana Talassemie ed Emoglobinopatie (SITE)**. **Recenti Prog Med** 2022;113:495-554.

BOOK CHAPTERS

- Barosi G, Marchetti M, Liberato NL, Ruperto N. *Metodologia della diagnosi medica: cap I (pp3-47) in: Progressi I – Fisiopatologia e Clinica – Diagnostica – Farmacoterapia*. Collana: **RECENTIA in MEDICINA**. UTET, Torino 2002.
- Benevolo G, Beggiato E, Biolé CA, Marchetti M, Melchio L, Milan A, Rapezzi D, Sartori C. *Gestione del rischio cardiovascolare nella Policitemia vera*. Collana: **In Focus**. Springer Healthcare Communications 2021
- “Philadelphia-negative Chronic Myeloproliferative neoplasms” in *Comprehensive Hematology and Stem Cell Research* (Elsevier, 2023)
<https://www.sciencedirect.com/science/article/pii/B9780443157172000159>

Tortona, 12th January 2026

Monia Marchetti



CURRICULUM VITAE

Andrea Patriarca, MD

PERSONAL DETAILS:

Full Name :	Andrea Patriarca
Specialty:	Hematology
Home Address:	via A. Avogadro 69, 13852, Quaregna-Cerreto
E-mail Address:	andrea.patriarca@uniupo.it
Telephone (home):	+390321/3733092
Telephone (mobile):	+393319949337
Nationality:	Italian
Gender:	Male
Date of Birth:	24 December 1980
Marital Status:	Married
GMC reg. number	7469997
Italian reg. number	863, Medical Index, Isernia

KNOWLEDGE OF LANGUAGES:

Language:	Skill
Italian	Native
English	B2
Danish	B1

QUALIFICATIONS/EDUCATION:

From (year):	To (year):	Name and location (city) of University	Subject or specialty	Level of course (diploma, degree, certificate, etc)
1999	2006	Medicine and Surgery, Università "G. d'Annunzio", Chieti (Advisor: Giovanni Davi)	Medicine and Surgery	Degree
2007	2011	Hematology specialty course, Università "G. d'Annunzio", Chieti (Advisor: Giovanni Davi)	General Hematology	Diploma
2021	2121	BLSD (basic live support 2nd Edition)	Mandatory training	Certificate
2022	2022	ACLS (Advanced Life Support)	Mandatory training	Certificate
2017	2023	GCP certificate	Mandatory training	Certificate

2020	2024	PhD in Medical Sciences and Biotechnology	PHD Course	Degree
------	------	---	------------	--------

MEDICAL AND ACADEMIC DEGREES:

Degree	Subject or Specialty	Year
Medicine and Surgery	General Medicine	2006
Hematologist diploma	General Clinical and Laboratory Hematology	2011
PhD in Medical Sciences and Biotechnology	PhD Medical Sciences and Biotechnology	2024

CURRENT EMPLOYMENT:

From (year):	To (year)	Employer	Location (City)	Position
2017		AOU Maggiore della Carità-Novara-Italy	Novara (NO)	Consultant in Hematology (Dirigente Medico in Ematologia)

PREVIOUS EMPLOYMENT:

From: (year)	To: (year)	Employer	Location (City)	Position
2007	2011	Università degli Studi "G. d'Annunzio"	Chieti	Young physician
2011	2012	Haematological Department, "S. Spirito" Hospital	Pescara	Freelance specialist on behalf of AIL
2012	2013	ASL Piemonte 11	Vercelli	Consultant in Hematology
2013	2014	Sygehuset Lillebælt	Vejle, Denmark	Consultant
2014	2014	Fondazione "Papa Giovanni Paolo II"	Campobasso (IT)	Assistant
2015	2015	"Infermi" Hospital	Biella (IT)	Locum Consultant
2015	Feb 2016	"Northern Lincolnshire NHS Trust"	Grimsby (UK)	Locum Consultant
Feb 2016	March 2017	IRCCS (Cancer Scientific and Research Center) CROB	Rionero in Vulture (IT)	Locum Consultant

TEACHING RESPONSIBILITIES

- 2017-present: Lecturer of Haematology, Nursing Degree (Corso di Studio in Infermieristica, Università del Piemonte Orientale, Novara.

- 2018-present: Lecturer of Morphology, Residency Program in Hematology (Scuola di Specializzazione in Ematologia), Università del Piemonte Orientale, Novara
- 2020-present: Lecturer of Hematopoietic Stem Cell Biology and Transplantation, Master Degree in Medical Biotechnologies, (international degree), Università del Piemonte Orientale, Novara
- 2020-present: Lecturer of Hematology, Residence Program in Hematology (Scuola di Specializzazione in Ematologia), Università del Piemonte Orientale, Novara
- 2020-present: Lecturer of Hematology, Residency Program in Paediatrics, Università del Piemonte Orientale, Novara

RESEARCH AND PUBLICATIONS

CLINICAL TRIALS

1. 2008-2010: Subinvestigator protocol A8851009 “A prospective, randomized trial comparing the efficacy of anidulafungin and voriconazole in combination to that of voriconazole alone when used for primary therapy of proven or probable invasive aspergillosis”.
2. 2008: Subinvestigator protocol Studio 01GIMEMA EudraCT: 2006-006210- 14: “Studio prospettico, randomizzato, multicentrico, controllato, sulla terapia antibiotica empirica della febbre nel paziente oncoematologico neutropenico: piperacillina/tazobactam + tigeciclina Vs. una monoterapia con piperacillina/tazobactam.”
3. 2007: Management of *Italian Thrombocythemia Registry* (RIT) for “Centro malattie rare del Sangue e degli Organi emopoietici”, Hematology Department “S. Santo” Hospital, Pescara
4. 2017: Principal Investigator for study GIMEMA ESTIT ITP 0815: Eltrombopag as Second line Therapy in adult patients with primary Immune Thrombocytopenia (ESTIT study) in an attempt to achieve long-term remission: a single arm multicenter phase II clinical and biological study. Eudract 2015-001327-23, CE 62/16
5. 2017-: Principal Investigator for study Low-PV randomized trial, benefit/risk profile of Pegylated proline-Interferon alpha-2b (AOP2014) added to the best available strategy based on phlebotomies in low-risk patients with Polycythemia Vera (PV). Eudract 2015-004717-25, CE 84/16
6. 2018-: Principal Investigator in Randomized phase III study of decitabine with or without HU in CMML. Eudract 2014-000200-10, CE 101/15
7. 2018-: Principal Investigator for study Eltrombopag for the treatment of thrombocytopenia due to low- and intermediate risk myelodysplastic syndromes. (EQoI-MDS). Eudract 2010-022890-33, CE 85/18
8. 2018-: Principal Investigator for study MPN-K: Secondary Cancers in Myeloproliferative Neoplasms, CE 34/18
9. 2018-: Principal investigator in A Phase 2, Open-Label Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia. Eudract 2017-003652-22, CE 149/18
10. 2018-: Principal Investigator for study MANIFEST, a Phase 2 Study of CPI-0610, a Bromodomain and Extraterminal Domain Inhibitor (BETi), alone or in Combination with Ruxolitinib Primary Myelofibrosis. Eudract 2018-000579-34, CE 17/19
11. 2019-: Principal Investigator in a phase II, single-arm, multicenter study of full treatment free remission in patients with chronic myeloid leukemia in chronic phase treated with nilotinib in first-line therapy who have achieved a sustained deep molecular response for at least 1 year: DANTE study. Eudract 2018-002898-21, CE 20/19
12. 2019-: Principal Investigator in a Phase 3, randomized study of Guadecitabine (SGI-110) versus physician’s choice in adults with MDS or CMML previously treated with hypomethylating agents. Eudract 2015-005257-12, CE 75/18
13. A Randomized, Double-blind, Phase 3 Study to Evaluate the Activity of Momelotinib (MMB) Versus Danazol (DAN) in Symptomatic, Anemic Subjects With Primary Myelofibrosis (PMF), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis Who Were Previously Treated With JAK Inhibitor Therapy
14. 2019-: Principal Investigator for study GIMEMA ITP0918, Italian registry of ITP. Clinical trial number NCT03465020, CE 88/19
15. 2019-: Principal investigator for study Manifest-1 Phase 1/2 study of CPI-0610, a small inhibitor of BET protein; phase 1 (dose finding in patients with hematological malignancies) and phase 2

(expansion with or without ruxolitinib in patients with myelofibrosis)

16. 2019-: Principal investigator for the study CAMN107AIT15 A phase II, single-arm, multicenter study of full treatment-free remission in patients with chronic myeloid leukemia in chronic phase treated with nilotinib in first-line therapy who have achieved a sustained deep molecular response for at least 1 year: DANTE study
17. 2020-: Principal Investigator for study 74494550MDS2001, A Phase 2, Randomized, Open-label Study of Cusatuzumab in Combination with Azacitidine Compared with Azacitidine Alone in Patients with Higher-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) and who are not candidates for Hematopoietic Stem Cell Transplantation (HSCT). Eudract 2019-003576-40, CE 174/20
18. 2020-: Principal Investigator for study SRA-MMB-301, SA Randomized, Double-Blind, Phase 3 Study to Evaluate the Activity of Mometinib (MMB) versus Danazol (DAN) in Symptomatic, Anemic Subjects with Primary Myelofibrosis (PMF), Post-Polycythemia Vera (PV) Myelofibrosis, or Post Essential Thrombocythemia (ET) Myelofibrosis who were Previously Treated with JAK Inhibitor Therapy. Eudract 2019-000583-18, CE 107/20
19. 2020-: Principal Investigator for study MOM-M281-006, Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study. Eudract 2019-000720-17, CE 173/19
20. 2020-: Principal Investigator for study FORWARD, a randomized study of Phase 3 multicenter, double-blind, placebo-controlled, parallel group study to investigate the efficacy of 24 weeks of treatment with fostamatinib (R788) vs. placebo in achieving a hemoglobin response in subjects with wAIHA. Eudract 2018-004774-97, CE 10/20
21. 2020-: Principal investigator for the trial TAK-079-1004 A Phase 2, Randomized, Double-blind, Placebo-Controlled Study to Evaluate Safety, Tolerability, and Efficacy of TAK-079 in Patients With Persistent/Chronic Primary Immune Thrombocytopenia
22. 2020-: Principal Investigator for study EMPATHY, Evaluating Patient-Reported Outcomes Monitoring in Routine Care of Patients with Chronic Myeloid Leukemia for Increasing Adherence and Clinical Response to Therapy: The EMPATHY Pilot Study, CE 173/20
23. 2020-: Principal Investigator for study ARGX-113-1801 (ADVANCE), A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX-113) 10 mg/kg Intravenous Thrombocytopenia. Eudract 2019-002100-41, CE 77/20
24. 2020-: Principal Investigator for study ARGX-113-1803 (ADVANCE+), A Phase 3, Multicenter, open label Trial to Evaluate the Efficacy and Safety of Efgartigimod (ARGX-113) 10 mg/kg Intravenous Thrombocytopenia. Eudract 2019-002101-21, CE 172/20
25. 2020-: Principal investigator for study MOM-M281-006 Efficacy and Safety of M281 in Adults with Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study
26. 2021-: Principal investigator for study Gilead ENHANCE 5F9009 A Randomized, Double-blind, Multicenter Study Comparing Magrolimab in Combination with Azacitidine versus Azacitidine Plus Placebo in Treatment-naïve Patients with Higher Risk Myelodysplastic Syndrome.
27. 2021-: Principal investigator for study Syros SY1425 A randomized, double-blind, placebo-controlled phase 3 study of sy-1425 plus azacitidine versus placebo plus azacitidine in newly diagnosed, rars-positive adult patients with higher-risk myelodysplastic syndrome
28. 2021-: Principal investigator for the trial Limber A Randomized, Double-Blind, Placebo-Controlled Study of the PI3K δ Inhibitor Piasclisib Plus Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib
29. 2021-: Principal investigator for the trial Independence A phase 3, double-blind, randomized study to compare the efficacy and safety of luspatercept (ACE-536) versus placebo in subjects with myeloproliferative neoplasm-associated myelofibrosis on concomitant jak2 inhibitor therapy and who require red blood cell transfusions
30. 2021-: Principal investigator for trial Bores A Phase 2/3 Randomized, Controlled, Open-Label Study of KRT 232 in Subjects With Primary Myelofibrosis (PMF), Post Polycythemia Vera MF (Post-PV-MF), Or Post Essential Thrombocythemia MF (Post-ET-MF) Who Are Relapsed or Refractory to Janus Kinase (JAK) Inhibitor Treatment
31. 2021-: Principal investigator for study Manifest-2 A Phase 3, Randomized, Double-blind,

Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients

32. 2021-: Principal investigator for study Telios TL-895-201 A Phase 2, Open-label, Multicenter Study of TL-895 in Subjects with Relapsed/Refractory Myelofibrosis, Janus Kinase Inhibitor Intolerant Myelofibrosis and Janus Kinase Inhibitor Treatment Ineligible Myelofibrosis
33. 2021-: Principal investigator for study ANX-wAIHA-01 A Study to Evaluate the Complement Signature of Subjects with Warm Autoimmune Hemolytic Anemia
34. 2021-: Principal investigator for study ANX-wAIHA-02 A Phase 2, Open-Label, Repeat Dose Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Proof-of-Concept of Intravenous ANX005 in Subjects with Warm Autoimmune Hemolytic Anemia
35. 2021-: Principal investigator for the study Gimema RD0120 Langerhans Cell Histiocytosis in Adults: a Collaborative, Prospective-retrospective, Observational **GIMEMA** Study
36. 2021-: Principal investigator for the study Gimema Prophecy QoL-MPN0118 Patient-Reported Outcomes in Philadelphia-negative Cytogenetic myeloproliferative Neoplasms (PROPHECY): A GIMEMA Observational Registry for Italian MPN Patients
37. 2021-: Principal investigator for the study EMPATHY Evaluating Patient-Reported Outcomes Monitoring in Routine Care of Patients With Chronic Myeloid Leukemia for Increasing Adherence and Clinical Response to Therapy: The EMPATHY Pilot Study
38. 2021-: Principal investigator for the trial ALLIANCE An onLine-pLatform to improve patient-centered care in the COVID-19 pandemic and post-pandemic era: a GIMEMA surveillance program in hematologic malignancies
39. 2021-: Principal investigator for the trial ARGX-113-2004 A Phase 3, Multicenter, Randomized, Double Blinded, Placebo-Controlled Trial to evaluate the efficacy and Safety of efgartigimod (ARGX-113) PH20 Subcutaneous in Adult Patients with Primary Immune Thrombocytopenia
40. 2022-: Principal investigator for the study INCB50465-309 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Parsaclisib in Participants With Primary Warm Autoimmune Hemolytic Anemia
41. 2020-2022: Phase 3 multi-center, randomized, double-blind, placebo-controlled, parallel group study to investigate the efficacy of 24 weeks of treatment with fostamatinib (R788) vs. placebo in achieving a hemoglobin response in subjects with wAIHA, SGI-110-07
42. Valutazione della qualità di vita in pazienti con neoplasie mieloproliferative Philadelphia-negative. Registro osservazionale GIMEMA per pazienti MPN italiani. Gimema Prophecy QoL-MPN0118.
43. A Phase 3, Randomized, Double-blind, Placebo-controlled Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients with Cold Agglutinin Disease (CAD). Sobi-PEGCET-101.
44. A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF SY-1425 PLUS AZACITIDINE VERSUS PLACEBO PLUS AZACITIDINE IN NEWLY DIAGNOSED, RARA-POSITIVE ADULT PATIENTS WITH HIGHER-RISK MYELODYSPLASTIC SYNDROME. Syros SY1425.
45. Studio randomizzato, in doppio cieco, controllato verso placebo sull'inibitore di PI3Kδ parsaclisib più ruxolitinib in partecipanti affetti da mielofibrosi con risposta subottimale a ruxolitinib. INCB 50465-304 (Limber).
46. Efficacy and Safety of Luspatercept for the Treatment of Anemia Due to Myelodysplastic Syndromes with del5q refractory/resistant/intolerant to Prior Treatments, Who Require Red Blood Cell Transfusion. QOL-ONE Phoenix
47. A Multi-Country, Real-World Study to Explore Treatment Patterns, Effectiveness and Healthcare Resource Utilization for Patients Diagnosed with Myelofibrosis through Chart Review.
48. "Studio di fase III, randomizzato, controllato, per confrontare pacritinib con la scelta terapeutica del medico in pazienti con mielofibrosi primaria, mielofibrosi post (conta piastrinica <50.000/μL)" trombocitemia essenziale con trombocitopenia grave policitemia vera o mielofibrosi post. Pacifica PAC303
49. Observational study on the use of ropeginterferon alfa-2b in polycythemia vera (ROPEG-PV).
50. A phase 3, randomized, double-blind, study to assess efficacy and safety of ionalumab (VAY736) versus placebo in warm autoimmune hemolytic anemia (wAIHA) patients who failed

at least one line of treatment (VAYHIA). Novartis CVAY736O12301

51. A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY, WITH A SAFETY AND DOSE CONFIRMATION RUN-IN PERIOD, TO EVALUATE THE EFFICACY AND SAFETY OF OBEXELIMAB IN PATIENTS WITH WARM AUTOIMMUNE HEMOLYTIC ANEMIA (SAPHIARE). ZB012-03-002.
52. Thrombotic risk and mortality in patients with cold agglutinin disease (CAD) in Europe: a retrospective chart review. GER-CAD-19-11180
53. A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of depemokimab in adults with hypereosinophilic syndrome (HES). GSK Desti
54. IMMUNE THROMBOCYTOPENIA (ITP) AND COVID-19: national retrospective and prospective observational investigation on the incidence and course of COVID-19 in patients with prior, ongoing or de novo ITP. Evaluation of the impact of COVID-19 pandemic on the management of ITP.

PUBLICATIONS

1. **Patriarca A**, Pompetti F, Malizia R, Iuliani O, Di Marzio I, Spadano A, Dragani A. Is JAK2V617F mutation absence a risk factor for bleeding in Essential Thrombocythemia? An analysis on 106 patients. *Blood Transfusion Blood Transfus* 2010; 8: 21-7.
2. Salutati P, **Patriarca A**, D'Arcangelo L, Fioritoni G. Chylous ascites. *BloodMed.com* 2009 Case report and images.
3. **Patriarca A**, Colaizzo D, Tiscia G, Spadano R, Di Zaccaro S, Spadano A, Villanova I, Margaglione M, Grandone E, Dragani A. TET2 mutations in Ph- negative-Myeloproliferative Neoplasms: identification of three novel mutations and relationship with clinical and laboratory findings. *Biomed Res Int*. 2013;2013:929840. doi: 10.1155/2013/929840.
4. **Patriarca A**, Salutati P, Pulini S. Images 374: plasma cell leukaemia recurring with serous effusion. *BloodMed.com* 2014
5. **Patriarca A**, Salutati S, Di Zaccaro S. The impact of molecular genetic in Acute Myeloid Leukemias. *J Blood Disorders Transf* 6:252. doi: 10.4172/2155-9864.1000252
6. Giordano G, Mondello P, Tambaro R, Perrotta N, D'Amico F, D'Aveta A, Berardi G, Carabellese B, **Patriarca A**, Corbi MG, Di Marzio L, Licianci A, Berardi D, Di Lullo L, Di Marco R. Biosimilar epoetin alpha is as effective as originator epoetin-alpha plus liposomal iron (Sideral), vitamin B12 and folates in patients with refractory anemia: a retrospective real-life approach. *Molecular and Clinical Oncology* 2015; 3: 781-784.
7. **Patriarca A**, Giordano G. Reed Sternberg Cells in Bone Marrow Touch Imprints. *J Blood Disord Transfus* 2015, S4:1 <http://dx.doi.org/10.4172/2155-9864.1000S4-i101>
8. Moia R, Favini C, Rasi S, Deambrogi C, Ferri V, Schipani M, Sagiraju S, Mahmoud AM, Kodipad AA, Adhinaveni R, **Patriarca A**, Nassi L, Gaidano G. Liquid biopsy in lymphomas: a potential tool for refining diagnosis and disease monitoring. *J Cancer Metastasis Treat* 2019;5:67
9. Barbui T, Gharardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, De Stefano V, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Delaini F, Bonifacio M, Scaffidi L, **Patriarca A**, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Bertolotti L, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Finazzi G. Second cancer in Philadelphia negative myeloproliferative

neoplasms (MPN-K). A nested case-control study. *Leukemia*. 2019 Aug;33(8):1996-2005.

10. Ecsedi M, Lengline E, Knol-Bout C, Bosman P, Eikema DJ, Afanasyev B, Maschan A, Dreger P, Halkes CJM, Drexler B, Cortelezzi A, Drénou B, **Patriarca A**, Bruno B, Onofrillo D, Lanino E, Pulanic D, Serventi-Seiwerth D, Garnier A, Ljungman P, Bonifazi F, Giammarco S, Tournilhac O, Pioltelli P, Rovó A, Risitano AM, Peffault de Latour R, Dufour C, Passweg J. Use of eltrombopag in aplastic anemia in Europe. *Ann Hematol*. 2019 Jun;98(6):1341-1350.
11. Diop F, Moia R, Favini C, Spaccarotella E, De Paoli L, Bruscaggini A, Spina V, Terzi-di-Bergamo L, Arruga F, Tarantelli C, Deambrogi C, Rasi S, Adhinaveni R, **Patriarca A**, Favini S, Sagiraju S, Jabangwe C, Kodipad AA, Peroni D, Mauro FR, Del Giudice I, Forconi F, Cortelezzi A, Zaja F, Bomben F, Rossi FM, Visco C, Chiarenza A, Rigolin GM, Marasca R, Coscia M, Perbellini O, Tedeschi A, Laurenti L, Motta M, Donaldson D, Weir P, Mills K, Thornton P, Lawless S, Bertoni F, Del Poeta G, Cuneo A, Follenzi A, Gattei V, Boldorini RL, Catherwood M, Deaglio S, Foá R, Gaidano G, Rossi D. Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. *Haematologica*. 2020 Jan 31;105(2):448-456.
12. Efficace F, Stagno F, Iurlo A, Breccia M, Cottone F, Bonifacio M, Abruzzese E, Castagnetti F, Caocci G, Crugnola M, Capodanno I, Martino B, Tiribelli M, **Patriarca A**, Gozzini A, Pregno P, Saussele S, Cascavilla N, Fozza C, Bergamaschi M, Binotto G, Vignetti M, Rosti G. Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. *Leukemia*. 2020 Feb;34(2):488-498.
13. Moia R, **Patriarca A**, Deambrogi C, Rasi S, Favini C, Kodipad AA, Schipani M, Gaidano G. An update on: molecular genetics of high-risk chronic lymphocytic leukemia. *Expert Rev Hematol*. 2020 Feb;13(2):109-116.
14. De Stefano V, Ghirardi A, Masciulli A, Carobbio A, Palandri F, Vianelli N, Rossi E, Betti S, Di Veroli A, Iurlo A, Cattaneo D, Finazzi G, Bonifacio M, Scaffidi L, **Patriarca A**, Rumi E, Casetti IC, Stephenson C, Guglielmelli P, Elli EM, Palova M, Rapezzi D, Erez D, Gomez M, Wille K, Perez-Encinas M, Lunghi F, Angona A, Fox ML, Beggiato E, Benevolo G, Carli G, Cacciola R, McMullin MF, Tieghi A, Recasens V, Isfort S, Marchetti M, Griesshammer M, Alvarez-Larran A, Vannucchi AM, Rambaldi A, Barbui T. Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. *Blood*. 2020 Jan 30;135(5):381-386.
15. Moia R, Boggio E, Gigliotti L, Crisà E, De Paoli L, Margiotta Casaluci G, Rolla R, **Patriarca A**, Gaidano G, Dianzani U, Bruna R. Anti-rasburicase antibodies induce clinical refractoriness by inhibiting the enzyme catalytic activity. *Hematol Oncol*. 2020 Apr;38(2):204-206.
16. Caocci G, Vignetti M, **Patriarca A**, Breccia M, Platzbecker U, Palumbo GA, Stauder R, Cottone F, Petranovic D, Voso MT, Tafuri A, Invernizzi R, Caers J, Luppi M, La Nasa G, Niscola P, Efficace F. High serum ferritin levels in newly diagnosed patients with myelodysplastic syndromes are associated with greater symptom severity. *Int J Hematol*. 2020 Aug;112(2):141-146.
17. Efficace F, Cottone F, Oswald LB, Cella D, **Patriarca A**, Niscola P, Breccia M, Platzbecker U, Palumbo GA, Caocci G, Stauder R, Ricco A, Petranovic D, Caers J, Luppi M, Fianchi L, Frairia C, Capodanno I, Follini E, Sarlo C, Fazi P, Vignetti M. The IPSS-R more accurately captures fatigue severity of newly diagnosed patients with myelodysplastic syndromes compared with the IPSS index. *Leukemia*. 2020 Sep;34(9):2451-2459.
18. Pinato DJ, Lee AJX, Biello F, Seguí E, Aguilar-Company J, Carbó A, Bruna R, Bower M, Rizzo G, Benafif S, Carmona C, Chopra N, Cruz CA, D'Avanzo F, Evans JS, Galazi M, Garcia-Fructuoso I, Dalla Pria A, Newsom-Davis T, Ottaviani D, **Patriarca A**, Reyes R, Sharkey R,

Sng CCT, Wong YNS, Ferrante D, Scotti L, Avanzi GC, Bellan M, Castello LM, Marco-Hernández J, Mollà M, Pirisi M, Ruiz-Camps I, Sainaghi PP, Gaidano G, Brunet J, Tabernero J, Prat A, Gennari A. Presenting Features and Early Mortality from SARS-CoV-2 Infection in Cancer Patients during the Initial Stage of the COVID-19 Pandemic in Europe. *Cancers (Basel)*. 2020 Jul 8;12(7):1841.

19. **Patriarca A**, Gaidano G. A step ahead toward precision medicine for chronic lymphocytic leukemia. *Haematologica*. 2020 Jun 5;105(10):2352-2355.
20. Moia R, Greco M, Boggione P, Nicolosi M, Bruna R, **Patriarca A**, Gaidano G, Lunghi M. Cerebrospinal fluid xanthochromia after pegasparaginase hepatotoxicity in B-cell acute lymphoblastic leukemia. *Clin Case Rep*. 2020 Jul 16;8(11):2293-2294.
21. Moia R, Boggione P, Mahmoud AM, Kodipad AA, Adhinaveni R, Sagiraju S, **Patriarca A**, Gaidano G. Targeting p53 in chronic lymphocytic leukemia. *Expert Opin Ther Targets*. 2020 Dec;24(12):1239-1250
22. Crisà E, Nicolosi M, Ferri V, Favini C, Gaidano G, **Patriarca A**. Atypical Chronic Myeloid Leukemia: Where Are We Now? *Int J Mol Sci*. 2020 Sep 18;21(18):6862.
23. Pinato DJ, Zambelli A, Aguilar-Company J, Bower M, Sng C, Salazar R, Bertuzzi A, Brunet J, Mesia R, Segui E, Biello F, Generali D, Grisanti S, Rizzo G, Libertini M, Maconi A, Harbeck N, Vincenzi B, Bertulli R, Ottaviani D, Carbo A, Bruna R, Benafif S, Marrari A, Wuerstlein R, Carmona-Garcia MC, Chopra N, Tondini C, Mirallas O, Tovazzi V, Betti M, Provenzano S, Fotia V, Cruz CA, Dalla Pria A, D'Avanzo F, Evans JS, Saoudi-Gonzalez N, Felip E, Galazi M, Garcia-Fructuoso I, Lee AJX, Newsom-Davis T, **Patriarca A**, Garcia-Illescas D, Reyes R, Dileo P, Sharkey R, Wong YNS, Ferrante D, Marco-Hernandez J, Sureda A, Maluquer C, Ruiz-Camps I, Gaidano G, Rimassa L, Chiudinelli L, Izuzquiza M, Cabrita A, Franchi M, Santoro A, Prat A, Tabernero J, Gennari A. Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. *Cancer Discov*. 2020 Jul 31;10(10):1465–74.
24. Bruna R, Moia R, Valpreda A, Dosio E, Rolla R, Federici A, Dianzani U, Gaidano G, **Patriarca A**. An acquired factor V inhibitor induced uncontrolled bleeding in a postsurgery patient. *Clin Case Rep*. 2020 Dec 1;9(1):98-101.
25. Agathangelidis A, Chatzidimitriou A, Gemenetzi K, Giudicelli V, Karypidou M, Plevova K, Davis ZA, Yan XJ, Jeromin S, Schneider C, Pedersen LB, Tschumper R, Sutton LA, Baliakas P, Scarfò L, van Gastel EJ, Armand M, Tausch E, Biderman B, Baer C, Bagnara D, Navarro A, de Septenville A, Guido V, Mitterbauer-Hohendanner G, Dimovski A, Brieghel C, Lawless S, Meggendorfer M, Stranska K, Ritgen M, Facco M, Tresoldi C, Visentin A, **Patriarca A**, Catherwood M, Bonello L, Sudarikov A, Vanura K, Roumelioti M, Skuhrova Francova H, Moysiadis T, Veronese SM, Giannopoulos K, Mansouri L, Karan-Djurasevic T, Sandaltzopoulos R, Bödör C, Fais F, Kater AP, Panovska-Stavridis I, Rossi D, Alshemmari S, Panagiotidis P, Costeas PA, Espinet B, Antic D, Foroni L, Montillo M, Trentin L, Stavroyianni N, Gaidano G, Francia di Celle P, Niemann CU, Campo E, Anagnostopoulos A, Pott C, Fischer K, Hallek M, Oscier DG, Stilgenbauer S, Haferlach C, Jelinek DF, Chiorazzi N, Pospisilova S, Lefranc MP, Kossida S, Langerak AW, Belessi C, Davi F, Rosenquist R, Ghia P, Stamatopoulos K. Higher-order connections between stereotyped subsets: implications for improved patient classification in CLL. *Blood*. 2021 Mar 11;137(10):1365-1376.
26. Fattizzo B, Michel M, Zaninoni A, Giannotta J, Guillet S, Frederiksen H, Vos JMI, Mauro FR, Jilma B, **Patriarca A**, Zaja F, Hill A, Berentsen S, Barcellini W. Efficacy of recombinant erythropoietin in autoimmune hemolytic anemia: a multicenter international study. *Haematologica*. 2021 Feb 1;106(2):622-625.
27. Efficace F, Iurlo A, **Patriarca A**, Stagno F, Bee PC, Ector G, Capodanno I, Elena C, Bonifacio

- M, Blijlevens NMA, Caocci G, Wan C, Abruzzese E, Breccia M, Cottone F, Okumura I, Oerlemans S, Cascavilla N, Albano F, Kota V, Sztankay M, Miggiano MC, Saussele S, Di Renzo N, Sorà F, Castagnetti F, Baccarani M, Vignetti M, Rosti G. Validation and reference values of the EORTC QLQ-CML24 questionnaire to assess health-related quality of life in patients with chronic myeloid leukemia. *Leuk Lymphoma*. 2021 Mar;62(3):669-678. .
28. Lunghi M, **Patriarca A**, Greco M, Taherinasab A, Della Starza I, Cavalli M, Gaidano G, Foà R, Chiaretti S. Ponatinib for the treatment of Ph-like acute lymphoblastic leukemia. *Leuk Lymphoma*. 2021 Mar;62(3):755-757.
 29. **Patriarca A**, Gaidano G. Investigational drugs for the treatment of diffuse large B-cell lymphoma. *Expert Opin Investig Drugs*. 2021 Jan;30(1):25-38.
 30. Barbui T, Vannucchi AM, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Rossi G, Elli E, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, **Patriarca A**, Elorza BN, Angona A, Mazo EM, Koschmieder S, Ruggeri M, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, De Stefano V, Harrison C, Rambaldi A. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. *Leukemia*. 2021 Feb;35(2):485-493.
 31. Barbui T, Vannucchi AM, De Stefano V, Masciulli A, Carobbio A, Ferrari A, Ghirardi A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, **Patriarca A**, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. *Lancet Haematol*. 2021 Mar;8(3):e175-e184.
 32. Motta I, Consonni D, Stroppiano M, Benedetto C, Cassinerio E, Tappino B, Ranalli P, Borin L, Facchini L, **Patriarca A**, Barcellini W, Lanza F, Filocamo M, Cappellini MD; Splenomegaly Gaucher group. Predicting the probability of Gaucher disease in subjects with splenomegaly and thrombocytopenia. *Sci Rep*. 2021 Jan 28;11(1):2594.
 33. Baumann T, Moia R, Gaidano G, Delgado J, Condoluci A, Villamor N, Payedimarri AB, Costa D, **Patriarca A**, Jiménez-Vicente C, Rossi D, Montserrat E. Lymphocyte doubling time in chronic lymphocytic leukemia modern era: a real-life study in 848 unselected patients. *Leukemia*. 2021 Aug;35(8):2325-2331.
 34. Barbui T, De Stefano V, Alvarez-Larran A, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Ferrari A, Cancelli V, Elli EM, Andrade-Campos MM, Kabat MG, Kiladjian JJ, Palandri F, Benevolo G, Garcia-Gutierrez V, Fox ML, Foncillas MA, Morcillo CM, Rumi E, Osorio S, Papadopoulos P, Bonifacio M, Cervantes KSQ, Serrano MS, Carreno-Tarragona G, Sobas MA, Lunghi F, **Patriarca A**, Elorza BN, Angona A, Mazo EM, Koschmieder S, Carli G, Cuevas B, Hernandez-Boluda JC, Abadia EL, Cirici BX, Guglielmelli P, Garrote M, Cattaneo D, Daffini R, Cavalca F, Bellosillo B, Benajiba L, Curto-Garcia N, Bellini M, Betti S, Harrison C, Rambaldi A, Vannucchi AM. Among classic myeloproliferative neoplasms, essential thrombocythemia is associated with the greatest risk of venous thromboembolism during COVID-19. *Blood Cancer J*. 2021 Feb 4;11(2):21.
 35. Lucchini E, Palandri F, Volpetti S, Vianelli N, Auteri G, Rossi E, **Patriarca A**, Carli G, Barcellini W, Celli M, Consoli U, Valeri F, Santoro C, Crea E, Vignetti M, Paoloni F, Gigliotti CL, Boggio E, Dianzani U, Giardini I, Carpenedo M, Rodeghiero F, Fanin R, Zaja F; for Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA). Eltrombopag second-line therapy in adult

patients with primary immune thrombocytopenia in an attempt to achieve sustained remission off-treatment: results of a phase II, multicentre, prospective study. *Br J Haematol*. 2021 Feb 22.

36. **Patriarca A**, Gaidano G. Intravascular lymphoma: from vessels to genes. *Blood*. 2021 Mar 18;137(11):1438-1439.
37. Gamper EM, Cottone F, Sommer K, Norman R, King M, Breccia M, Caocci G, **Patriarca A**, Palumbo GA, Stauder R, Niscola P, Platzbecker U, Caers J, Vignetti M, Efficace F. The EORTC QLU-C10D was more efficient in detecting clinical known group differences in myelodysplastic syndromes than the EQ-5D-3L. *J Clin Epidemiol*. 2021 Sep;137:31-44.
38. Dettorre GM, Dolly S, Loizidou A, Chester J, Jackson A, Mukherjee U, Zambelli A, Aguilar-Company J, Bower M, Sng CCT, Salazar R, Bertuzzi A, Brunet J, Mesia R, Sita-Lumsden A, Seguí E, Biello F, Generali D, Grisanti S, Seeva P, Rizzo G, Libertini M, Maconi A, Moss C, Russell B, Harbeck N, Vincenzi B, Bertulli R, Ottaviani D, Liñan R, Marrari A, Carmona-García MC, Chopra N, Tondini CA, Mirallas O, Tovazzi V, Fotia V, Cruz CA, Saoudi-Gonzalez N, Felip E, Roqué A, Lee AJX, Newsom-Davis T, García-Illescas D, Reyes R, Wong YNS, Ferrante D, Scotti L, Marco-Hernández J, Ruiz-Camps I, **Patriarca A**, Rimassa L, Chiudinelli L, Franchi M, Santoro A, Prat A, Gennari A, Van Hemelrijck M, Tabernero J, Diamantis N, Pinato DJ; OnCovid study group. Systemic pro-inflammatory response identifies patients with cancer with adverse outcomes from SARS-CoV-2 infection: the OnCovid Inflammatory Score. *J Immunother Cancer*. 2021 Mar;9(3):e002277.
39. Crisà E, Boggione P, Nicolosi M, Mahmoud AM, Al Essa W, Awikeh B, Aspesi A, Andorno A, Boldorini R, Dianzani I, Gaidano G, **Patriarca A**. Genetic Predisposition to Myelodysplastic Syndromes: A Challenge for Adult Hematologists. *Int J Mol Sci*. 2021 Mar 3;22(5):2525.
40. Palandri F, Rossi E, Bartoletti D, Ferretti A, Ruggeri M, Lucchini E, Carrai V, Barcellini W, **Patriarca A**, Rivolti E, Consoli U, Cantoni S, Oliva EN, Chiurazzi F, Caocci G, Giuffrida G, Borchellini A, Auteri G, Baldacci E, Carli G, Nicolosi D, Sutto E, Carpenedo M, Cavo M, Mazzucconi MG, Zaja F, De Stefano V, Rodeghiero F, Vianelli N. Real-world use of thrombopoietin receptor agonists in elderly patients with primary immune thrombocytopenia. *Blood*. 2021 Aug 19;138(7):571-583.
41. Pinato DJ, Scotti L, Gennari A, Colomba-Blameble E, Dolly S, Loizidou A, Chester J, Mukherjee U, Zambelli A, Aguilar-Company J, Bower M, Galazi M, Salazar R, Bertuzzi A, Brunet J, Mesia R, Sita-Lumsden A, Colomba J, Pommeret F, Seguí E, Biello F, Generali D, Grisanti S, Rizzo G, Libertini M, Moss C, Evans JS, Russell B, Wuerstlein R, Vincenzi B, Bertulli R, Ottaviani D, Liñan R, Marrari A, Carmona-García MC, Sng CCT, Tondini C, Mirallas O, Tovazzi V, Fotia V, Cruz CA, Saoudi-Gonzalez N, Felip E, R Lloveras A, Lee AJX, Newsom-Davis T, Sharkey R, Chung C, García-Illescas D, Reyes R, Sophia Wong YN, Ferrante D, Marco-Hernández J, Ruiz-Camps I, Gaidano G, **Patriarca A**, Sureda A, Martinez-Vila C, Sanchez de Torre A, Rimassa L, Chiudinelli L, Franchi M, Krengli M, Santoro A, Prat A, Tabernero J, V Hemelrijck M, Diamantis N, Cortellini A; OnCovid study group. Determinants of enhanced vulnerability to coronavirus disease 2019 in UK patients with cancer: a European study. *Eur J Cancer*. 2021 Jun;150:190-202.
42. Mahmoud AM, Biello F, Maggiora PM, Bruna R, Burrafato G, Cappelli M, Varughese F, Martini V, Platini F, Deambrogi C, **Patriarca A**, Nicolosi M, Vachanaram AR, Pisani C, Ferrara E, Catania E, Azzolina D, Barone-Adesi F, Krengli M, Gaidano G, Gennari A. A randomized clinical study on the impact of Comprehensive Geriatric Assessment (CGA) based interventions on the quality of life of elderly, frail, onco-hematologic patients candidate to anticancer therapy: protocol of the ONCO-Aging study. *BMC Geriatr*. 2021 May 19;21(1):320.
43. Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Rossi G, Harrison C, Alvarez-Larran A,

- Elli EM, Kiladjian JJ, Gasior Kabat M, Marin Sanchez A, Palandri F, Andrade-Campos MM, Vannucchi AM, Carreno-Tarragona G, Papadopoulos P, Quiroz Cervantes K, Angeles Foncillas M, Fox ML, Sagues Serrano M, Rumi E, Osorio S, Benevolo G, **Patriarca A**, Navas Elorza B, Garcia-Gutierrez V, Magro Mazo E, Lunghi F, Bonifacio M, De Stefano V, Hernandez-Boluda JC, Lopez Abadia E, Angona A, Xicoy Cirici B, Ruggeri M, Koschmieder S, Sobas MA, Cuevas B, Cattaneo D, Daffini R, Bellini M, Curto-Garcia N, Garrote M, Cavalca F, Benajiba L, Bellosillo B, Guglielmelli P, Borsani O, Betti S, Salmoiraghi S, Rambaldi A. Long-term follow-up of recovered MPN patients with COVID-19. *Blood Cancer J*. 2021 Jun 16;11(6):115.
44. Moia R, Favini C, Ferri V, Forestieri G, Terzi Di Bergamo L, Schipani M, Sagiraju S, Andorno A, Rasi S, Adhinaveni R, Talotta D, Al Essa W, De Paoli L, Margiotta Casaluci G, **Patriarca A**, Boldorini RL, Rossi D, Gaidano G. Multiregional sequencing and circulating tumour DNA analysis provide complementary approaches for comprehensive disease profiling of small lymphocytic lymphoma. *Br J Haematol*. 2021 Oct;195(1):108-112.
 45. Jalink M, Berentsen S, Castillo JJ, Treon SP, Cruijssen M, Fattizzo B, Cassin R, Fotiou D, Kastritis E, De Haas M, Oosten LEM, Frederiksen H, **Patriarca A**, D'Sa S, Vos JMI. Effect of ibrutinib treatment on hemolytic anemia and acrocyanosis in cold agglutinin disease/cold agglutinin syndrome. *Blood*. 2021 Nov 18;138(20):2002-2005.
 46. Moia R, **Patriarca A**, Schipani M, Gaidano G. The Biology of Chronic Lymphocytic Leukemia: Diagnostic and Prognostic Implications. *Cancer J*. 2021 Jul-Aug 01;27(4):266-274.
 47. Specchia G, Pregno P, Breccia M, Castagnetti F, Monagheddu C, Bonifacio M, Tiribelli M, Stagno F, Caocci G, Martino B, Luciano L, Pizzuti M, Gozzini A, Scortechini AR, Albano F, Bergamaschi M, Capodanno I, **Patriarca A**, Fava C, Rege-Cambrin G, Sorà F, Galimberti S, Bocchia M, Binotto G, Reddiconto G, DiTonno P, Maggi A, Sanpaolo G, De Candia MS, Gai V, Abruzzese E, Miggiano MC, La Barba G, Pietrantuono G, Guella A, Levato L, Mulas O, Saccona F, Rosti G, Musto P, Di Raimondo F, Pane F, Baccarani M, Saglio G, Ciccone G. Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. *Front Oncol*. 2021 Aug 26;11:739171.
 48. Fattizzo B, Michel M, Giannotta JA, Hansen DL, Arguello Marina M, Sutto E, Bianchetti N, **Patriarca A**, Cantoni S, Mingot-Castellano ME, McDonald V, Capecchi M, Zaninoni A, Consonni D, Vos JMI, Vianelli N, Chen F, Glenthøj A, Frederiksen H, Gonzalez-Lopez TJ, Barcellini W. Evans syndrome in adults: an observational multicentre study. *Blood Adv*. 2021 Dec 28;5(24):5468-5478.
 49. Nicolosi M, **Patriarca A**, Andorno A, Mahmoud AM, Gennari A, Boldorini R, Gaidano G, Crisà E. Precision Medicine in Systemic Mastocytosis. *Medicina (Kaunas)*. 2021 Oct 20;57(11):1135.
 50. Pinato DJ, Tabernero J, Bower M, Scotti L, Patel M, Colomba E, Dolly S, Loizidou A, Chester J, Mukherjee U, Zambelli A, Dalla Pria A, Aguilar-Company J, Ottaviani D, Chowdhury A, Merry E, Salazar R, Bertuzzi A, Brunet J, Lambertini M, Tagliamento M, Pous A, Sita-Lumsden A, Srikantharajah K, Colomba J, Pommeret F, Seguí E, Generali D, Grisanti S, Pedrazzoli P, Rizzo G, Libertini M, Moss C, Evans JS, Russell B, Harbeck N, Vincenzi B, Biello F, Bertulli R, Liñan R, Rossi S, Carmona-García MC, Tondini C, Fox L, Baggi A, Fotia V, Parisi A, Porzio G, Saponara M, Cruz CA, García-Illescas D, Felipe E, Roqué Lloveras A, Sharkey R, Roldán E, Reyes R, Earnshaw I, Ferrante D, Marco-Hernández J, Ruiz-Camps I, Gaidano G, **Patriarca A**, Bruna R, Sureda A, Martinez-Vila C, Sanchez de Torre A, Cantini L, Filetti M, Rimassa L, Chiudinelli L, Franchi M, Krengli M, Santoro A, Prat A, Van Hemelrijck M, Diamantis N, Newsom-Davis T, Gennari A, Cortellini A; OnCovid study group. Prevalence and impact of COVID-19 sequelae on treatment and survival of patients with cancer who recovered from SARS-CoV-2 infection: evidence from the OnCovid retrospective, multicentre registry study.

51. Moia R, Cittone MG, Boggione P, Manfredi GF, Favini C, Awikeh B, Pedrinelli AR, Mahmoud AM, Nicolosi M, Bellan M, Sainaghi PP, Pirisi M, Gaidano G, **Patriarca A**, Rigamonti C. Stiffer Spleen Predicts Higher Bone Marrow Fibrosis and Higher JAK2 Allele Burden in Patients With Myeloproliferative Neoplasms. *Front Oncol*. 2021 Oct 26;11:777730.
52. OnCovid Study Group, Pinato DJ, Patel M, Scotti L, Colomba E, Dolly S, Loizidou A, Chester J, Mukherjee U, Zambelli A, Dalla Pria A, Aguilar-Company J, Bower M, Salazar R, Bertuzzi A, Brunet J, Lambertini M, Tagliamento M, Pous A, Sita-Lumsden A, Srikandarajah K, Colomba J, Pommeret F, Seguí E, Generali D, Grisanti S, Pedrazzoli P, Rizzo G, Libertini M, Moss C, Evans JS, Russell B, Harbeck N, Vincenzi B, Biello F, Bertulli R, Ottaviani D, Liñan R, Rossi S, Carmona-García MC, Tondini C, Fox L, Baggi A, Fotia V, Parisi A, Porzio G, Queirolo P, Cruz CA, Saoudi-Gonzalez N, Felip E, Roqué Lloveras A, Newsom-Davis T, Sharkey R, Roldán E, Reyes R, Zoratto F, Earnshaw I, Ferrante D, Marco-Hernández J, Ruiz-Camps I, Gaidano G, **Patriarca A**, Bruna R, Sureda A, Martinez-Vila C, Sanchez de Torre A, Berardi R, Giusti R, Mazzoni F, Guida A, Rimassa L, Chiudinelli L, Franchi M, Krengli M, Santoro A, Prat A, Tabernero J, Van Hemelrijck M, Diamantis N, Gennari A, Cortellini A. Time-Dependent COVID-19 Mortality in Patients With Cancer: An Updated Analysis of the OnCovid Registry. *JAMA Oncol*. 2022 Jan 1;8(1):114-122. doi: 10.1001/jamaoncol.2021.6199. PMID: 34817562; PMCID: PMC8777559.
53. Borgogna C, Bruna R, Griffante G, Martuscelli L, De Andrea M, Ferrante D, **Patriarca A**, Mahmoud AM, Gaidano V, Marchetti M, Rapezzi D, Lai M, Pistello M, Ladetto M, Massaia M, Gaidano G, Gariglio M. Patterns of neutralizing humoral response to SARS-CoV-2 infection among hematologic malignancy patients reveal a robust immune response in anti-cancer therapy-naïve patients. *Blood Cancer J*. 2022 Jan 18;12(1):8. doi: 10.1038/s41408-022-00608-6. PMID: 35042847; PMCID: PMC8764505.
54. Barbui T, Iurlo A, Masciulli A, Carobbio A, Ghirardi A, Carioli G, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, Bonifacio M, Alvarez-Larran A, Kiladjian JJ, Bolaños Calderón E, **Patriarca A**, Quiroz Cervantes K, Griessammer M, Garcia-Gutierrez V, Marin Sanchez A, Magro Mazo E, Ruggeri M, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Sagues Serrano M, Kusec R, Navas Elorza B, Angona A, Xicoy Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, Masternak Kulikowska de Nałęcz A, Cavalca F, Borsani O, Betti S, Benajiba L, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi AM. Second versus first wave of COVID-19 in patients with MPN. *Leukemia*. 2022 Mar;36(3):897-900.
55. Efficace F, **Patriarca A**, Luppi M, Potenza L, Caocci G, Tafuri A, Fazio F, Cartoni C, Petrucci MT, Carmosino I, Moia R, Margiotta Casaluci G, Boggione P, Colaci E, Giusti D, Pioli V, Sparano F, Cottone F, De Fabritiis P, Ardu NR, Niscola P, Capodanno I, Leporace AP, Pelliccia S, Lugli E, La Sala E, Rigacci L, Santopietro M, Fozza C, Siragusa S, Breccia M, Fazi P, Vignetti M. Physicians' Perceptions of Clinical Utility of a Digital Health Tool for Electronic Patient-Reported Outcome Monitoring in Real-Life Hematology Practice. Evidence From the GIMEMA-ALLIANCE Platform. *Front Oncol*. 2022 Mar 17;12:826040.
56. Cortellini A, Gennari A, Pommeret F, Patel G, Newsom-Davis T, Bertuzzi A, Viladot M, Aguilar-Company J, Mirallas O, Felip E, Lee AJX, Pria AD, Sharkey R, Brunet J, Garcia MC, Chester J, Mukherjee U, Scotti L, Dolly S, Sita-Lumsden A, Ferrante D, Van Hemelrijck M, Moss C, Russell B, Seguí E, Biello F, Krengli M, Marco-Hernández J, Gaidano G, **Patriarca A**, Bruna R, Roldán E, Fox L, Pous A, Griscelli F, Salazar R, Martinez-Vila C, Sureda A, Loizidou A, Maluquer C, Stoclin A, Iglesias M, Pedrazzoli P, Rizzo G, Santoro A, Rimassa L, Rossi S, Harbeck N, de Torre AS, Vincenzi B, Libertini M, Provenzano S, Generali D, Grisanti S, Berardi R, Tucci M, Mazzoni F, Lambertini M, Tagliamento M, Parisi A, Zoratto F, Queirolo P,

Giusti R, Guida A, Zambelli A, Tondini C, Maconi A, Betti M, Colomba E, Diamantis N, Sinclair A, Bower M, Ruiz-Camps I, Pinato DJ; OnCovid study group. COVID-19 Sequelae and the Host Pro-Inflammatory Response: An Analysis From the OnCovid Registry. *J Natl Cancer Inst.* 2022 Apr 13:djac057. doi: 10.1093/jnci/djac057. Epub ahead of print. PMID: 35417006; PMCID: PMC9047221.

57. Pinato DJ, Ferrante D, Aguilar-Company J, Bower M, Salazar R, Mirallas O, Sureda A, Bertuzzi A, Brunet J, Lambertini M, Maluquer C, Pedrazzoli P, Biello F, Lee AJX, Sng CCT, Liñan R, Rossi S, Carmona-García MC, Sharkey R, Eremiev S, Rizzo G, Bain HD, Yu T, Cruz CA, Perachino M, Saoudi-Gonzalez N, Fort-Culillas R, Doonga K, Fox L, Roldán E, Zoratto F, Gaidano G, Ruiz-Camps I, Bruna R, Patriarca A, Shawe-Taylor M, Fusco V, Martinez-Vila C, Berardi R, Filetti M, Mazzoni F, Santoro A, Delfanti S, Parisi A, Queirolo P, Aujayeb A, Rimassa L, Prat A, Tabernero J, Gennari A, Cortellini A; OnCovid study group. Vaccination against SARS-CoV-2 protects from morbidity, mortality and sequelae from COVID19 in patients with cancer. *Eur J Cancer.* 2022 Aug;171:64-74
58. Cortellini A, Gennari A, Pommeret F, Patel G, Newsom-Davis T, Bertuzzi A, Viladot M, Aguilar-Company J, Mirallas O, Felip E, Lee AJX, Dalla Pria A, Sharkey R, Brunet J, Carmona-García M, Chester J, Mukherjee U, Scotti L, Dolly S, Sita-Lumsden A, Ferrante D, Van Hemelrijck M, Moss C, Russell B, Seguí E, Biello F, Krengli M, Marco-Hernández J, Gaidano G, Patriarca A, Bruna R, Roldán E, Fox L, Pous A, Griscelli F, Salazar R, Martinez-Vila C, Sureda A, Loizidou A, Maluquer C, Stoclin A, Iglesias M, Pedrazzoli P, Rizzo G, Santoro A, Rimassa L, Rossi S, Harbeck N, Sanchez de Torre A, Vincenzi B, Libertini M, Provenzano S, Generali D, Grisanti S, Berardi R, Tucci M, Mazzoni F, Lambertini M, Tagliamento M, Parisi A, Zoratto F, Queirolo P, Giusti R, Guida A, Zambelli A, Tondini C, Maconi A, Betti M, Colomba E, Diamantis N, Sinclair A, Bower M, Ruiz-Camps I, Pinato DJ; OnCovid study group. COVID-19 Sequelae and the Host Proinflammatory Response: An Analysis From the OnCovid Registry. *J Natl Cancer Inst.* 2022 Jul 11;114(7):979-987.
59. Pinato DJ, Aguilar-Company J, Ferrante D, Hanbury G, Bower M, Salazar R, Mirallas O, Sureda A, Plaja A, Cucurull M, Mesia R, Townsend S, Jackson A, Dalla Pria A, Newsom-Davis T, Handford J, Sita-Lumsden A, Apthorp E, Vincenzi B, Bertuzzi A, Brunet J, Lambertini M, Maluquer C, Pedrazzoli P, Biello F, Sinclair A, Bawany S, Khalique S, Rossi S, Rogers L, Murphy C, Belessiotis K, Carmona-García MC, Sharkey R, García-Illescas D, Rizzo G, Perachino M, Saoudi-Gonzalez N, Doonga K, Fox L, Roldán E, Gaidano G, Ruiz-Camps I, Bruna R, Patriarca A, Martinez-Vila C, Cantini L, Zambelli A, Giusti R, Mazzoni F, Caliman E, Santoro A, Grosso F, Parisi A, Queirolo P, Aujayeb A, Rimassa L, Prat A, Tucci M, Libertini M, Grisanti S, Mukherjee U, Diamantis N, Fusco V, Generali D, Provenzano S, Gennari A, Tabernero J, Cortellini A; OnCovid study group. Outcomes of the SARS-CoV-2 omicron (B.1.1.529) variant outbreak among vaccinated and unvaccinated patients with cancer in Europe: results from the retrospective, multicentre, OnCovid registry study. *Lancet Oncol.* 2022 Jul;23(7):865-875.
60. Fattizzo B, Cecchi N, Bortolotti M, Giordano G, Patriarca A, Glenthøj A, Cantoni S, Capecchi M, Chen F, Mingot-Castellano M E, Napolitano M, Frederiksen H, Gonzalez-Lopez T J, Barcellini W. Thrombopoietin receptor agonists in adult Evans syndrome: an international multicenter experience. *Blood* 2022 Aug 18;140(7):789-792.
61. Harrison CN, Gupta VK, Gerds AT, Rampal R, Verstovsek S, Talpaz M, Kiladjian JJ, Mesa R, Kuykendall AT, Vannucchi AM, Palandri F, Grosicki S, Devos T, Jourdan E, Wondergem MJ, Al-Ali HK, Buxhofer-Ausch V, Alvarez-Larrán A, Patriarca A, Kremyanskaya M, Mead AJ, Akhiani S, Sheikine Y, Colak G, Mascarenhas J. Phase III MANIFEST-2: pelabresib + ruxolitinib vs placebo + ruxolitinib in JAK inhibitor treatment-naïve myelofibrosis. *Future Oncol.* 2022 Sep;18(27):2987-2997.
62. Borgogna C, Bruna R, Griffante G, Martuscelli L, De Andrea M, Ferrante D, **Patriarca A**,

- Mahmoud AM, Ucciero MAM, Gaidano V, Marchetti M, Rapezzi D, Lai M, Pistello M, Ladetto M, Massaia M, Gaidano G, Gariglio M. Induction of robust humoral immunity against SARS-CoV-2 after vaccine administration in previously infected haematological cancer patients. *Br J Haematol*. 2022 Sep 5. doi: 10.1111/bjh.18429. Epub ahead of print. PMID: 36062472.
63. Rigamonti C, Cittone MG, Manfredi GF, Sorge A, Moia R, **Patriarca A**, Donato MF, Gaidano G, Pirisi M, Fraquelli M. High reproducibility of spleen stiffness measurement by vibration-controlled transient elastography with a spleen-dedicated module. *Hepatology Commun*. 2022 Sep 9. doi: 10.1002/hep4.2070. Epub ahead of print. PMID: 36082990.
 64. Cortellini A, Dettorre GM, Dafni U, Aguilar-Company J, Castelo-Branco L, Lambertini M, Gennatas S, Angelis V, Sita-Lumsden A, Rogado J, Pedrazzoli P, Viñal D, Prat A, Rossi M, Berardi R, Alonso-Gordoa T, Grisanti S, Dimopoulou G, Queirolo P, Pradervand S, Bertuzzi A, Bower M, Arnold D, Salazar R, Tucci M, Harrington KJ, Mazzoni F, Mukherjee U, Tsourti Z, Michielin O, Pommeret F, Brunet J, Vincenzi B, Tonini G, **Patriarca A**, Biello F, Krenkli M, Tabernero J, Pentheroudakis G, Gennari A, Peters S, Romano E, Pinato DJ. Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries. *J Immunother Cancer*. 2022 Nov;10(11):e005732. doi: 10.1136/jitc-2022-005732. PMID: 36450384; PMCID: PMC9716413.
 65. Barbui T, Carobbio A, Ghirardi A, Iurlo A, Sobas MA, Elli EM, Rumi E, De Stefano V, Lunghi F, Marchetti M, Daffini R, Gasior Kabat M, Cuevas B, Fox ML, Andrade-Campos MM, Palandri F, Guglielmelli P, Benevolo G, Harrison C, Foncillas MA, Bonifacio M, Alvarez-Larran A, Kiladjian JJ, Bolaños Calderón E, **Patriarca A**, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Marin Sanchez A, Magro Mazo E, Carli G, Hernandez-Boluda JC, Osorio S, Carreno-Tarragona G, Sagues Serrano M, Kusec R, Navas Elorza B, Angona A, Xicoy Cirici B, Lopez Abadia E, Koschmieder S, Cattaneo D, Bucelli C, Cichocka E, de Nałęcz AK, Cavalca F, Borsani O, Betti S, Bellini M, Curto-Garcia N, Rambaldi A, Vannucchi AM. Determinants of early triage for hospitalization in myeloproliferative neoplasm (MPN) patients with COVID-19. *Am J Hematol*. 2022 Dec;97(12):E470-E473.
 66. Barbui T, Carobbio A, Ghirardi A, Iurlo A, De Stefano V, Sobas MA, Rumi E, Elli EM, Lunghi F, Gasior Kabat M, Cuevas B, Guglielmelli P, Bonifacio M, Marchetti M, Alvarez-Larran A, Fox L, Bellini M, Daffini R, Benevolo G, Carreno-Tarragona G, Patriarca A, Al-Ali HK, Andrade-Campos MMM, Palandri F, Harrison C, Foncillas MA, Osorio S, Koschmieder S, Magro Mazo E, Kiladjian JJ, Bolaños Calderón E, Heidel FH, Quiroz Cervantes K, Griesshammer M, Garcia-Gutierrez V, Sanchez AM, Hernandez-Boluda JC, Lopez Abadia E, Carli G, Sagues Serrano M, Kusec R, Xicoy Cirici B, Guenova M, Navas Elorza B, Angona A, Cichocka E, Kulikowska de Nałęcz A, Cattaneo D, Bucelli C, Betti S, Borsani O, Cavalca F, Carbonell S, Curto-Garcia N, Benajiba L, Rambaldi A, Vannucchi AM. Breakthrough infections in MPN-COVID vaccinated patients. *Blood Cancer J*. 2022 Nov 15;12(11):154. doi: 10.1038/s41408-022-00749-8. PMID: 36379921; PMCID: PMC9664028.
 67. Itzykson R, Santini V, Thepot S, Ades L, Chaffaut C, Giagounidis A, Morabito M, Droin N, Lübbert M, Sapena R, Nimubona S, Goasguen J, Wattel E, Zini G, Torregrosa Diaz JM, Germing U, Pelizzari AM, Park S, Jaekel N, Metzgeroth G, Onida F, Navarro R, Patriarca A, Stamatoullas A, Götze K, Puttrich M, Mossuto S, Solary E, Gloaguen S, Chevret S, Chermat F, Platzbecker U, Fenaux P. Decitabine Versus Hydroxyurea for Advanced Proliferative Chronic Myelomonocytic Leukemia: Results of a Randomized Phase III Trial Within the EMSCO Network. *J Clin Oncol*. 2023 Apr 1;41(10):1888-1897.
 68. Fattizzo B, Bortolotti M, Fantini NN, Glenthøj A, Michel M, Napolitano M, Raso S, Chen F, McDonald V, Murakhovskaya I, Vos JMI, Patriarca A, Mingot-Castellano ME, Giordano G, Scarrone M, González-López TJ, Trespidi L, Prati D, Barcellini W. Autoimmune hemolytic anemia during pregnancy and puerperium: an international multicenter experience. *Blood*. 2023 Apr 20;141(16):2016-2021.

69. Verstovsek S, Gerds AT, Vannucchi AM, Al-Ali HK, Lavie D, Kuykendall AT, Grosicki S, Iurlo A, Goh YT, Lazaroiu MC, Egyed M, Fox ML, McLornan D, Perkins A, Yoon SS, Gupta V, Kiladjian JJ, Granacher N, Lee SE, Oroteala L, Passamonti F, Harrison CN, Klencke BJ, Ro S, Donahue R, Kawashima J, Mesa R; MOMENTUM Study Investigators. Mometotinib versus danazol in symptomatic patients with anaemia and myelofibrosis (MOMENTUM): results from an international, double-blind, randomised, controlled, phase 3 study. *Lancet*. 2023 Jan 28;401(10373):269-280.
70. Mascarenhas J, Kremyanskaya M, **Patriarca A**, Palandri F, Devos T, Passamonti F, Rampal RK, Mead AJ, Hobbs G, Scandura JM, Talpaz M, Granacher N, Somerville TCP, Hoffman R, Wondergem MJ, Salama ME, Colak G, Cui J, Kiladjian JJ, Vannucchi AM, Verstovsek S, Curto-García N, Harrison C, Gupta V. MANIFEST: Pelabresib in Combination With Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Myelofibrosis. *J Clin Oncol*. 2023 Nov 10;41(32):4993-5004.
71. Cortellini A, Tabernero J, Mukherjee U, Salazar R, Sureda A, Maluquer C, Ferrante D, Bower M, Sharkey R, Mirallas O, Plaja A, Cucurull M, Mesia R, Dalla Pria A, Newsom-Davis T, Van Hemelrijck M, Sita-Lumsden A, Aphorp E, Vincenzi B, Di Fazio GR, Tonini G, Pantano F, Bertuzzi A, Rossi S, Brunet J, Lambertini M, Pedrazzoli P, Biello F, D'Avanzo F, Lee AJX, Shawe-Taylor M, Rogers L, Murphy C, Cooper L, Andaleeb R, Khalique S, Bawany S, Ahmed S, Carmona-García MC, Fort-Culillas R, Liñan R, Zoratto F, Rizzo G, Perachino M, Doonga K, Gaidano G, Bruna R, **Patriarca A**, Martinez-Vila C, Pérez Criado I, Giusti R, Mazzoni F, Antonuzzo L, Santoro A, Parisi A, Queirolo P, Aujayeb A, Rimassa L, Diamantis N, Bertulli R, Fulgenzi CAM, D'Alessio A, Ruiz-Camps I, Saoudi-Gonzalez N, Garcia Illescas D, Medina I, Fox L, Gennari A, Aguilar-Company J, Pinato DJ; OnCovid study group. SARS-CoV-2 omicron (B.1.1.529)-related COVID-19 sequelae in vaccinated and unvaccinated patients with cancer: results from the OnCovid registry. *Lancet Oncol*. 2023 Mar 7:S1470-2045(23)00056-6. doi: 10.1016/S1470-2045(23)00056-6. Epub ahead of print. PMID: 36898391.
72. Oliva EN, Riva M, Niscola P, Santini V, Breccia M, Gai V, Poloni A, **Patriarca A**, **Crisà E**, Capodanno I, Salutati P, Reda G, Cascavilla N, Ferrero D, Guarini A, Tripepi G, Ianni G, Russo E, Castelli A, Fattizzo B, Beltrami G, Bocchia M, Molteni A, Fenaux P, Germing U, Ricco A, Palumbo GA, Impera S, Di Renzo N, Rivellini F, Buccisano F, Stamatoullas-Bastard A, Liberati AM, Candoni A, Delfino IM, Arcadi MT, Cufari P, Rizzo L, Bova I, D'Errigo MG, Zini G, Latagliata R. Eltrombopag for Low-Risk Myelodysplastic Syndromes With Thrombocytopenia: Interim Results of a Phase-II, Randomized, Placebo-Controlled Clinical Trial (EQOL-MDS). *J Clin Oncol*. 2023 Oct 1;41(28):4486-4496.
73. Barbui T, Vannucchi AM, De Stefano V, Carobbio A, Ghirardi A, Carioli G, Masciulli A, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, **Patriarca A**, Cascavilla N, Mora B, Cacciola E, Mannarelli C, Loscocco GG, Guglielmelli P, Gesullo F, Betti S, Lunghi F, Scaffidi L, Bucelli C, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A. Ropeginterferon versus Standard Therapy for Low-Risk Patients with Polycythemia Vera. *NEJM Evid* 2023 May;2(6).
74. Salwa A, Ferraresi A, Secomandi E, Vallino L, Moia R, Patriarca A, Garavaglia B, Gaidano G, Isidoro C. High BECN1 Expression Negatively Correlates with BCL2 Expression and Predicts Better Prognosis in Diffuse Large B-Cell Lymphoma: Role of Autophagy. *Cells*. 2023 Jul 25;12(15):1924. doi: 10.3390/cells12151924.
75. Griffin M, Eikema DJ, Verheggen I, Kulagin A, Tjon JM, Fattizzo B, Ingram W, Zaidi U, Desnica L, Giammarco S, Drozd-Sokolowska J, Xicoy B, **Patriarca A**, Loschi M, Szmigielska-Kaplon A, Beier F, Cignetti A, Drexler B, Gavrilaki E, Lanza F, Orvain C, Risitano AM, De la Camara R, De Latour RP. SARS-CoV-2 vaccination in 361 non-transplanted patients with aplastic anemia and/or paroxysmal nocturnal hemoglobinuria. *Haematologica*. 2023 Aug 17.

doi: 10.3324/haematol.2023.283863. Epub ahead of print.

76. Ucciero A, Pagnoni F, Scotti L, Pisterna A, Barone-Adesi F, Gaidano G, **Patriarca A**, Lunghi M. Venetoclax with Hypomethylating Agents in Newly Diagnosed Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis of Survival Data from Real-World Studies. *Cancers (Basel)*. 2023 Sep 18;15(18):4618. doi: 10.3390/cancers15184618.
77. Efficace F, Cottone F, Yanez B, Kota V, Castagnetti F, Caocci G, Bonifacio M, **Patriarca A**, Capodanno I, Miggiano MC, Tiribelli M, Breccia M, Luciano L, Gai V, Iurlo A, Abruzzese E, Fava C, Dinner S, Altman JK, Rosti G, Cortes J, Vignetti M, Cella D. Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia. *Cancer*. 2023 Oct 6. doi: 10.1002/cncr.35021. Epub ahead of print.
78. Broome CM, McDonald V, Miyakawa Y, Carpenedo M, Kuter DJ, Al-Samkari H, Bussel JB, Godar M, Ayguasanosa J, De Beuf K, Rodeghiero F, Michel M, Newland A; **ADVANCE Investigator Study Group**. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial. *Lancet*. 2023 Nov 4;402(10413):1648-1659.
79. Efficace F, Cottone F, Yanez B, Kota V, Castagnetti F, Caocci G, Bonifacio M, **Patriarca A**, Capodanno I, Miggiano MC, Tiribelli M, Breccia M, Luciano L, Gai V, Iurlo A, Abruzzese E, Fava C, Dinner S, Altman JK, Rosti G, Cortes J, Vignetti M, Cella D. Patient-reported symptom monitoring and adherence to therapy in patients with newly diagnosed chronic myeloid leukemia. *Cancer*. 2024 Jan;130(2):287-299.
80. Barbui T, Carobbio A, De Stefano V, Alvarez-Larran A, Ghirardi A, Carioli G, Fenili F, Rossi E, Ciceri F, Bonifacio M, Iurlo A, Palandri F, Benevolo G, Pane F, Ricco A, Carli G, Caramella M, Rapezzi D, Musolino C, Siragusa S, Rumi E, **Patriarca A**, Cascavilla N, Mora B, Cacciola E, Calabresi L, Loscocco GG, Guglielmelli P, Gesullo F, Betti S, Ramundo F, Lunghi F, Scaffidi L, Bucelli C, Cattaneo D, Vianelli N, Bellini M, Finazzi MC, Tognoni G, Rambaldi A, Vannucchi AM. Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes. *Ann Hematol*. 2024 Feb;103(2):437-442. doi: 10.1007/s00277-023-05577-9.
81. Mazzucconi MGG, Rodeghiero F, Avvisati G, De Stefano V, Gugliotta L, Ruggeri M, Vianelli N, Fazi P, Paoloni F, Sargentini V, Baldacci E, Ferretti A, Martino B, Vincelli ID, Carli G, Fortuna S, Di Ianni M, Ranalli P, Palandri F, Polverelli N, Lugli E, Rivolti E, **Patriarca A**, Rago A, D'Adda M, Gentile M, Siragusa S, Sibilla S, Carella AM, Rossi E, Battistini R, Zaja F, Bocchia M, Di Renzo N, Musto P, Crugnola M, Giuffrida AC, Krampera M, Tafuri A, Santoro C. Prednisone vs high-dose dexamethasone in newly diagnosed adult primary Immune Thrombocytopenia: a randomised trial. *Blood Adv*. 2024 Jan 17:bloodadvances.2023010975. doi: 10.1182/bloodadvances.2023010975. Epub ahead of print. PMID: 38231017.
82. Ucciero A, Traversa G, Pisterna A, Cardinali V, Sciabolacci S, Poloni A, Capelli D, Gaidano G, **Patriarca A**, Lunghi M. Prescription patterns of venetoclax in acute myeloid leukemia. *Hematol Oncol*. 2024 Jul;42(4):e3298.
83. Fattizzo B, Marchetti M, Michel M, Cantoni S, Frederiksen H, Giordano G, Glenthøj A, González-López TJ, Murakhovskaya I, Napolitano M, Mingot ME, Arguello M, **Patriarca A**, Raso S, Vianelli N, Barcellini W. Diagnosis and management of Evans syndrome in adults: first consensus recommendations. *Lancet Haematol*. 2024 Jul 2:S2352-3026(24)00144-3.
84. Fattizzo B, Carrai V, Crugnola M, Baldacci E, Bellini M, Bosi C, Buzzatti E, Caramazza D, Carli G, Carpenedo M, Clissa C, Danesin C, De Paolis MR, Giannotta JA, Innao V, Marchetti M, Markovic U, Morotti A, Napolitano M, **Patriarca A**, Pettine L, Poloni A, Rivolti E, Rossi E, Santeremo TM, Santoro C, Zannier ME, Zaja F, Cantoni S, Palandri F, De Stefano V. Evans

syndrome: Disease awareness and clinical management in a nation-wide ITP-NET survey. *Eur J Haematol.* 2024 Oct;113(4):472-476.

85. Barcellini W, Pane F, **Patriarca A**, Murakhovskaya I, Terriou L, DeSancho MT, Hanna WT, Leopold L, Rappold E, Szeto K, Wei S, Jäger U. Parsaclisib for the treatment of primary autoimmune hemolytic anemia: Results from a phase 2, open-label study. *Am J Hematol.* 2024 Dec;99(12):2313-2320.
86. Bellia M, Greco M, Lunghi M, Moia R, Gaidano G, **Patriarca A**. A Rare Case of Life-Threatening Jaundice Caused by Epstein-Barr Virus Infection and Secondary Cold Agglutinin Syndrome Successfully Treated with Rituximab. *Int Med Case Rep J.* 2024 Oct 22;17:861-867. doi: 10.2147/IMCRJ.S477296.
87. Fattizzo B, Marchetti A, Bosi A, Gurnari C, Giannotta JA, Pedone GL, Rossi E, Carrai V, Guido A, Brioschi F, Carpenedo M, Crugnola M, Caramazza D, Leuzzi L, Marchetti M, Merati G, Malato S, Vianello F, **Patriarca A**, Awada H, Bortolotti M, Canzi M, Bolli N, Capecchi M, Chen F, Artoni A, Maciejewski JP, Barcellini W. Clonal hematopoiesis in patients with autoimmune thrombocytopenia: an international multicenter study. *Blood Adv.* 2024 Nov 13:bloodadvances.2024014984. doi: 10.1182/bloodadvances.2024014984
88. Metafuni E, Brioschi FA, **Patriarca A**, Leoni C, Battipaglia G, Carlino D, Condorelli A, Di Giacomo V, Markt S, Marzilli MA, Miglino M, Oliva EN, Sau A, Ricco A, Sanpaolo G, Trolese A, Iori AP, Sica S, Barcellini W, Fattizzo B. Real-world evidence of pegcetacoplan in patients with paroxysmal nocturnal haemoglobinuria: A nationwide Italian study. *Br J Haematol.* 2025 Feb 22. doi: 10.1111/bjh.20025. Epub ahead of print. PMID: 39985320.
89. Rampal RK, Grosicki S, Chraniuk D, Abruzzese E, Bose P, Gerds AT, Vannucchi AM, Palandri F, Lee SE, Gupta V, Lucchesi A, Oh ST, Kuykendall AT, **Patriarca A**, Álvarez-Larrán A, Mesa R, Kiladjian JJ, Talpaz M, Scandura JM, Lavie D, Harris M, Kays SK, Li Q, Boxhammer R, Brown B, Jegg AM, Harrison CN, Mascarenhas J. Pelabresib plus ruxolitinib for JAK inhibitor-naïve myelofibrosis: a randomized phase 3 trial. *Nat Med.* 2025 Mar 10. doi: 10.1038/s41591-025-03572-3. Epub ahead of print.
90. Sacchetti S, Bellia M, Vidali M, Zanotti V, Giacomini L, Gaidano G, **Patriarca A**, Dianzani U, Rolla R. Comparative Analysis of the Performance of Automated Digital Cell Morphology Analyzers for Leukocyte Differentiation in Hematologic Malignancies: Mindray MC-80 Versus West Medical Vision Hema. *Int J Lab Hematol.* 2025 Mar 27. doi: 10.1111/ijlh.14470. Epub ahead of print. PMID: 40148102.
91. Sicuranza A, Breccia M, Iuliano F, Gugliotta G, Castagnetti F, Lunghi M, **Patriarca A**, Intermesoli T, Luciano L, Russo Rossi A, Rege Cambrin G, Vucinic V, Malagola M, Malato A, Abruzzese E, D'Adda M, Galimberti S, Defina M, Sammartano V, Cafarelli C, Cencini E, Cartocci A, Pacelli P, Piciocchi A, Rughini A, Niederwieser D, Bocchia M. Therapeutic Vaccinations with p210 Peptides in Imatinib-Treated Chronic Myeloid Leukemia Patients: 10 Years Follow-Up of GIMEMA CML0206 and SI0207 Studies. *Vaccines (Basel).* 2025 Apr 16;13(4):419. doi: 10.3390/vaccines13040419. PMID: 40333294; PMCID: PMC12031404.
92. DeZern AE, Thepot S, De Botton S, **Patriarca A**, Deeren D, Torregroze Diaz JM, Marconi G, Bernal Del Castillo T, Bergua Burgues JM, Xicoy B, Jonasova A, Zeidan AM, Dimicoli-Salazar S, Simand C, Valcárcel D, Díez-Campelo M, Chai-Ho W, Saini L, Garnier A, Geissler K, Ofran Y, Nagy Z, Krishnamurthy P, Lübbert M, Basak GW, Carraway HE, Sallman DA, Borate U, Santini V, Campbell V, Fenaux P, Braun T, Lanza F, Zaucha JM, Roth DA, Paul S, Roy P, Kelly M, Volkert A, Chisolm J, Abdul Malak T, Klimek V, Cluzeau T. Pivotal Results of SELECT-MDS-1 Phase 3 Study of Tamibarotene with Azacitidine in Newly Diagnosed Higher-Risk MDS. *Blood Adv.* 2025 May 7:bloodadvances.2025016229. doi: 10.1182/bloodadvances.2025016229. Epub ahead of print. PMID: 40334070.

93. Breccia M, Rossi AR, Gai V, Martino B, Fava C, Annunziata M, Abruzzese E, Binotto G, Baratè C, Nardoza AP, Misto A, Coco P, Calafiore V, Carraro MC, Cattina F, Cavazzini F, Corsetti MT, Crucitti L, Crugnola M, Di Veroli A, Ditunno P, Ermacora A, Ferrara F, Genua A, Gozzini A, Impera S, Iurlo A, Levato L, Luciano L, Miggiano MC, De Gobbi M, Santoro M, Scappini B, Scortechini AR, **Patriarca A**, Rosati S, Russo S, Sancetta R, Sanpaolo G, Santeramo TM, Sibilla S, Sorà F, Sportoletti P, Stagno F, Trabacchi E, Castagnetti F. Real-World Efficacy Profile of Compassionate Use of Asciminib in an Italian, Multi-Resistant Chronic-Phase Chronic Myeloid Leukemia (CML-CP) Patient Population. *Hematol Oncol*. 2025 May;43(3):e70101. doi: 10.1002/hon.70101. PMID: 40344674.
94. Gai V, Rosso T, Castagnetti F, Pregno P, Bonifacio M, Capodanno I, Tiribelli M, Stagno F, Caocci G, Gozzini A, Luciano L, Galimberti S, Bocchia M, **Patriarca A**, Lanzarone G, Martino B, Guella A, Scortechini AR, Fava C, Fozza C, Sica S, Di Renzo N, Musto P, Pastore D, Maggi A, Pizzuti M, Antonia Melillo LM, Carella AM, Tarantini G, Mele A, Calistri E, Coppi MR, Saccona F, Scalzulli E, Battaglio B, Iezza M, Bitetti C, Freilone R, Rosti G, Albano F, Pane F, Specchia G, Ciccone G, Saglio G, Breccia M. Chronic myeloid leukemia outcomes according to baseline risk and first-line treatment in real-world settings: Data from the Italian Network/CML Campus. *Cancer*. 2025 Jul 1;131(13):e35963.
95. Bellia M, Moia R, Schipani M, Sella C, Greco M, Al Essa W, Mahmoud AM, Gaidano G, **Patriarca A**. Innovative Use of Fostamatinib in Managing Refractory Immune Thrombocytopenia in an HIV-Positive Patient: A Case Report. *Clin Case Rep*. 2025 Jun 26;13(7):e70577.
96. Lucchini E, Vianelli N, Consoli U, Carli G, Carrai V, Carpenedo M, De Stefano V, Gaidano G, Palandri F, Auteri G, Rossi E, **Patriarca A**, Innao V, Marchesini G, Ballerini M, Rossetti MC, Mosini G, Sciancalepore P, Agnelli Giacchello J, Musto P, Rivolti E, Soverini G, Borchellini A, Clissa C, Pane F, Galimberti S, Pavone V, Poloni A, Buccisano F, Musso M, Fazi P, Paoloni F, Gorreo Renzulli L, Zaja F. Real-world efficacy and safety of fostamatinib in ITP patients: Italian multicentre experience. GIMEMA ITP1122 study. *Br J Haematol*. 2025 Aug 25. doi: 10.1111/bjh.70069. Epub ahead of print. PMID: 40855761.

Books and chapters:

1. **Patriarca A**, Gaidano G. Leucemia linfatica cronica, Hairy Cell Leukemia, Leucemia prolinfocitica, LGL Leukemia, in *Ematologia per Medicina – Scienze Biologiche – Biotecnologie Mediche*, a cura di Nicola Giuliani ed Attilio Olivieri. Idelson Gnocchi 2020; ISBN: 9788879477093.
2. Bjoerg Kristensen H, **Patriarca A**, Delaisse J-M. Visualizing Normal and Malignant Human Stem and Progenitor Cells in Histological Sections, In *Encyclopedia of Bone Biology* 2020, Pages 50-61. Elsevier. DOI: 10.1016/B978-0-12-801238-3.11159-6.
3. **Patriarca A**, Gaidano G. Chronic lymphoproliferative disorders, in *HEMATOLOGY for Medical Students and General Practitioners*. Idelson Gnocchi 2021, Pages 261-268. ISBN: 9788879477727

Bibliometric indexes (captured on Scopus on 02/JUN/2025):

1. Citations: 2166 citations
2. H-Index: 28



Curriculum Vitae

Informazioni personali

Cognome e Nome	PRATO GIUSEPPINA CARLA
Data di nascita	16/09/1970
Cellulare	339 3588372
Residente	Moncalieri-10024 (TO), via Pastrengo, 4
E-mail	gprato@cittadellasalute.to.it
Indirizzo mail PEC	giuseppina.prato@pec.enpab.it
Codice Fiscale	PRTGPP70P56L219G

Titoli di Studio e Professionali ed Esperienze Lavorative

Titolo di studio	LAUREA MAGISTRALE IN SCIENZE BIOLOGICHE (110/110 e lode) ABILITAZIONE ALL'ESERCIZIO DELLA PROFESSIONE DI BIOLOGO	
Altri titoli di studio e professionali	SPECIALIZZAZIONE IN PATOLOGIA CLINICA (70/70 e lode)	
ESPERIENZE PROFESSIONALI (incarichi ricoperti) in AMMINISTRAZIONI PUBBLICHE	2022-oggi	Incarico a tempo indeterminato presso SC anatomia patologica 1U – CITTA DELLA SALUTE DI TORINO
	2019-2022	Incarico a tempo indeterminato presso SC anatomia patologica – ASL CN2 ALBA-BRA
	12/2017	Incarico a tempo determinato come dirigente biologo, Lab. analisi e SC anatomia patologica – ASL CN2 ALBA-BRA
	2017	Incarico libero professionale ASL VC Ospedale S Andrea come biologo svolgimento di attività relative allo screening cervico-vaginale Laboratorio area ematologia settore citofluorimetria, Synlab Italia srl, Castenedolo Brescia Incarico come dirigente biologo, Lab. analisi– ASL CN2 ALBA-BRA
	2015 -2016	Incarico di libera professione come biologo a progetto presso: - Laboratorio area ematologia settore citofluorimetria, Synlab Italia srl, Castenedolo Brescia - SS di Citometria-SC Anatomia Patologica OSPEDALE S.ANDREA DI VERCELLI - Lab. Patologia Oncoematologica, SC anatomia patologica - AO ORDINE MAURIZIANO DI TORINO - SPACE IMPORT EXPORT srl (Milano) start up e sviluppo nuovi test commerciali

	2012 a 2014	Incarico di libera professione come biologo a progetto presso: - SS di Citometria-SC Anatomia Patologica OSPEDALE S.ANDREA DI VERCELLI -Lab.Patologia Oncoematologica, SC anatomia patologica - AO ORDINE MAURIZIANO DI TORINO		
	2008-2011	Incarico come dirigente biologo, Lab.Immunopatologia, SC anatomia patologica - AO ORDINE MAURIZIANO DI TORINO		
	2003-2007	Incarichi di prestazione d'opera, presidio I.R.C.C. di Candiolo AO ORDINE MAURIZIANO DI TORINO		
	2001-2002	Borsa di studio biennale del Gruppo di Cooperazione in Cancerologia, presidio IRCC di Candiolo – AO ORDINE MAURIZIANO DI TORINO		
	1996-1998	Borsa di studio - AO O.I.R.M.- S. ANNA (Torino)		
ESPERIENZE PROFESSIONALI (incarichi ricoperti) in AZIENDE PRIVATE	2015-2017	Incarico di libera professione come biologo a progetto presso: - Synlab Italia srl, Castenedolo Brescia - SPACE import export s.r.l. - Osp. S Andrea Vercelli		
	2012	Responsabile scientifico organizzazione giornata:" Citometria multiparametrica:dalla routine alle applicazioni più complesse" per la Instrumentation Laboratory SpA.		
	2007	Docente e Responsabile Scientifico del corso di formazione in citometria a flusso "Cases Training" presso l'Azienda Instrumentation Laboratory SpA.		
	2006	Contratto di lavoro dipendente, inquadrata al primo livello del CCNL presso la ditta Valter Occhiena s.r.l. (Torino)		
	2000-1998	Contratto di lavoro, inquadrata al secondo livello del CCNL presso la ditta Valter Occhiena s.r.l. di Torino		
Capacità linguistiche	Lingua	Livello parlato	Livello scritto	
	Inglese	Fluente	Fluente	
	Francese	Scolastico	Scolastico	
	(1) I fascia – II fascia (2)Scolastico – Fluente- Eccellente – Madrelingua			
Capacità nell'uso delle tecnologie	CONOSCENZE DI BASE INFORMATICHE di base di Windows, Open Office* CONOSCENZE SOFTWARE APPLICATIVI PROFESSIONALI			
FORMAZIONE (partecipante/relatore)				

Partecipazione attiva a corsi di formazione ECM sia in qualità di partecipante sia di relatore. Responsabile scientifico nell'organizzazione di corsi di formazione relativamente al settore della citofluorimetria.

PUBBLICAZIONI

Autore	Giuseppe Bertuglia, ¹ Enrico Amaducci, ¹ Davide Stella, ¹ Angela Dattolo, ² Giorgia Andrea Impalà, ³ Sabrina Aliberti, ³ Giuseppina Prato, ³ Mauro Giorgi, ² Benedetto Bruno ¹ and Francesca Gay ¹
Titolo	
Nome della testata o del volume	Haematologica 111 January 2025
Data pubblicazione	September 4, 2025

Autore	Dr. Enrico Aidala, Maria Teresa Cascarano; Isabella Molinari; Stefania Iannandrea; Cristiana Caorsi; Giuseppina Prato; Sabrina Aliberti; Milena Gilestro; Carlo Pace Napoleone
Titolo	LONG-TERM EFFICACY OF DARATUMUMAB IN A CHILD LISTED FOR HEART RE-TRANSPLANTATION AFTER MULTIPLE ANTIBODY-MEDIATED REJECTIONS
Nome della testata o del volume	American Journal of Transplantation
Data pubblicazione	Ottobre 2025

Autore	V. Gaidano, V. Tenace, N. Santoro, S. Varvello, A. Cignetti, G. Prato, G. Saglio, G. De Rosa & M. Geuna.
Titolo	A clinically applicable approach to the classification of B-cell Non-Hodgkin Lymphomas with flow cytometry and machine learning.
Nome della testata o del volume	Cancers 2020,12, 1684.
Data pubblicazione	2020 Jun 24

Autore	Falco P, Levis A, Stacchini A, Ciriello MM, Geuna M, Notari P, Omedè P, Pautasso M, Prato G , Strola G, Gioia D, Bonferroni M, Cametti G, Ferrero D, Freilone R, Gaidano G, Marinone C, Marmont F, Pollio B, Salvi F, Saglio G, Girotto M;
Titolo	Prognostic relevance of cytometric quantitative assessment in patients with myelodysplastic syndromes.
Nome della testata o del volume	<u>Eur J Haematol.</u> 2011 Jun 29.
Data pubblicazione	2011 Jun 29

Autore	<u>Zucchetto A¹, Cattarossi I, Nanni P, Zaina E, Prato G, Gilestro M, Marconi D, Bulian P, Rossi FM, Del Vecchio L, Omedè P, Geuna M, Del Poeta G, Gattei V.</u>
Titolo	Cluster analysis of immunophenotypic data: the example of chronic lymphocytic leukemia.
Nome della testata o del volume	Immunol Lett. 2011 Jan 30;134(2):137-44 IF 2.906
Data pubblicazione	2011 Jan 30

Autore	<u>Guida G¹</u> , <u>Vallario A</u> , <u>Stella S</u> , <u>Boita M</u> , <u>Circosta P</u> , <u>Mariani S</u> , <u>Prato G</u> , <u>Heffler E</u> , <u>Bergia R</u> , <u>Sottile A</u> , <u>Rolla G</u> , <u>Cignetti A</u> .
Titolo	Clonal CD8+ TCR-Vb expanded populations with effector memory phenotype in Churg Strauss Syndrome.
Nome della testata o del volume	Clinical Immunology, 2008, Jul; 128 (1): 94-102 IF 3.606
Data pubblicazione	2008, Jul

Autore	<u>Ghia P¹</u> , <u>Prato G</u> , <u>Stella S</u> , <u>Scielzo C</u> , <u>Geuna M</u> , <u>Caligaris-Cappio E</u> .
Titolo	Age-dependent accumulation of monoclonal CD4+CD8+ double-positive T lymphocytes in the peripheral blood of the elderly.
Nome della testata o del volume	Br J Haematol. 2007 Dec;139(5):780-90 IF 4.498
Data pubblicazione	2007 Dec

Autore	_____ <u>Prato G</u> _____
Titolo	Alternative BCR/ABL splice variants in Philadelphia chromosome positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches.
Nome della testata o del volume	Cancer Research, 2007; 67: (11). June1, 2007 IF 7.656
Data pubblicazione	2007 Jun

Autore	<u>Zanotti R¹</u> , <u>Ambrosetti A</u> , <u>Lestani M</u> , <u>Ghia P</u> , <u>Pattaro C</u> , <u>Remo A</u> , <u>Zanetti F</u> , <u>Stella S</u> , <u>Perbellini O</u> , <u>Prato G</u> , <u>Guida G</u> , <u>Caligaris-Cappio F</u> , <u>Menestrina F</u> , <u>Pizzolo G</u> , <u>Chilosi M</u> .
Titolo	ZAP-70 expression, as detected by immunohistochemistry on bone marrow biopsies from early phase CLL patients, is a strong adverse prognostic factor.
Nome della testata o del volume	Leukemia. 2007 Jan;21(1):102-9 IF 6.146
Data pubblicazione	2007 Jan

Autore	<u>Ghia P¹</u> , <u>Prato G</u> , <u>Scielzo C</u> , <u>Stella S</u> , <u>Geuna M</u> , <u>Guida G</u> , <u>Caligaris-Cappio F</u> .
Titolo	Monoclonal CD5+ and CD5- B-lymphocyte expansions are frequent in the peripheral blood of the elderly.
Nome della testata o del volume	Blood. 2004 Mar 15;103(6):2337-42 IF 10.370
Data pubblicazione	2007 Mar 15

ULTERIORI INFORMAZIONI ALTRE ATTIVITA'	Coordinatore e docente di corsi di formazione on line e residenziali di citofluorimetria per aziende pubbliche e private. Membro del Gruppo di Citofluorimetria per SIPMEL (Società italiana di laboratorio). Socio fondatore 'APS Sfere Creative' per organizzazione attività culturali e teatrali.
---	---

Moncalieri, 30 novembre 2022

Dott.ssa Giuseppina Prato

Davide Rapezzi è un medico operante nel campo dell'ematologia a Cuneo.

Ecco i dettagli rilevati:

- **Ruolo:** Ematologo.
- **Sede di lavoro:** Divisione di Ematologia, Azienda Ospedaliera Santa Croce e Carle di Cuneo, via Michele Coppino 26.
- **Attività scientifica:** Collabora con il gruppo di lavoro sulle sindromi mieloproliferative (MPN) della Rete Oncologica del Piemonte e della Valle d'Aosta. Ha contribuito a pubblicazioni scientifiche, in particolare riguardo all'Atypical Chronic Myeloid Leukemia (Leucemia Mieloide Cronica Atipica).

Matilde Scaldaferri

Data di nascita: 08/08/1978

Luogo di nascita: CIRIE' (TO)

Farmacista ospedaliero presso AOU San Giovanni Battista

Torino, Piemonte, Italia

Esperienza

Farmacista ospedaliero

AOU San Giovanni Battista

feb 2007 - Presente 17 anni e 11 mesi

Formazione

UNIVERSITA' DI TORINO

Laurea in Chimica e tecnologie farmaceutiche Facoltà di Farmacia

Università degli Studi di Torino

Specializzazione in Farmacia Ospedaliera Scuola di specializzazione in Farmacia ospedaliera

2007 - 2009

Università degli Studi di Torino

Master di 2o livello in Malattie rare

2011 - 2012

Università degli Studi di Milano

Master di 2o livello in Farmacia e Farmacologia oncologica Master di 2o livello

Università degli Studi di Roma Unitelma Sapienza

Master di 1o livello in Dietetica e Nutrizione clinica Master di 1o livello

Università degli Studi di Roma Unitelma Sapienza

Master di 2o livello in Gestione del paziente oncologico complesso Master di 2o livello

Università Telematica Pegaso

Master 1o livello Microbioma

2020 - 2020

Società Italiana di farmacia ospedaliera

Corso di alta specializzazione Terapie geniche biotecnologie farmacogenetica e farmacogenomica

2022 - 2022

Universidad Europea de Valencia

Postgrado Diploma de Especialización de Inmunoterapia y Terapia Celular Antineoplásica.

2023 - 2023



Europass Curriculum Vitae

Informazioni personali

Nome(i) / Cognome(i) **Gianluca UBEZIO**
Indirizzo(i) C.so Carbonara, 9B int. 19; 16125 – Genova, Italia

Telefono(i) 010-5221771
Cellulare: 333-5769415
E-mail gianluca.ubezio@hsanmartino.it gianluca.ubezio@simti.it

Cittadinanza Italiana

Data e Luogo di nascita 13 Dicembre 1978 – Roma

Sesso M

Codice BZUGLT78T13H501Q

Fiscale

Esperienze Lavorative

Date **Settembre 2023 - Oggi**
Lavoro o posizione ricoperti Docente Laurea per Tecnico di Laboratorio Biomedico
Principali attività e responsabilità Docente per corsi di Immunoematologia I e II
Nome ed indirizzo del datore di lavoro Università degli Studi di Genova

Date **1 Aprile 2022 - Oggi**
Lavoro o posizione ricoperti Responsabile SS Produzione e Qualificazione emocomponenti
Principali attività e responsabilità Responsabile della produzione emocomponenti dell'area centro – levante della regione Liguria e del polo di qualificazione biologica emocomponenti a valenza regionale (Regione Liguria).
Nome ed indirizzo del datore di lavoro Direttore Generale Ospedale Policlinico San Martino di Genova
Direttore UOC Medicina Trasfusionale, Ospedale Policlinico San Martino di Genova, Dott.ssa Vanessa Agostini

Date **30 Agosto 2021 - Oggi**
Lavoro o posizione ricoperti Responsabile Qualità per il Nuovo Accordo Interregionale per la Plasmaderivazione – Delibera n. 23030 Azienda Zero, Regione del Veneto
Principali attività e responsabilità Responsabile della Qualità per l'invio di plasma finalizzato alla produzione di farmaci plasmaderivati, per de Regioni Abruzzo, Friuli Venezia Giulia, Liguria, Provincia Autonoma di Bolzano, Provincia Autonoma di Trento, Umbria, Valle D'Aosta, Basilicata, Veneto
Nome ed indirizzo del datore di lavoro Coordinamento Regionale per le Attività Trasfusionali (CRAT), Regione del Veneto

Date **Febbraio 2021 – Febbraio 2023**
Lavoro o posizione ricoperti Consulente presso Centro Nazionale Sangue – Ist. Superiore di Sanità

Curriculum vitae
Candida Vitale, MD, PhD

Personal data

Place of birth: Torino, Italy

Citizenship: Italian

Current position: Assistant Professor – Ricercatrice a tempo determinato in *Tenure Track*, Department of Molecular Biotechnology and Health Sciences, University of Torino, Italy

Work address: S.C. Ematologia Universitaria, A.O.U. Città della Salute e della Scienza di Torino, Via Genova 3, 10126, Torino

Tel. +39 3471551761

E-mail: candida.vitale@unito.it

Work experience

March 2020 – present	Ricercatrice a Tempo Determinato - Assistant Professor, Department of Molecular Biotechnology and Health Sciences, University of Torino, Italy
January 2019 – February 2020	Fellowship “Fondazione Pezcoller - Ferruccio ed Elena Bernardi” in collaboration with SIC (Società Italiana di Cancerologia), University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Italy
September 2017- February 2020	Collaboration with FO.NE.SA. (Fondazione Neoplasie Sangue) Onlus for clinical management and implementation of clinical studies and experimental therapies for patients with chronic lymphocytic leukemia, University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino, Italy
September 2017 – August 2018	Research Fellowship, Hematology Section, Department of Molecular Biotechnology and Health Sciences, University of Torino, Italy
August 2015 – August 2017	Fellowship AIL (<i>Associazione Italiana contro le Leucemie</i>) for Hematology Specialist, Department of Molecular Biotechnology and Health Sciences, University of Torino, Italy
July 2014 – July 2015	Leukemia Fellowship Program, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
July 2009 – July 2014	Residency/Fellowship in Hematology, University of Torino, Italy (Prof. Massimo Massaia – Dr. Marta Coscia)
March 2007 - June 2009	Internship, Laboratory of Hematological Oncology (CeRMS) and University Division of Hematology, A.O.U. Città della Salute e della Scienza di Torino and Department of Molecular Biotechnology and Health Sciences, University of Torino, Italy (Prof. Massimo Massaia – Dr. Marta Coscia)
March 2003 - October 2005	Internship, Laboratory of Immunogenetics, Department of Genetics, Biology and Biochemistry, University of Torino, Italy (Prof. Fabio Malavasi)

Education and training

September 2018 – October 2018	<i>Observership</i> , Department of Lymphoma/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
December 2012 – January 2017	PhD School in Molecular Medicine, University of Torino, Italy
November 2016 – June 2017	EHA (European Hematology Association) Clinical Research Training in Hematology

July 2014 – July 2015	<i>Leukemia Fellowship Program</i> , Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
August 2013 – September 2013	<i>Observership</i> , Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
July/September 2013	United States Medical Licensing Examination – STEP 1 (score 220), STEP 2 CK (score 241), STEP 2 CS
July 2009 – July 2014	Postgraduate School in Hematology, University of Torino, Italy
February 2009	Italian Board Examination for MD
2002 - 2008	School of Medicine, University of Torino, Italy (110/110 cum laude)
1997 - 2002	High School Liceo Classico Massimo D'Azeglio, Torino, Italy (100/100)

Technical skills and competences

Inward and outpatient care of neoplastic and non-neoplastic hematological patients, with a special interest in management and record of patients with chronic lymphocytic leukemia, marginal zone lymphoma and Hodgkin's lymphoma. Co-investigator in national and international phase II and III Clinical Trials. Well acquainted with Good Clinical Practice for clinical trials.

Good experience in cell biology, cell culture, cytofluorimetric analysis (immunophenotypic characterization of different cell populations, cytotoxic assay, apoptosis); experience in molecular biology.

Scientific interests

Biology and treatment of hematological malignancies, with a special focus on chronic lymphocytic leukemia, marginal zone lymphoma and Hodgkin's lymphoma. Prospective and observational studies in chronic lymphocytic leukemia, marginal zone lymphoma and Hodgkin's lymphoma. Interactions between the neoplastic clone, tumor microenvironment and immune system, and mechanisms of drug resistance. Tumor-related immune dysfunctions and immunomodulatory properties of new targeted drugs in chronic lymphocytic leukemia. Immunotherapy strategies for patients with hematologic malignancies.

Clinical and research activity

Regular inpatient and outpatient clinical activity within the University Division of Hematology, Città della Salute e della Scienza University Hospital of Torino, Italy. Investigator in >30 clinical trials investigating the role of new drugs for the treatment of patients with chronic lymphocytic leukemia and lymphomas.

Teaching activity

Lecturer in the Master Program II level - Stem cells in Regenerative Medicine and Cell Factory Management (Modules on CAR T-cell therapy), University of Torino, Italy (2020-present)

Lecturer in the Post-graduate School of Hematology, University of Torino, Italy (2020-present)

Lecturer in the School of Medicine, University of Torino, Italy (2020-present)

Editorial activity

Expert reviewer of abstracts submitted under the topic "Gene therapy, cellular immunotherapy and vaccination - Biology & Translational Research", for the EHA2022 Congress.

Peer reviewer for Frontiers in Oncology, Cancer Immunology, Immunotherapy, Therapeutic Advances in Hematology. Member of the "Reviewer Board" for Cancers.

Membership of scientific societies

- European Hematology Association (EHA)
- Società Italiana di Ematologia (SIE)
- European Research Initiative on CLL (ERIC)
- Membro della European Association for Cancer Research (EACR)
- Society of Hematologic Oncology (SOHO)
- Società Italiana di Cancerologia (SIC)
- FIL (Fondazione Italiana Linfomi)

Torino, 27/02/2026

Candida Vitale

